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 Abstract 
Herpes  simplex  virus  (HSV-1)  ICP27  is  a  multifunctional  immediate  early  (IE) 
protein,  which  has  counterparts  in  every  herpesvirus  of  mammals  and  birds 
sequenced  so  far,  indicating  the  importance  of  this  key  viral  protein  that  is  a 
potential  antiviral  target.  It  is  required  for  expression  of  several  early  and  late 
genes and acts at transcriptional and posttranscriptional levels. ICP27 is an RNA 
binding  protein  and  inhibits  pre-mRNA  splicing,  stimulates  pre-mRNA  3' 
processing and affects mRNA stability. Also it has been shown that ICP27 can 
directly stimulate mRNA translation.  
ICP27 contains both a nuclear localization signal and a nuclear export signal and 
shuttles between the nucleus
 and the cytoplasm. It interacts directly with various 
cellular proteins including REF and cellular mRNA export receptor TAP to export 
viral  mRNAs.  However,  other  transport  mechanisms  such  as  CRM1-dependent 
and  independent  pathways  may  also  be  employed.  Different  studies  about 
shuttling  functions  suggested  alternative  pathways,  in  addition  to  the  existing 
routes, for transport of proteins and mRNA in HSV-1-infected cells. 
HSV-1  is  a  nuclear  replicating  virus.  All  transport  across  the  nuclear  envelope 
must occur via the nuclear pore complex (NPC), a very large, complex structure 
that consists of interacting fixed and mobile proteins called nucleoporins (NUPs). 
NUPs  act  to  regulate  the  transport  cargos  by  interaction  with  mRNA-bound 
proteins and transport receptors, karyopherins. Many features of NUPs make them 
the best option for interaction with ICP27 to shuttle it as a cargo-free or cargo-
dependent  protein.  These  include  their  transport  direction  through  NPCs,  the 
ability  of  FG-repeat  domains  in  NUPs  to  undergo  multiple  interactions 
simultaneously, the transience of their binding, the unfolded structure of the FG-
repeat domains and the mobility of most nucleoporins. 
This work aimed to further explore the transport requirements for ICP27 and viral 
mRNA export. I investigated
 direct interaction of ICP27 with nucleoporins in vitro 
and  in  infected cells.  NUP 62, a key  FG-repeat NUP  was the first nucleoporin 
tested  in  interaction  with  ICP27.  Using  fusion  protein  binding  and  co-
immunoprecipitations assays with specific antibodies I show direct interaction of these two proteins in vitro and in infected cells and both the N-terminus and C-
terminus portions of ICP27 may be associated in this interaction. Also RNase I 
treatment  indicated  that  this  interaction  is  not  mediated  via  RNA.  Furthermore, 
interaction of ICP27 with nuclear FG-repeat NUP 153 that is important in cargo-
free  and  cargo-dependent  transport  was  investigated.  Both  in  vitro  pull  down 
assay  and  co-immunoprecipitation  experiments  showed  possible  interaction  of 
ICP27 and NUP 153 and again the N-terminus and the C-terminus parts of ICP27 
were required for these interactions. 
The only cytoplasmic nucleoporin that was tested in this Ph.D. thesis was NUP 
214. FG-repeat truncates of this NUP were used in an in vitro experiments and 
showed possibility of direct involvement of ICP27 with NUP 214. In vivo studies 
confirmed this interaction. The N- and C-termini of ICP27 may participate in this 
interaction. Interaction studies of non FG-repeat nucleoporins such as NUP 107 
and Rae1 did not show any interaction allowing me to conclude that interaction of 
ICP27 and nucleoporins might be via FG-repeat domains of nucleoporins.  
The  next  aim  was  to  investigate  an  involvement  of  a  region  of  ICP27  that  is 
conserved between this protein and another protein involved in nucleocytoplasmic 
transport, hnRNP K. This region is called the SADET region according to its amino 
acid sequence and is known to be essential for transport of hnRNP K. However, I 
could  not  demonstrate  any  association  of  this  SADET  region  in  interaction  of 
ICP27 and NUPs in my study.  
Finally, some RNA viruses disrupt the nucleocytoplasmic transport machinery by 
degradation  of  some  nucleoporins.  However,  my  investigations  in  infected  and 
transfected  cell  extracts  did  not  show  any  change  in  the  level  of  FG-repeat 
nucleoporins indicating that HSV-1 does not degrade NUPS. 
In conclusion, ICP27 alone or in complex with viral mRNA might interact directly 
with  NUPs  and  provide  a  docking  site  to  translocate  in  the  NPC  and  transfer 
ICP27 either to the nucleus or the cytoplasm. The NUPs that are located in the 
cytoplasmic face of the NPC could associate with ICP27 and provide it to other 
NUPs, such as NUP 62, in the central gated channel and then to nuclear NUPs to 
dissociate in the nucleus. On the other hand, nuclear face NUPs could bind to ICP27 in the nucleus and shuttle to the central basket and pass it through the NPC 
to  cytoplasmic  NUPs  to  dissociate  in  the  cytoplasm.  Alternatively  it  has  been 
proposed that sometimes cargoes can bind to two transport receptor systems and 
may  utilise  both  receptors  simultaneously  to  translocate  through  the  NPC.  I 
suggest  that  in  HSV-1-infected  cells  cargos  might  interact  with  either  TAP  and 
ICP27 or CRM1 and ICP27 simultaneously and translocate through NPC to shuttle 
between the nucleus and the cytoplasm.  
The literature of this thesis has been stopped on 2007. 
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GAPDH  Glyceraldehyde-3-phosphate dehydrogenase  
GDP  guanosine diphosphate 
GFP  green fluorescent protein 
G-MEM  Glasgow Modified Eagle's Medium 
GST  glutathione-S-transferase 
GTP  guanosine-5’-triphosphate 
h  hour 
HCMV  human cytomegalovirus 
HCV  hepatitis C virus 
HeLa cells  continuous cell line derived from Henrietta Lacks  
HEPES  N-2-hydroxyethylpiperazine-N’-2-ethanesulphonic acid 
HHV-1 to 8  human herpesvirus 1-8 HIV  human immunodeficency virus  
HLA  human leukocyte antigen complex 
hnRNP  heterogeneous nuclear ribonuclear protein 
hPAN  human poly(A) nuclease 
hpi  hours post-inoculation  
HPV  human papilloma virus 
HRP  horseradish peroxidase 
HSV-1 / 2  herpes simplex virus type 1/ type 2 
HVS  herpes virus saimiri 
ICP  infected cell protein 
IDU  5-Iodo-2'-deoxy-L-uridine  
IE  immediate early 
IF  immunofluorescence 
IFA  immunofluorescence assays 
IFN  interferon 
Ig  immunoglobulin 
IL  interleukin 
IP  immunoprecipitation  
IPG  immobilised pH gradient  
IPTG  isopropyl thiogalactopyranoside 
kb  kilo-bases 
kDa  kilo-daltons 
KH  hnRNP K homology 
KNS  hnRNP K nuclear shuttling signal 
KS  Kaposi's sarcoma 
KSHV  Kaposi's sarcoma-associated herpesvirus 
l  litre 
L  late 
lacZ  bacterial gene that encodes β-galactosidase 
LANA  latency-associated nuclear antigen 
LAT  latency associated transcript 
LB  Luria-Bertani media 
LMB  leptomycin B 
LMW  low molecular weight marker LPF  late processing factor 
LRR  leucine-rich region 
LTR  long terminal repeat 
M  molar 
m  milli 
MAb  monoclonal antibody 
MHC  major histocompatibility complex 
MI  mock infected 
min
  minutes 
miRNA  microRNA 
MOI  multiplicity of infection 
mRNA  messenger RNA 
mRNPs  messenger ribonucleoproteins 
MS2  MS2 coat protein 
n  nano 
N  amino (-terminal end of protein) or nuclear 
NA  not applicable 
ND  not determined 
ND10  nuclear domain 10 
NES  nuclear export signal 
NK  natural killer 
NLS  nuclear localisation signal 
NMD  nonsense-mediated decay 
NMS  normal mouse serum 
NP40  Nonidet P40 
NPC  nuclear pore complex 
NR  neutral red 
NRS  normal rabbit serum 
NS  non-structural 
nt  nucleotides 
Nu  nucleolar 
OD  optical density 
ORF  open reading frame 
ori  origin of replication p  pico 
PABP1  Poly (A) binding protein 1 
PAGE  polyacrylamide gel electrophoresis 
PAP  poly(A) polymerase 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
pfu  plaque forming unit 
PKA  protein kinase A 
PKC  protein kinase C 
PML  promyelocytic leukemia protein 
PMSF  phenylmethylsuphonyl fluoride 
pre-mRNA  precursor mRNA 
REFs  RNA and export factor binding proteins 
RGG  arginine rich RNA binding motif 
RNA  ribonucleic acid 
RNAi  RNA interference   
RNAP II  RNA polymerase II 
RNase  ribonuclease 
RNP  ribonucleoprotein 
RRM  RNA-recognition motif 
rRNA  ribosomal RNA 
RT  room temperature 
RT-PCR  reverse transcriptase-polymerase chain reaction 
RXP  arginine-X-proline repeating motif 
S  Svedberg sedimentation unit 
SAP  splicing associated protein 
SDS  sodium dodecyl sulphate 
sec  seconds 
siRNA  small interference RNA 
snRNA  small nuclear RNA 
snRNP  small nuclear ribonucleoprotein particle 
SR protein  Ser-Arg-rich protein 
SRPK1  SR protein kinase 1 
SUMO  small ubiquitin-like
 modifier SV40  simian virus 40 
T  thymine 
TAF  TATA-binding protein associated factor 
TBB  4,5,6,7-tetrabromobenzotriazole 
TBP  TATA-binding protein 
TE  Tris EDTA 
TEMED  N, N, N’, N’-tetramethylethylenediamine 
TF  transcription factor 
TGF  transforming growth factor 
TK  thymidine kinase  
TNF-α  tumour necrosis factor alpha 
TOP  terminal oligopyrimidine tract 
tRNA  transfer RNA 
ts  temperature-sensitive  
U  uridine or units 
UL  unique long domain 
US  unique short domain 
USE  upstream sequence enhancer 
USP  ubiquitin-specific protease 
UTR  untranslated region 
UV  ultra-violet 
V  volts 
v/v  volume/volume 
vhs  virion associated host shut off  
vIRFs  viral interferon regulatory factors 
Vmw  apparent weight of virion polypeptide 
VSV  vesicular stomatitis virus 
VZV  varicella-zoster virus 
w/v  weight/volume 
WB  western blott 
WT  wild type 
Zn  zinc 
α-TIF  alpha trans-inducing factor 
µ  micro             Amino acid symbols 
One letter symbol  Three letter symbol  Amino acid (aa) 
          A 
          C 
          D 
          E 
          F 
          G 
          H 
          I 
          K 
          L 
          M 
          N 
          P 
          Q 
          R 
          S 
          T 
          V 
          W 
          Y 
  START CODON 
  STOP CODON 
         Ala 
         Cys 
         Asp 
         Glu 
         Phe 
         Gly 
         His 
         Ile 
         Lys 
         Leu 
         Met 
         Asn 
         Pro 
         Gln 
         Arg 
         Ser 
         Thr 
         Val 
         Trp 
         Tyr 
         ATG 
   TAA   TAG   TGA 
Alanine 
Cysteine 
Aspartic acid 
Glutamic acid 
Phenyalanine 
Glycine 
Histidine 
Isoleucine 
Lysine 
Leucine 
Methionine 
Asparagine 
Proline 
Glutamine 
Arginine 
Serine 
Threonine 
Valine 
Tryptophan 
Tyrosine 
 
                                                                                                                    Chapter 1, Introduction                 
  1 
1 Introduction 
1.1  Herpesviridae 
1.1.1  General features 
The Herpesviridae are a family of DNA viruses that cause diseases in humans and 
animals and they are believed to be extremely ancient, evolving over a period of 
400 million years (Thiry, Muylkens et al. 2005). Herpesviridae is one of the most 
important virus families that are involved in a wide range of significant medical and 
veterinary diseases. Their ubiquitous occurrence, genetic complexity, evolutionary 
diversity, and widely differing biological properties have motivated great research 
efforts worldwide, so that our understanding of these agents is now considerable 
(Davison and Clements 2005). The number of herpesviruses in nature is likely to 
exceed  the  approximately  130  herpesviruses  identified  to  date  (Roizman  and 
Pellett 2001). They infect a wide range of vertebrates, including fish, amphibians, 
reptiles, birds, marsupials, and other mammals including humans, and at least one 
invertebrate, the oyster (Davison and Clements 2005). Nine herpesviruses have 
been isolated from humans (Table1.1). These viruses are ubiquitous and highly 
successful intracellular parasites, but each is usually restricted in natural infection 
to  a  single  species  and  spreads  from  host  to  host  by  direct  contact  or  by  the 
respiratory route (Roizman and Pellett 2001; Davison 2002; Davison and Clements 
2005).  
Four essential biological properties of the Herpesviridae family that characterize 
them are: herpesviruses can express a number of enzymes that are involved in 
nucleic acid metabolism, DNA synthesis and protein handling. The next property of 
these  viruses  is  replication  and  maturation  in  the  nucleus.  Thirdly,  they  induce 
cytopathic effects in infected cells and finally, herpesviruses can establish a latent 
form and reactivate in stressed cells. Latency involves stable maintenance of the 
viral genome in the nucleus with limited expression of a small subset of viral genes 
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1.1.2  Classification 
The  Herpesviridae  were  classified  into  three  subfamilies  on  the  basis  of  their 
biological properties before the DNA sequences of the individual members of the 
family  were  known  (Roizman  and  Pellett  2001;  Davison  2002;  Davison  and 
Clements 2005). 
1.1.2.1   Alphaherpesvirinae 
Members of this subfamily are classified in three genera: Simplexvirus (HSV-1, 2), 
Varicellovirus  (VZV)  and  Mardivirus  that  have  variable  host  range  and  a  short 
reproductive  life  cycle.  They  are  rapid  spreading  in  culture  and  cause  efficient 
destruction of infected cells. Their ability to establish latency primarily in sensory 
ganglia has been clear.  
1.1.2.2    Betaherpesvirinae 
Members of this subfamily are classified in three genera Cytomegalovirus (HCMV), 
Muromegalovirus (murine cytomegalovirus), and Roseolovirus (HHV-7). They have 
restricted host range and a long reproductive life cycle. Their infection progression 
is slow in culture and latency established in these genera happens in variety of 
tissues including secretary glands, lymphoreticular cells, kidneys, and others. 
1.1.2.3  Gammaherpesvirinae 
Members of this subfamily are classified in two genera include: Lymphocryptovirus 
(EBV)  and  Rhadinovirus  (KSHV).  Usually  they  are  specific  for  either  T  or  B-
lymphocytes and a latency form has been demonstrated in lymphoid tissue. All 
members replicate and persist in lymphocytes and some also cause lytic infections 
in some types of epithelioid and fibroblastic cells. The experimental host range of 
these genera is limited to the family or order to which the natural host belongs. 
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1.1.3  Clinical features of Human Herpesviruses 
Human herpesviruses are the causative agent of variety of diseases, which are a  
growing problem. HSV-1 is ubiquitous and causes skin/eye/mouth lesions, as well 
as  conjunctivitis  and  encephalitis.  Direct  contact,  intrauterine,  neonatal  and 
postnatal infections all occur in HSV-1 (Further information in section 12.2).  
HSV-2 is the cause of most cases of genital herpes (10-15% is HSV-1) and infects 
roughly  20%  of  adults  in  the  U.S  (Whitely  2001;  Whitley  and  Roizman  2001). 
Prevalence  of  HSV-2  is  rising  and  neonatal  infections  can  occur  and  may  be 
severe. After initial infection, HSV-2 persists. Viruses are taken up by nerve ending 
and the viruses migrate rapidly in nerve fibers (axons), travelling up to the cell body 
of the nerve cell (the ganglion). HSV infections recur in response to signals such 
as  sunlight,  stress,  colds  or  immune  suppression  (Whitely  2001;  Whitley  and 
Roizman 2001).  
VZV is another alpha-herpesvirus that is spread by a respiratory route, and primary 
infection occurs mainly in children, where disease can be asymptomatic or may be 
manifested as varicella (chickenpox), which is a mild febrile illness with a blister-
type rash. The virus then establishes a latent infection in the sensory ganglia of the 
spinal or cranial nerves, and can be reactivated by age, hormones (pregnancy) or 
immune  suppression.  When  VZV  reactivates,  It  is  known  as  zoster  (shingles), 
which  can  be  painful  (neuralgia)  and  may  be  severe  (Arvin  2001;  Mettenleiter 
2002; Ku, Besser et al. 2005). 
Human herpesviruses 6 and 7 (HHV-6, HHV-7) are  β herpesviruses,  which are 
relatively primitive in genetic terms, and share important common properties with 
HSV-1. They do not encode thymidine kinase and thus are not highly sensitive to 
acyclovir. Both HHV-6 and HHV-7 establish lytic infections in vitro, and are slow 
growing (like CMV that will be detailed later). HHV-6 is a pan-lymphotropic virus 
that infects several immune cell types, including T-cells and NK cells, as well as 
cells of the CNS. The virus uses CD46 as its primary cellular receptor. In terms of 
pathogenesis,  HHV-6  has  been  linked  to  febrile  illnesses,  including  roseola 
(exanthemsubitum)  in  infants.  HHV-6  is  an  important  pathogen  in 
immunocompromised  individuals,  where  it  may  cause  pneumonia  and,  in  bone                                                                                                                    Chapter 1, Introduction                 
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marrow transplant recipients, bone marrow failure. Two variants of HHV-6 exist – 
HHV6A and HHV6B. These differ by roughly 5% at the sequence level, but appear 
to have distinct biological properties, tropism and pathogenesis. Generally HHV6A 
is more pathogenic. Human herpesvirus 7 (HHV-7) is interesting because it has 
been reported that the virus uses the CD4 receptor as a component of its receptor. 
HHV-7 may also cause some cases of roseola and has been postulated to play a 
role in the pathogenesis of Pityriasis rosea. Both viruses infect almost all (>90%) of 
children  by  age  3,  and  persist  life-long  (Caserta,  Mock  et  al.  2001;  Yamanishi 
2001). 
Human  cytomegalovirus  (CMV)  is  a  b-herpesvirus  whose  genome  encodes  a 
number  of  genes  that  function  to  downregulate  the  antiviral  immune  response. 
Mainly a respiratory route spreads CMV, and roughly 80% of over 35 year olds are 
CMV positive. It is an important cause of congenital or neonatal infections, which 
can be severe (fatal in 5-10% of cases), in part because of its ability to cross the 
placenta. It is reactivated in much the same way as other herpesviruses, and can 
cause pneumonia in immunosuppressed individuals, as well as retinitis. Since the 
virus lacks the TK gene, CMV infections are usually treated with ganciclovir (Pass 
2001). 
 Epstein-Barr virus (EBV) is one of the most extensively characterized members of 
the gamma subfamily of herpesviruses and a common human virus that causes 
infectious mononucleosis. Symptoms of infectious mononucleosis are fever, sore 
throat, and swollen lymph glands. EBV remains dormant or latent in a few cells in 
the throat and blood for the rest of the person's life. Periodically, the virus can 
reactivate and is commonly found in the saliva of infected persons. Transmission 
of  EBV  requires  intimate  contact  with  the  saliva  of  an  infected  person.  Strong 
evidence  links  EBV  to  the  development  of  a  spectrum  of  human  diseases, 
including Burkitt's lymphoma (BL), Hodgkin lymphomas (HL), post-transplant and 
AIDS-related lymphomas, nasopharyngeal carcinoma, and a small subset of T cell 
lymphomas, gastric carcinomas, leiomyosarcomas, follicular dendritic tumors, and 
other epithelial carcinomas but is probably not the sole cause of disease (Rikinson 
and Kieff 2001; Kutok and Wang 2006).                                                                                                                    Chapter 1, Introduction                 
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Kaposi's sarcoma (KS) is a mesenchymal tumour involving blood and lymphatic 
vessels. In children, it is believed that KS is a manifestation of primary infection, 
whereas in adults, it has been suggested that KS occurs after primary infection. 
Most evidence indicates that HHV8 is sexually transmitted among men, probably 
by receptive anal intercourse. Classic KS is primarily a skin disease that appears 
as  multiple  firm,  purple-reddish-brown  plaques  and  nodules  on  the  lower 
extremities.  It  may  be  complicated  by  lymphoedema  or  hyperkeratosis.  Under 
different  geographical  and  other  condition  there  are  several  clinically  distinct 
patterns of KS. Endemic African KS has four clinically distinct patterns. KS has 
also been described in iatrogenic immunosuppressed organ transplant recipients. 
AIDS associated KS is common in this group of people (Moore and Chang 2001; 
Roizman and Knipe 2001; Hengge, Ruzicka et al. 2002).  
1.2  Herpes simplex type 1 
1.2.1  Definition 
Human HSV-1 (herpes simplex virus type 1) is a double stranded DNA virus that 
replicates in the nucleus. After infection, its 152 kb genome, encodes about 90 
transcriptional  units  and  84  are  translated  to  proteins.  The  viral  genes  are 
expressed  in  a  temporal  co-ordinated  fashion  and  can  be  divided  into  three 
classes: α (immediate early), β (delayed early) and γ (late). The virion-associated 
VP16 protein stimulates transcription of the five α gene and their expression does 
not require prior protein synthesis. α gene products regulate expression of the β 
proteins, which are involved in viral DNA replication and metabolism. The γ gene 
class,  are  necessary  for  virion  assembly,  maturation  and  egress,  and  can  be 
subdivided  into  the  γ1  genes,  whose  expression  is  stimulated  by  viral  DNA 
synthesis but is not dependent on it, and the γ2 genes, whose expression shows a 
complete requirement for viral DNA replication (Roizman and Knipe 2001; Smith, 
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1.2.2  Clinical features and epidemiology  
HSV-1  is  normally  associated  with  orofacial  infections  and  encephalitis. 
Intrauterine, neonatal and postnatal infections all occur, and a common sequela of 
such infections is encephalitis. The illness caused by the HSV-1 virus can vary 
greatly,  ranging  from  asymptomatic  to  severe  systemic  illness,  which  is 
occasionally  fatal.  It  infects  the  oral  mucosa,  and  travels  up  to  the  trigeminal 
ganglia in the face. In children 1-3 years  of age, the major symptom of HSV-1 
infection is gingivostomatitis, an infection of the gums, tongue, mouth, lips, facial 
area and pharynx. HSV-1 infections recur in response to signals such as sunlight, 
stress, colds or immune suppression. Reactivated virus infection usually results in 
lesions of the skin in the area served by the trigeminal ganglia e.g. herpes labialis 
(cold sores). Such recurrences are generally localised, but can be generalised if 
the host is immunocompromised (Whitely 2001; Whitley and Roizman 2001). HSV-
1  infections  occur  throughout  the  world  with  approximately  one  third  of  the 
population  in  developing  and  the  lower  socio-economic  classes  of  developed 
countries seroconverting to HSV-1 by 5 years of age, and the frequency increases 
to  70-80%  during  adolescence.  In  the  developed  world  this  is  delayed  and 
seroprevalence  by  20-40  years  of  age  is  around  40-60%  (Wentworth  and 
Alexander 1971; Whitely 2001; Whitley and Roizman 2001).  For HSV-1 infection 
to occur, the virus must come into contact with mucosal surfaces or grazed skin.  
Following replication at the site of primary infection, virus is transported by neurons 
to dorsal root ganglia where latency is established (Rock and Fraser 1983). HSV 
can  affect  all  areas  of  the  nervous  system  and  cause  meningitis,  myelytis  and 
radiculitis among other diseases. Other rare complications can include keratitis and 
a  disseminated  infection  involving  organs  such  as  the  liver  and  adrenal  glands 
(Whitely 2001; Whitley and Roizman 2001).  
1.2.3  Prevention and therapy 
Host response to HSV-1 occurs in two phases, a non-specific containment phase 
and  a  later  HSV-1  specific  effector  phase.    Host  genetic  background, 
macrophages, natural killer cells, specific T cell subpopulations, specific antibodies 
and  lymphokine  responses  have  been  implicated  as  important  factors  in  host                                                                                                                    Chapter 1, Introduction                 
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defences against HSV-1 infections (Lopez, Arvin et al. 1993; Xu, Screaton et al. 
2001;  Ellermann-Eriksen  2005).  No  treatment  is  currently  available  to  eliminate 
HSV-1 infection, however a new range of antiviral agents have become available 
since  the  1980s.    Acyclovir  (Zovirax),  a  synthetic  acyclic  purine-nucleoside 
analogue, was introduced in the early 1980s and has been shown to produce a 
clinical benefit in primary genital herpes when administered either intravenously or 
orally (Mindel, Adler et al. 1982).  Acyclovir reduces the clinical severity of disease 
episodes,  shortens  their  duration,  prevents  complications  and  reduces 
symptomatic viral shedding, but does not eliminate the infection (Kinghorn 1993). 
Acyclovir is a particularly effective inhibitor of HSV replication in vitro and in vivo 
(Schaeffer, Beauchamp et al. 1979). The efficacy and antiviral specificity of the 
acyclic nucleoside analogues is due in part to their selective phosphorylation in 
virally infected cells (Biron, Stanat et al. 1985).  The HSV thymidine kinase enzyme 
(tk) phosphorylates acyclovir, converting it to a monophosphorylated form, which is 
then phosphorylated further by cellular kinases before it is incorporated into newly 
synthesised  DNA  resulting  in  the  arrest  of  DNA  synthesis  and  leading  to 
subsequent  DNA  fragmentation  (Reardon  and  Spector  1989;  Clercq  2004).  As 
DNA synthesis is required for acyclovir to function, the drug cannot destroy the 
virus during the latent period.  In addition, valaciclovir, famciclovir, penciclovir are 
its  oral  prodrugs  (Balfour  1999;  Clercq  2004).  The  only  herpesvirus  vaccine 
licensed for human use in the US is the chickenpox vaccine for VZV, which is a 
live,  attenuated,  vaccine  that  is  70-90%  effective.  Vaccines  for  HCMV,  HSV-2, 
HSV-1 and EBV are in development. Recently, three types of prophylactic vaccine 
are in clinical trials, an adjuvant subunit using viral surface gB and gD antigens, a 
replication incompetent viral mutant, and DNA vaccines (Stanberry 1995; Bernstein 
and  Stanberry  1999;  Corey,  Langenberg  et  al.  1999;  Gomi,  Sunamachi  et  al. 
2002). Additionally, genetically attenuated HSV mutants and vectors are in pre-
clinical development (Whitley and Roizman 2001). 
1.2.4  Structure of the virion 
HSV-1 particles consist of the viral genome packaged as linear dsDNA, present in 
the icosahedral capsid. The capsid is roughly 100 nm in diameter and composed of 
162 individual capsomers. A tegument that is unique to herpesviruses surrounds it,                                                                                                                    Chapter 1, Introduction                 
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and it includes proteins as well as virion RNAs that the virus needs to initiate its 
lifecycle in the infected cell (figure 1.1). The virion together with cellular RNAs may 
allow for immediate synthesis of new gene products following virus entry, setting 
up the cell for efficient virus replication. This particle and tegument is wrapped in a 
lipid-rich envelope, which includes up to 11 different viral glycoproteins and there 
might  be  as  many  as  1,000  copies  of  individual  glycoproteins  in  the  envelope 
(Roizman and Knipe 2001; Sciortino, Taddeo et al. 2002; Terhune, Schroer et al. 
2004). 
1.2.5  Viral genome 
Physical characterisation studies showed the HSV-1 genome is 152 kbp. Like all 
herpes virus DNAs it is comprised of linear, dsDNA but has an unusually high G+C 
content of 68% (McGeoch, Dolan et al. 1986; McGeoch, Dalrymple et al. 1988; 
Perry and McGeoch 1988; Roizman and Knipe 2001).The genome is composed of 
long (L) and short (S) unique segments flanked by terminal repeat regions.  The 
unique long (UL) region is 107.9 kbp and the unique short (US) region is 13 kbp.  
The unique sequences are flanked by inverted repeats, RL (9 kbp) and RS (6.5 
kbp) (McGeoch, Dalrymple et al. 1988). RL and RS are not related in sequence 
apart from the ‘a’ sequence (400 bp) located at the genome termini.  One copy of 
the ‘a’ sequence is located at the S terminus, whereas the L terminus may have 
more than one copy.  The ‘a’ sequence is also located at the L-S junction as an 
inverted repeat and again can be present as more than one copy (Wagner and 
Summers 1978). The two unique segments can invert relative to each other via the 
repeats such that a population of HSV DNA molecules consists of four equimolar 
isomers. Each gene has its own promoter to direct transcription, although some 
transcripts share 3' ends (Figure 1.2) (Roizman and Knipe 2001). 
1.2.6  Viral life cycle 
The viral life cycle is summarised in Figure 1.3. In fully permissive tissue culture 
cells  e.g  BHK  cells,  the  entire  process  takes  approximately  18-20  hours.  This 
process includes attachment, entry, gene expression, assembly and egress that I 
will discuss briefly.                                                                                                                    Chapter 1, Introduction                 
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1.2.6.1  Cell attachment 
In  HSV-1,  attachment is mediated mainly  by the  envelope  glycoprotein C (gC), 
which  interacts  with  heparin  sulphate  (HS)  side-chains  on  cell  surface 
proteoglycans (WuDunn and Spear 1989; Shieh, WuDunn et al. 1992). Heparin 
sulphate  is  the  primary  receptor  for  HSV-1  (Shieh,  WuDunn  et  al.  1992)  but 
perhaps  not  the  sole  receptor  for  HSV-1  (Gruenheid,  Gatzke  et  al.  1993).  
Proposed candidates for secondary or co-receptors have included the fibroblast 
growth factor receptor (FGFR) (gBaird, Florkiewicz et al. 1990). Understanding the 
envelope glycoproteins which are involved in binding to heparin sulphate has come 
from the studies of viral mutants lacking functional versions of one or more of the 
twelve  known  glycoproteins  (gB,  gD,  gH  and  gL)  and  one  non  envelope 
glycoprotein (gK) that have been found to be essential for productive infection in 
cell culture (Desai, Schaffer et al. 1988; Fuller and Lee 1992; Hutchinson, Browne 
et al. 1992; Hutchinson and Johnson 1995).  
 
1.2.6.2  Cell penetration 
After  attachment,  the  virus  then  interacts  with  one  of  three  possible  entry 
receptors, via glycoprotein D (gD). These are firstly, Herpes Virus Entry Mediator 
(HVEM), a TNF receptor super family member (Montgomery, Warner et al. 1996). 
Nectin 1 and 2 are the second family of co receptors which are immunoglobulin-
gene super family members that are present in both human and nonhuman cells 
and  act  as  intercellular  adhesion  molecules.  They  mediate  entry  of  all  HSV-1 
strains  tested  (Geraghty,  Krummenacher  et  al.  1998).  Thirdly,  modified  heparin 
sulphate sites generated by 3-O-sulfotransferases which mediate efficient HSV-1 
entry  but not HSV-2  entry (Shukla,  Liu et  al. 1999). Binding to these receptors 
triggers a conformational change in gD facilitating fusion but also gB/gH and gL 
that are needed also for fusion. Following penetration and internalisation, several 
of the tegument proteins have important functions. These include the virion host 
shut off (vhs) protein which indiscriminately degrades mRNA and so causes an 
early shut down of host protein synthesis (Kwong and Frenkel 1987). Virus capsids 
are transported to the nucleus where the viral DNA and at least some tegument 
proteins enter the nucleoplasm by an unknown mechanism.  Here the course of                                                                                                                    Chapter 1, Introduction                 
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infection depends on whether the virus enters the lytic cycle or establishes a latent 
infection (Whitely 2001; Spear and Longnecker 2003). 
1.2.6.3  DNA replication 
In HSV-1, the complete set of seven viral genes required for replication is known 
and  replication  of  a  HSV-1  replication  origin  containing  plasmid  can  be 
reconstituted  using  these  proteins  expressed  from  baculovirus  vectors  (Stow 
1992). Viral replication typically peaks between 10- 20 hours post infection (hpi). It 
has  long  been  thought  that  HSV-1  DNA  rapidly  circularises  during  productive 
infection of target cells, but studies by Jackson and Deluca suggest that this view 
may not in fact be correct (Jackson and DeLuca 2003). Circular forms of HSV DNA 
are  not  present  during  productive  infection,  and  occur  only  in  latent  infection 
(Figure.1.4). This switch is regulated by the expression of ICP0, which prevents 
genome circularisation. Productive HSV-1 DNA replication most likely proceeds via 
a  complex,  multi-phase  mechanism:  The  initial  phase  of  herpesvirus  replication 
occurs  at  specific  origins  of  lytic-phase  replication,  via  a  putative  theta-form 
intermediate (i.e., a replication “bubble”). Replication initiates via local unwinding of 
an  AT-rich  region  within  the  origin  of  DNA  replication.  This  is  triggered  by  the 
interaction of a virally-encoded origin-binding protein (OBP; aka UL9) with specific 
DNA  sequences  at  the  origin  that  this  initial  phase  of  DNA  replication  uses  a 
cellular DNA polymerase and primase. Later, the genome is believed to become 
nicked and to form a rolling circle template, resulting in the generation of head-to-
tail  concatamers  containing  many  copies  of  the  HSV-1  genome  during  the  late 
phase of DNA replication  (Lehman and Boehmer 1999). Replication during this 
phase  occurs  in  an  origin-independent  manner.  The  viral  helicase-primase 
complex  protein  (ICP5/8/52)  then  further  unwinds  the  “open”  DNA,  in  an  ATP-
dependent fashion. This allows the viral DNA polymerase to load on to the origin 
and  to  begin  new  DNA  synthesis,  using  RNA  primers  made  by  the  helicase-
primase  complex.  Further  studies  contrary  to  the  work  of  Jackson  and  DeLuca 
showed that circularization of the HSV-1 DNA occurs early in lytic infection and this 
process  is  independent  of  both  viral  genome  and  protein  synthesis  (Martinez, 
Sarisky et al. 1996; Lehman and Boehmer 1999; Crumpacker and Schaffer 2002; 
Strang and Stow 2005).                                                                                                                    Chapter 1, Introduction                 
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1.2.7  The lytic life cycle 
The general pattern of HSV gene expression in productively infected cells was first 
described over 20 years ago (Figure.1.5). Herpesviruses replicate in the nucleus. 
Their  gene  expression  is  tightly  regulated,  and  has  two  key  features.  First, 
herpesvirus proteins fall into groups, whose synthesis is coordinately regulated that 
is, all genes within a given group are expressed at the same time and are switched 
on and off by the same signals. Second, the viral protein groups are expressed in a 
cascade fashion starting with the immediate early (IE) group, followed by the early 
(E) and then the late (L) groups. This occurs because the IE proteins are needed 
to make the E proteins, which are, in turn, needed to make the L proteins (Honess 
and Roizman 1974). In HSV-1, tegument protein known as trans-activator of alpha 
genes (aka VP16 or UL48) initiates viral transcription, and it activates transcription 
from  the  viral  immediate-early  genes  by  acting  in  concert  with  several  cellular 
transcription  factors.  VP16  cannot  bind  DNA  directly  so  it  is  dependent  on  the 
cellular Oct-1 transcription factor and at least one other cellular factor, known as 
host cell factor  (HCF) to form a multi-component  complex  on the TAATGARAT 
motifs which are present in all the IE gene promoters (Gaffney, McLauchlan et al. 
1985; O'Hare 1993). During HSV infection, HCF binds to VP16 to promote stable 
interaction with Oct-1 and may act as a nuclear import factor for VP16, particularly 
in the early stage of infection (La Boissiere, Hughes et al. 1999). In addition, HSV 
infection alters the sub-cellular distribution of HCF (LaBoissiere and O'Hare 2000). 
These cellular factors are critical in determining whether HSV-1 expresses its lytic 
genes. The other key regulatory protein, which is present in the viral tegument, is 
vhs  or  the  virion-host  shutoff  protein  (aka  UL41).  vhs  is  not  essential  for  viral 
replication, but it increases the efficiency of virus production, by causing the non-
specific degradation of mRNAs, and by shutting off synthesis of macromolecules 
after infection of the cell. This allows HSV-1 to completely take over the host cell’s 
synthetic machinery. It is important to know that vhs-induced mRNA degradation is 
indiscriminate, and so the virus must carefully regulate vhs. This may be achieved 
in part by the binding of VP16 to vhs at later times in viral infection after cellular 
mRNAs  have  been  eliminated.  Following  this  transactivation,  the  lytic  gene 
cascade ensues. This cascade is well ordered and tightly regulated and dictates                                                                                                                    Chapter 1, Introduction                 
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the controlled expression of three classes of genes: the IE or a genes, the E or b 
genes and the L or g genes (Honess and Roizman 1974; Whitely 2001). 
1.2.7.1  Immediate early proteins 
The first group of viral genes to be expressed after about 2 to 4 h post infection 
(hpi) is the immediate-early (α) genes, which can be expressed in the presence of 
inhibitors of protein synthesis. For the most part, these immediate-early proteins 
are regulatory proteins, which switch on the expression of other viral genes. These 
encode  a  total  of  6  immediate-early  (IE)  genes,  which  are  designated  as  ICP 
(infected cell proteins) 0, ICP4, ICP22, ICP27 and ICP47, plus Us1.5. Of these, 
only ICP4 and ICP27 are required for viral replication in tissue culture, although 
ICP0 deletion mutants also replicate less well than wild-type virus. All 3 of these 
proteins are transcriptional regulators of the viral early and late genes, and ICP4 
also inhibits expression of the IE genes, which helps to shut off these genes during 
the later stages of viral infection (Roizman and Knipe 2001). 
ICP0 
ICP0  a  110  KDa  multifunctional  protein  that  plays  a  central  role  in  regulating 
whether HSV-1 virus progresses to lytic or latent infection. It  does transactivate all 
three classes of IE, E and late genes of HSV and is required to induce efficient lytic 
gene expression and consequently efficient viral replication (Warren, Devlin et al. 
1977; Cai and Schaffer 1992; Cohen, Muggeridge et al. 1992);(Everett, Boutell et 
al. 2004; Kummer, Turza et al. 2007; Boutell, Everett et al. 2008). It is a strong and 
global transactivator of both viral and cellular genes and phosphorylation regulates 
ICP0 function (Davido, von Zagorski et al. 2005). ICP0 is phosphorylated by both 
viral and cellular kinases and three regions in ICP0 identified for phosphorylation 
that is required for maximal transactivation activity (Royston and Aurelian 1970; 
Boutell, Everett et al. 2008). However, it has become apparent that ICP0 acts at or 
before the initiation of mRNA synthesis (Jordan and Schaffer 1997). ICP0 interacts 
with different cellular proteins such as cyclin D3, translation elongation factor EF-1, 
centomeric protein CENP-C, a ubiquitin-specific protease USP7, a class II histone 
deacetylase and the transcription factor BMAL1 (Kawaguchi, Tanaka et al. 2001; 
Boutell,  Canning  et  al.  2005).  Early  in  infection  (3  hrs),  ICP0  was  observed  to 
localise in the nucleus at pre-existing nuclear sub-structures, ND10, that are also                                                                                                                    Chapter 1, Introduction                 
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known as PML (promyelocytic leukaemia nuclear) bodies. Within a few hours these 
structures are disrupted, and this disruption required the RING finger domain of 
ICP0 and can  be inhibited by  proteosome  inhibitor drugs. The view from these 
observations is that ICP0 induces the degradation of specific cellular targets, and 
that this degradation is an integral component of the mechanism by which ICP0 
activates  viral  gene  expression  during  a  productive  infection  (Parkinson,  Lees-
Miller et al. 1999; Everett 2000; Everett and Murray 2005; Boutell, Everett et al. 
2008).There is a suggestion that it might have a role in reactivation from latency. 
Further, in certain cells such as neurons, in which ICP0 expression is deficient, 
latency would be more likely than productive infection (Everett 2000). It has been 
suggested  that  ICP0  regulates  the  balance  between  lytic  and  latent  HSV-1 
infection  (Loiacono,  Taus  et  al.  2003).  It  has  been  indicated  that  ICP0  plays  a 
critical role in both of initiation of lytic replication and the reactivation of latent viral 
genomes (Boutell, Everett et al. 2008; Everett, Parada et al. 2008). It has recently 
shown  that  involvement  of  ICP0  and  PML  contribute  to  a  cellular  antiviral 
repression mechanism (Everett, Rechter et al. 2006). Further study also suggested 
ICP0 has crucial role in the viral immune escape mechanism by downregulation of 
CD83 expression (Kummer, Turza et al. 2007).   
ICP27 
ICP27 is an essential, multifunctional α protein that is required for expression of 
several  classes  of  post-α  genes,  (Oakes  and  Rosemond-Hornbeak  1978; 
Stavraky, Rawls et al. 1983; Sacks, Greene et al. 1985; Ward and Roizman 1994; 
Uprichard  and  Knipe  1996).It  acts  transcriptionally  and  posttranscriptionally.  An 
RNA binding protein (Mears and Rice 1996; Sokolowski, Scott et al. 2003), ICP27 
inhibits pre-mRNA splicing
 (Hardy  and Sandri-Goldin 1994; Bryant, Wadd et  al. 
2001;  Lindberg  and  Kreivi  2002;  Sciabica,  Dai  et  al.  2003;  Smith,  Malik  et  al. 
2005), stimulates pre-mRNA 3' and processing (McLauchlan, Phelan et al. 1992; 
McGregor, Phelan et al. 1996), affects mRNA stability (Brown, Nakamura et al. 
1995), and shuttles between the nucleus
 and the cytoplasm (Phelan and Clements 
1997; Mears and Rice 1998) promoting viral RNA nuclear export (Sandri-Goldin 
1998; Koffa, Clements et al. 2001; Chen, Sciabica et al. 2002; Ellison, Maranchuk 
et al. 2005). Two recent reports have
 provided indirect evidence for a role in the 
cytoplasm.  Firstly,  ICP27  stimulates  the  polysomal  association  of  HSV-1
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RNA and the levels of VP16 protein (Ellison, Maranchuk et al. 2005). Secondly, 
ICP27 directly stimulates mRNA translation (Larralde, Smith et al. 2006). ICP27 
will be discussed in more detail later. 
ICP4 
Similar  to  ICP27,  ICP4  is  an  essential  regulatory  protein  in  all  experimental 
systems (in vitro and in vivo). The RS1 gene, which is present in two copies in the 
viral  genome,  encodes  this  175-kDa  protein.  Multiple  functional  domains  within 
ICP4 have been identified, e.g. domains for transactivation, dimerisation, nuclear 
localisation, repression, and DNA binding. It is the major transcriptional regulator of 
HSV-1 (DeLuca, McCarthy et al. 1985). ICP4 is necessary to transactivate most, if 
not  all,  E  and  L  genes  (Roizman  and  Knipe  2001).  ICP4  is  a  transcriptional 
transactivator for viral genes of every class. The DNA binding domain is absolutely 
required for this but there is eveidence that if is not sufficient. ICP4 binds DNA 
even at sequences that are degenerate compared to the consensus binding site. 
Both the TATA box and initiator (INR) elements are required for ICP4's activation 
of  viral  late  promoters  (Gu  and  DeLuca  1994;  Kim,  Zabierowski  et  al.  2002). 
Recent  evidence  has  suggested  that  ICP4  may  also  regulate  chromatin 
remodelling,  giving another  avenue  for this  protein to  regulate  gene expression 
(Everett, Sourvinos et al. 2003). ICP4 has also been demonstrated to repress the 
activity of the latency promoters, either on its own or in combination  with ICP0 
(Batchelor and O'Hare 1990; Goins, Sternberg et al. 1994). It has been shown that 
ICP4 is required for efficient HSV-1 reactivation in infected neuronal cells but ICP0 
is not required for efficient stress-induced reactivation (Miller, Danaher et al. 2006). 
 
ICP22 and US1.5 
ICP22  is  non-essential  for  viral  growth  but  has  been  demonstrated  to  promote 
efficient  late  gene  expression  in  a  cell  type  dependent  manner.  The  carboxy 
terminus  of ICP22 is also  encoded by a second overlapping transcript that has 
been  designated  as  US1.5  (Carter  and  Roizman  1996).  Analysis  of  ICP22  and 
US1.5 has shown that viruses containing a deletion of the amino terminal portion of 
ICP22,  i.e.  the  domains  unique  to  ICP22,  are  avirulent  in  experimental  animal 
systems (Ogle and Roizman 1999).  Other domains in the amino terminus have 
also been identified, including a putative nuclear localisation signal and a domain                                                                                                                    Chapter 1, Introduction                 
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that interacts with a cellular protein, p78.  Domains in the carboxy portion of ICP22 
common  to  both  ICP22  and  US1.5  are  necessary  for  optimal  expression  of  a 
subset of late genes, and virus mutants lacking these domains are also avirulent in 
animal  models  of  infection.    ICP22  has  been  implicated  in  the  production  of  a 
unusually  phosphorylated form  of cellular RNA polymerase II  (Rice, Long  et al. 
1995; Long, Leong et al. 1999). 
ICP47 
ICP47  is  one  of  the  IE  gene  that  is  not  essential  for  replication  and  is  a  non-
regulatory IE gene (Mavromara-Nazos, Ackermann et al. 1986). It is supposed that 
it has immunological capacity allowing virus to escape from the host defence. It is 
known to inhibit antigen presentation to CD8- T lymphocytes, possibly providing a 
mechanism by which HSV-1 escapes immune surveillance by the host (York, Roop 
et  al.  1994)  and  HSV-1  modulates  antigen  processing  at  the  level  of  the 
transporters of antigen processing (TAP) (Hill, Jugovic et al. 1995).  
1.2.7.2  Early gene products 
The next proteins to be made in the gene expression cascade are those, which are 
encoded by the early genes. It seems that between about 4 to 8 hpi the b proteins 
are expressed at peak rates. These are made before viral DNA replication, and 
therefore include enzymes involved in DNA metabolism (such as thymidine kinase 
[TK] and ribonucleotide reductase [RR]) as well as enzymes, which are involved 
directly in DNA replication (such as DNA polymerase and DNA helicase). The tk 
gene, which apparently contains all of the cis-acting regulatory elements sufficient 
for expression in the eukaryotic cell, is not expressed when present in the viral 
genome  until  HSV  IE  proteins  are  synthesised.  It  has  become  clear  from 
subsequent studies that not only is ICP4 necessary for expression of the tk gene in 
the viral genome, but also that this transactivation is mediated through the TATA 
element of the tk promoter (Imbalzano, Coen et al. 1991). 
1.2.7.3  Late gene products 
Expression of the L genes is activated by the IE genes. They are expressed at 
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intimately linked, since inhibition of DNA replication also inhibits L gene expression 
and prolongs the expression of E genes. These include structural proteins, which 
are required to form viral particles, as well as VP16 and vhs, which become part of 
the tegument. Like most of the IE and E promoters, L promoters require a TATA 
element, and there seems to be no difference between L promoter TATA elements 
and other viral or eukaryotic TATA elements that account for temporal expression 
(Steffy  and  Weir  1991;  Imbalzano  and  DeLuca  1992;  Perera  2000).    ICP4  is 
necessary for the activation of L gene expression. Further, it has been shown that 
the viral regulatory proteins ICP4 and ICP22 co-localise with RNA Polymerase II 
and viral DNA replication protein late in infection (Leopardi, Ward et al. 1997). The 
DNA binding protein ICP8 is required for L gene expression. The role of ICP8 in L 
gene  expression has  been  difficult to separate from its  role in DNA replication, 
since it is one of the viral proteins absolutely required for replication. Some ICP8 
mutants inhibit L gene expression to a far greater extent than they inhibit viral DNA 
replication, suggesting a more direct role in L gene expression (Chen and Knipe 
1996; McNamee, Taylor et al. 2000).  
1.2.7.4  Assembly and budding 
Following the expression of the L genes, the replicated viral DNA is cleaved into 
genome length units and packaged into the capsids. Capsids then bud through 
areas  of the nuclear envelope that have been modified with viral glycoproteins, 
thus forming the viral envelope. The newly synthesised virions then pass through 
the ER and the cytoplasm and into the  extracellular space. The  observation  of 
partially enveloped virions at cytoplasmic membranes has led to the suggestion 
that some virions may lose and re-acquire their envelopes during transit through 
the  ER.  The  first  newly  formed  capsids  appear  in  the  nucleus  within  6  hrs  of 
infection and the entire lytic cycle takes approximately 10 hrs (Roizman and Knipe 
2001; Mettenleiter 2002). 
1.2.8  The latent life cycle 
HSV-1 enters sensory neurons innervating the cells of the mucosal membranes.  It 
is  then  transported  to  the  neuronal  cell  body  where  it  is  able  to  persist  in  an 
episomal state for the lifetime of the host. This is characterised by the continued                                                                                                                    Chapter 1, Introduction                 
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presence of the viral genome, in the absence of viral gene expression except for 
latency associated transcripts (LATs) (Stevens, Wagner et al. 1987; Roizman and 
Knipe  2001).  Indeed,  in  the  case  of  HSV-1,  no  virally  encoded  functions  are 
required for establishment of the latent state. Neurons that are latently infected by 
HSV-1 contain 10 or more viral genomes per cell. There are two suggestions that 
either several viruses infect each cell or the cellular machinery replicates HSV-1 
DNA during the latency period. Roizman and colleagues have shown that the HSV-
1 genome contains a host dependent origin of DNA replication (ie, an origin that 
utilises  cellular  DNA  polymerase)  that  could  support  the  second  idea.  The 
molecular  biology  of  HSV-1  latency  remains  rather  unclear.  Only  a  single  viral 
promoter appears to remain active during latency, and this drives expression of 
non-coding  RNA  species  that  have  been  designated  latency-associated 
transcripts. The function of these transcripts remains unclear however there is a 
hypothesis  that  on  LATs  function  to  cause  a  block  to  IE  expression.  Periodic 
reactivation of HSV-1 can occur, leading to lytic infections in the same dermatomal 
distribution as the initial infection. Reactivation can occur spontaneously or can be 
induced by stress and other signals, either directly to the neurons or to the whole 
organism (Stevens, Wagner et al. 1987; Roizman and Knipe 2001). 
1.2.9  Virus host shut off function 
HSV-1 induces early and delayed shut-off of host cell protein synthesis. Host shut-
off is  achieved largely through the complementary actions  of two viral proteins, 
virion host shut-off (vhs) and ICP27. The tegument vhs that is encoded by gene UL 
41 is involved in early infection host shut-off. Vhs causes the degradation of pre-
existing and newly transcribed mRNA during early infection but in later infection it 
will  be  inactived  by  another  viral  protein,  VP16.  However,  vhs  does  not 
discriminate  between  viral  and  cellular  mRNAs.  It  shows  nuclease  activity  and 
functions as an endoribonuclease in the absence of other cellular or viral proteins. 
Two distinct pathways defined for global shutoff include: decline in the level of host 
mRNA  and  alteration  of  the  function  of  the  host  translational  apparatus  by 
interaction with eIF4H and eIF4B (Smibert, Popova et al. 1994; Karr and Read 
1999; Doepker, Hsu et al. 2004; Taddeo and Roizman 2006; Taddeo, Zhang et al. 
2006). ICP27 is the second factor that is implicated in host shutoff by inhibiting                                                                                                                    Chapter 1, Introduction                 
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cellular mRNA biogenesis through preventing pre-mRNA splicing and may have a 
direct effect on translation (Doepker, Hsu et al. 2004; Larralde, Smith et al. 2006).        
 
1.3  The HSV-1 ICP27 protein 
1.3.1  General features 
ICP27 (IE63) is an immediate early (IE), multifunctional regulatory protein of 512 
amino  acids,  which  is  required  for  HSV-1  productive  infection.  This  63  KDa 
phosphoprotein is essential for appropriate expression of viral early and late gene 
products  and  contributes  to  the  shutoff  of  host  protein  synthesis.  It  has 
counterparts  in  every  herpesvirus  sequenced  and  is  a  potential  antiviral  target. 
ICP27 acts at both transcriptional and posttranscriptional levels (Figure 1.6) and is 
an RNA binding protein that inhibits pre-mRNA splicing, stimulates pre-mRNA 3' 
processing,  affects  mRNA  stability,  shuttles  between  the  nucleus
  and  the 
cytoplasm  and  promotes  viral  RNA  nuclear  export.  ICP27  directly  stimulates 
mRNA translation, interacts with various cellular proteins including, export factor 
REF and cellular mRNA export receptor TAP to export mRNA (Dai-Ju, Li et al. 
2006; Larralde, Smith et al. 2006).  
1.3.2  Transcriptional properties of ICP27 
It is appears that ICP27 contributes to the transcriptional regulation of HSV-1 early 
and late genes (Uprichard and Knipe 1996; Jean, LeVan et al. 2001). It has been 
shown that ICP27 mutant viral infections severely reduced accumulation of early 
and late gene products (Rice, Long et al. 1995; Jean, LeVan et al. 2001; Lengyel, 
Guy et al. 2002). However, the mechanism by which ICP27 stimulates transcription 
has  not  been  fully  elucidated.  ICP27  has  a  role  in  recruiting  cellular  RNA 
polymerase II (RNAP II) to sites of HSV-1 transcription by binding to the C-terminal 
domain of RNAP II. In cells infected with ICP27 mutant that do not interact with 
RNAP  II,  levels  of  the  viral  transcripts  are  reduced  in  comparison  to  wild  type 
infection.  Thus,  ICP27’s  role  in  transcription  may  be  linked  to  its  role  in                                                                                                                    Chapter 1, Introduction                 
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posttranscriptional regulation (Dai-Ju, Li et al. 2006). There is certain evidence that 
ICP27 interacts directly with ICP8 and plays a role in the stimulation of late gene 
transcription (Olesky, McNamee et al. 2005). 
1.3.3  Posttranscriptional properties of ICP27 
Posttranscriptional activities of ICP27 are revealed below.  
1.3.3.1  ICP27 inhibits splicing of host cell mRNAs 
At the early stage of HSV-1 infection ICP27 is involved in the inhibition of pre- 
mRNA  splicing  (Hardwicke  and  Sandri-Goldin  1994;  Hardy  and  Sandri-Goldin 
1994) and has been shown to inhibit splicing in the absence of other viral factors 
(Lindberg and Kreivi 2002). In contrast with cellular mRNAs, most HSV-1 mRNAs 
are intronless except four that are intron containing and require splicing. This down 
regulation  ability  of  ICP27  on  splicing  contributes  to  host  cell  protein  synthesis 
shut-off (Sacks, Greene et al. 1985). However, the mechanism of splicing inhibition 
is not yet understood but interaction of ICP27 with various cellular proteins that are 
involved  in  splicing  has  been  demonstrated.  ICP27  interacts  with  small  nuclear 
ribonucleoprotein particles (snRNPs) and co-localises with redistributed snRNPs 
that are directly involved in splicing reactions. This interaction is not sufficient to 
inhibit splicing (Martin, Barghusen et al. 1987; Phelan, Carmo-Fonseca et al. 1993; 
Sandri-Goldin, Hibbard et al. 1995; Sandri-Goldin and Hibbard 1996; Nilsen 2003). 
ICP27 interacts with different pre-mRNA processing factors including SR proteins 
(splicing regulatory factors) SRPK1 (SR protein kinase 1), p32 (an inhibitor of the 
SF2/ASF SR protein), SAP145 (spliceosome-associated protein 145, an essential 
splicing complex assembly factor) and mediates inhibition of splicing that could be 
significant part of host shut-off. The mechanism and functions of these interactions 
is under investigation (Gui, Tronchere et al. 1994; Bryant, Matthews et al. 2000; 
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  20 
1.3.3.2  ICP27 increases RNA 3’ processing at weak poly (A) sites of HSV-
1 mRNAs 
The  3′  ends  of  almost  all  eukaryotic  mRNAs  and  their  precursors  consist  of 
homopolymeric  tails  of  adenosine,  or  poly  (A)  that  are  added  by  poly  (A) 
polymerase (PAP) during the process of 3′ end formation. Experimental studies 
demonstrated expression of ICP27 alone increases the usage of certain poly (A) 
sites, specifically  the late genes, to stimulate RNA 3’ processing (McLauchlan, 
Simpson  et  al.  1989;  Sandri-Goldin  and  Mendoza  1992).  Further,  a  UV  cross-
linking  study  of  protein-RNA  interactions  showed  a  direct  role  of  ICP27  in 
enhancing the binding of the polyadenylation factor (CstF) to viral RNA poly (A) 
sites from all temporal classes. CstF acts to promote and stabilise polyadenylation 
complex  formation  and  virus  infection  in  the  absence  of  ICP27  resulted  in  lost 
binding enhancement of CstF. ICP27-induced stimulation of 3’ end processing was 
observed in certain late genes with weak poly (A) sites but not for a number of IE 
and E transcripts with strong poly (A) sites (McGregor, Phelan et al. 1996).  
1.3.3.3  Nucleocytoplasmic properties of ICP27 
The  association  of  ICP27  with  redistributed  snRNPs  on  intron-containing 
transcripts suggested an involvement of this multifunctional protein in regulation of 
nucleocytoplasmic  RNA  shuttling  (Phelan,  Dunlop  et  al.  1996).  Many  studies 
showed ICP27 shuttles between the nucleus and cytoplasm and has a direct role 
in  nuclear  export  of  viral  RNAs.  This  is  via  its  binding  with  intronless  viral  and 
cellular mRNAs (Phelan and Clements 1997; Soliman, Sandri-Goldin et al. 1997; 
Sandri-Goldin  1998;  Koffa,  Clements  et  al.  2001).  It  has  been  shown  that  two 
motifs of ICP27, an RGG box and a leucine-rich region nuclear export signal (NES) 
are putatively involved with RNA binding and export (Sandri-Goldin 1998; Lengyel, 
Guy et al. 2002). Experimental studies by using leptomycin B (LMB) that inhibits 
the CRM 1 export pathway and ICP27 mutants demonstrated these regions are 
required but not essential for nucleocytoplasmic transport of RNAs. So there must 
be pathways for export of viral RNAs other than the CRM 1 pathway(Phelan and 
Clements 1997; Soliman and Silverstein 2000; Koffa, Clements et al. 2001; Chen, 
Sciabica  et  al.  2002;  Lengyel,  Guy  et  al.  2002;  Chen,  Li  et  al.  2005;  Thiry, 
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receptor  (TAP)  mediated  that  associates  with  an  RNA-binding  protein  REF,  a 
component of the exon junction complex. It has been shown that ICP27 binds to 
viral mRNAs and interacts directly with REF as an adaptor protein and indirectly 
recruits TAP to viral mRNAs to stimulate their nuclear export through this cellular 
pathway (Koffa, Clements et al. 2001; Chen, Sciabica et al. 2002; Sandri-Goldin 
2004).  However,  certain  significant  information  about  this  model  is  unclear.  A 
moderate effect of RGG box and REF binding site ICP27 mutants on viral gene 
expression,  transport  by  the  CRM  1  dependent  pathway  and  export  of  some 
transcripts in the absence of ICP27 whose overall expression is ICP27 dependent 
show the TAP pathway is not the only way for export of viral RNAs (Soliman and 
Silverstein 2000; Lengyel, Guy et al. 2002; Pearson, Knipe et al. 2004). On the 
other hand, the role of the KNS domain of ICP27 in transport in not yet clarified. In 
addition, it is though that the tegument protein VP13/14 that contains a NES like 
element and shuttles may also be able to transport RNAs (Michael, Eder et al. 
1997; Donnelly and Elliott 2001). 
1.3.3.4  Translation properties of ICP27 
A  potential  role  of  ICP27  in  viral/host  mRNA  stability  and  translation  was 
demonstrated by investigation of the role of this protein in the cytoplasm. By direct 
or indirect effect on translation, HSV-1  wild type ICP27 stimulates levels of the 
HSV-1 VP16 virion protein and polysomal association of the VP16 RNA (Ellison, 
Maranchuk et al. 2005). ICP27 interacts with two translation initiation factor, eIF-
3G and eIF-4G as well as poly A binding protein 1 (PABP1) and shows promoting 
or  inhibiting  activity  on  translation  via  these  interactions  (Fontaine-Rodriguez, 
Taylor  et  al.  2004).  A  recent  study  in  our  laboratory  showed  ICP27  stimulates 
translation  directly  and  this  activity  correlates  with  its  ability  to  associate  with 
polyribosomes  in  HSV-1  infected  cells.  So  the  C-terminal  domain  of  ICP27  is 
essential to stimulate mRNA translation (Larralde, Smith et al. 2006).  
1.3.4  ICP27 and phosphorylation 
Different phosphorylation sites on ICP27 are suggested and on SDS-PAGE two 
forms of ICP27 could be detectable and up to  5 species by 2D isoelectric focusing 
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during infection and transfection is serine. It has been shown serine 114 is highly 
phosphorylated  by  protein  kinase  A  (PK  A).  But  the  role  of  phosphorylation  of 
ICP27 in infection is unclear (Zhi and Sandri-Goldin 1999). ICP27 interacts with 
casein  kinase  2  (CK2)  and  stimulates  CK2  activity  during  infection  and 
redistributes the holoenzyme from the nucleus to the cytoplasm (Wadd, Bryant et 
al. 1999; Koffa, Kean et al. 2003).  
1.3.5  Putative functional domains of ICP27 
Mutation  studies  on  different  regions  of  the  512  amino  acid  ICP27  protein 
characterised  various  functional  sites  on  this  protein  at  the  N  and  C  terminal 
regions (Figure 1.7). 
1.3.5.1  Essential acidic domain 
Amino acids 4-64 at the amino terminus of ICP27 that are present in all ICP27 
homologues (Figure 1.7) contain a high concentration of acidic residues. Glutamic 
and aspartic acids are the two main amino acids in this region. Deletion of this 
domain (d1-2) suggested an essential function in viral lytic replication. This mutant 
is deficient for growth, defective in viral replication, shows modest decrease in late 
gene expression and a delay in the repression of early genes. This ICP27 mutant 
can repress the expression of the immediate early protein ICP4 and also some late 
proteins, such as ICP15 (Rice, Lam et al. 1993). 
1.3.5.2  Nuclear export signal (NES) 
The nuclear export signal (NES) sequence is located in the acidic region to amino 
acid 3-17 (Figure 1.7) and resembles a leucine-rich NES as identified in the HIV-1 
Rev protein (Fischer, Huber et al. 1995). Resemblance of ICP27 NES to the HIV-1 
Rev NES was shown by the relocation of ICP27 to the cytoplasm after replacing 
the  endogenous  NES  with  that  of  Rev.  Also  mutation  of  the  ICP27  NES  gave 
nuclear retention of ICP27. Similar to the Rev protein NES, in ICP27 the NES is 
enough  to  export  a  heterologous  protein  (Sandri-Goldin  1998).  The  viral  ICP27 
NES mutant is named dLeu and has similar phenotype to d1-2. It is deficient for 
growth and shows a decline in virus yield compared with HSV-1 wild type infection.                                                                                                                    Chapter 1, Introduction                 
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Both dLeu and d1-2 encode mostly nuclear ICP27. This localisation is considerably 
different from wild type ICP27, They are more active in protein synthesis compare 
to  on  ICP27  null  mutant.  These  studies  showed  the  NES  and  acidic  domain 
mutants  can  significantly  stimulate  several  ICP27-dependent  genes  in  vivo  
suggesting they are not totally essential for virus replication (Lengyel, Guy et al. 
2002).  
1.3.5.3  Export control sequence (ECS) 
Residues 31-34 in the acidic domain of ICP27 (Figure 1.7) negatively regulate the 
activity of the NES and  are named the putative export control sequence (ECS) 
(Soliman and Silverstein  2000). On the  other hand,  a mutation  of  50 aa in the 
acidic domain confers viral resistance to LMB, an inhibitor of the CRM-1 nuclear 
export pathway (Murata, Goshima et al. 2001). It has  been suggested that this 
mutation can promote nuclear export by a negative effect on the role of the ECS 
(Soliman and Silverstein 2000; Murata, Goshima et al. 2001). 
1.3.5.4  Nuclear and nucleolar localisation signals (NLS & NuLS) 
Nuclear localisation of ICP27 is mediated mainly through a bipartite NLS, mapped 
at aas 110-137. Mutation at these sites is termed the d3-4 ICP27 mutant (Figure 
1.7). It has been shown that there are several weaker NLSs corresponding to aas 
152-512 in the C-terminus of ICP27 as infection with d3-4 and d1-5 viral mutants 
demonstrated predominant nuclear localisation of ICP27 (Mears, Lam et al. 1995). 
Also ICP27 contains a nucleolar localisation signal (NuLS) mapped to aas 110-152 
composed of a NLS and an arginine-rich sequence (138-152). It was suggested to 
interact  with the cell  nucleoli  and infection  of cells  by  d4-5,  d1-5, and to  some 
extent the d3-4 ICP27, failed to localise protein efficiently to the nucleoli (Lengyel, 
Guy et al. 2002). This data is consistent with the idea that the RGG box (138-152) 
forms part of the ICP27 NuLS (Mears, Lam et al. 1995).  
1.3.5.5  RNA-binding domains: RGG box and KH-like domains 
The RGG box is the structural domain of ICP27 that interacts with RNA (Figure 
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al.  1996)  and  has  been  shown  bind  to  intronless  HSV-1  RNAs  (Sandri-Goldin 
1998).  A  broad  range  of  HSV-1  mRNAs  binds  to  ICP27  through  its  RGG  box 
(Sokolowski,  Scott  et  al.  2003).  This  region  is  rich  in  R  and  G  residues  and 
posttranscriptionally modified by methylation (Mears and Rice 1996). KH domains 
that were identified firstly in hnRNP K as a triple repeat (Siomi, Matunis et al. 1993) 
are found in the C-terminal half of ICP27 and mapped as  KH1 (aa 288-350), KH2 
(368-421)  and  KH3  (451-512).  These  three  RNA  binding  motifs  recognised  in 
ICP27  have  homology to a series  of hnRNP K domains (KH)  based  on limited 
sequence  similarity.  They  are  conserved  in  alphaherpesvirinae  suggesting  their 
functional importance (Soliman and Silverstein 2000). Several ICP27 mutants have 
been made such as M11, M15 and M16 and these affect the function of the KH 
domains. These mutants have nuclear localisation and their shuttling abilities are 
reduced  significantly,  while  M15  cannot  shuttle  between  the  nucleus  and  the 
cytoplasm (Mears and Rice 1998). Further studies showed the M15 mutant impairs 
binding of ICP27  with certain  cellular  partners  and  decreases  the interaction  of 
HSV-1 RNAs with ICP27 in vivo (Bryant, Wadd et al. 2001; Sokolowski, Scott et al. 
2003; Chen, Li et al. 2005).  
1.3.5.6  Putative transport sequence (SADET) 
There  is  a  nucleocytoplasmic  shuttling  signal  (KNS)  located  in  the  hnRNP  K 
protein (Figure 1.7) (Michael, Eder et al. 1997) that has been suggested to mediate 
export  of  RNA  via  a  CRM1-independent  pathway  (Henderson  and  Eleftheriou 
2000). A sequence of ICP27 between the KH2 and KH3 domains (SADET aa 350-
354)  shows  some  similarity  to  KNS  and  is  well  conserved  among  alpha 
herpesvirus homologue proteins (Figure 1.8). 
1.3.5.7  Putative zinc finger, activator and repressor region  
In  vitro  interaction  of  the  C-terminus  (aa  407-512)  domain  of  ICP27  with  zinc 
identified a new function of this protein (figure 1.7) (Vaughan, Thibault et al. 1992). 
Putative zinc fingers are implicated in protein-protein interactions (Fox, Kowalski et 
al.  1998;  Mackay  and  Crossley  1998).  This  ability  of  zinc  fingers  to  interact  is 
shown by self-interaction of ICP27 through these motifs (Wadd, Bryant et al. 1999; 
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(Bryant,  Wadd  et  al.  2001),  splicing  factor  SRp20  (Sciabica,  Dai  et  al.  2003), 
nuclear export factor TAP (Chen, Li et al. 2005), casein kinase 2 (CK2) (Wadd, 
Bryant et al. 1999), RNA Polymerase II (Dai-Ju, Li et al. 2006) and poly (A) binding 
protein 1(Larralde, Smith et al. 2006). Thus the zinc finger domain is involved in 
gene  activation  by  correlation  with  increasing  polyadenylation  and  by  gene 
repression by inhibition (Hardwicke, Vaughan et al. 1989; McMahan and Schaffer 
1990; Chapman, Harris et al. 1992; McLauchlan, Phelan et al. 1992; Sandri-Goldin 
and Mendoza 1992; Hardwicke and Sandri-Goldin 1994). It has been suggested 
that ICP27 self-recognition is important for its function because point mutation of 
the zinc finger domain was lethal to the virus (Zhi, Sciabica et al. 1999). 
1.3.5.8  SM domain 
Embedded  between  and  overlapping  the  KH3  domain  in  the  C-terminal  half  of 
ICP27  (aas  426-488)  is  a  putative  SM  domain  that  is  conserved  among  the 
homologues  (Figure  1.7).  These  proteins  are  involved  in  forming  the  core 
splicosome  complex  through  protein-protein  interaction  (Kambach,  Walke  et  al. 
1999; Soliman and Silverstein 2000). In comparison to wt, HSV-1 ICP27 lacking 
the  SM  motif  is  deficient  for  viral  replication,  delayed  in  host  shut-off,  shows  a 
decrease in the accumulation of IE and E protein and a delay in the appearance of 
L proteins. Importantly, there is a defect in host cell shut off during infection with 
HSV-1 ICP27 lacking the SM motif (Soliman and Silverstein 2000). 
1.3.5.9  Extreme C-terminal GKYF sequence 
An  extreme  C-terminal  GKYF  motif  (aa  504-507)  that  is  conserved  throughout 
ICP27 herpesvirus homologues has a role in interaction with snRNPs (Figure 1.7). 
Mutation of a glycine in amino acid 504 of ICP27 led to loss of this interaction and 
indicated a role in protein-protein interaction (Sandri-Goldin and Hibbard 1996). 
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1.4  ICP27 homologues 
The  only  HSV-1  immediate  early  gene,  which  has  homologues  throughout  the 
Herpesviridae family, is ICP27 (Table 1.3). Although there is sequence similarity 
between  ICP27  homologues,  they  show  diversity  in  their  function.  The  amino 
termini  of herpesvirus ICP27  homologues are  not conserved and contain acidic 
and  basic  residues  however  the  central  region  is  conserved  within  the 
herpesviridae. 
1.4.1  Bovine herpesvirus 1 (BHV-1) ICP27 (BICP27) 
BHV-1 ICP27 is homologue of HSV-1 ICP27 that localises in the nucleus and is 
expressed in the early stage of infection in contrast to HSV-1 ICP27. But like  HSV-
1 ICP27 it is involved in promotion of processing efficiency of mRNAs containing 
weak poly (A) sites (Singh, Fraefel et al. 1996). 
1.4.2  Human cytomegalovirus UL69 (HCMV UL69) 
The  multifunctional  nuclear  phosphoprotein  UL69  of  β  herpesvirus  HCMV  is  a 
homologue of HSV-1 ICP27 but in contrast it is located in the virion and expressed 
during E and L stags of infection. It has a role in transactivating several viral and 
cellular  promoters  and  functions  as  a  nuclear  shuttling  protein.  Unlike  HSV-1 
ICP27, RNA binding is not a prerequisite for UL69-mediated export (Winkler, Rice 
et al. 1994; Winkler and Stamminger 1996; Toth, Lischka et al. 2006). 
1.4.3  Varicella zoster virus (VZV) ORF4 
VZV ORF4 is an IE protein that is essential for replication of the virus and shuttles 
between  the  nucleus  and  cytoplasm  similar  to  its  homologue  ICP27.  ORF4  is 
present in the virion tegument and its RNA and protein are detected in latently 
infected  human  ganglia.  These  two  proteins  have  considerable  amino  acid 
sequence homology and certain similar properties such as self-interaction, RNA 
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(Moriuchi,  Moriuchi  et  al.  1994;  Baudoux,  Defechereux  et  al.  2000;  Cohen, 
Krogmann et al. 2005). 
1.4.4  Human herpesvirus 8 (HHV-8) ORF57 
HHV-8 ORF57 is an essential regulatory protein. It is expressed from one of the 
few spliced mRNAs of HHV-8 in the lytic cycle and is homologous to ICP27. It 
localises in the nucleus and shuttles between the nucleus and cytoplasm using 
CRM1-dependent and cellular export TAP pathways. A number of ICP27 partner 
proteins  also  interact  with  ORF57  including  hnRNP  K,  CK2  and  REF  (Bello, 
Davison et al. 1999; Lukac, Kirshner et al. 1999; Malik, Blackbourn et al. 2004; 
Malik, Blackbourn et al. 2004; Malik and Clements 2004). 
1.4.5  Herpesvirus saimiri (HVS) ORF57 
The  multifunctional  regulatory  protein  ORF57  is  involved  in  activation  and 
repression  of E and L gene expression by its C-terminal domain. It has limited 
homology with ICP27. Similar to ICP27, HVS ORF57 shuttles between the nucleus 
and cytoplasm, binds to viral RNA and exports it. It has been demonstrated that 
ORF57 binds to importin-α as an adaptor by its NLS and importin-β as a transport 
receptor, which is important for efficient viral RNA export (Whitehouse, Cooper et 
al. 1998; Goodwin, Hall et al. 2000; Goodwin and Whitehouse 2001). 
1.4.6  Epstein- Barr virus (EBV) SM protein  
EBV SM protein has about 30% homology with ICP27 protein and transactivates 
expression of intronless reporter gene and transrepresses intron containing genes. 
It is essential for virion production. SM protein binds to RNA in vitro and in vivo and 
shuttles between nucleus and cytoplasm. Conflicting reports showed SM protein 
export  mediated  via  CRM  1  or  TAP  pathways  (Cook,  Shanahan  et  al.  1994; 
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1.5  ICP27 partner proteins 
ICP27  binds  to  several  cellular  proteins  (summarised  in  Table  1.4)  that  are 
involved in its functions. 
1.5.1  hnRNP K 
Heterogeeous  ribonucleoprotein  K  is  a  multifunctional  protein  with  three  K-
homology domains (KH) that mediate DNA and RNA binding and contains both 
nuclear localisation (NLS) and nuclear shuttling domains (KNS). Based on these 
domains it was supposed that the hnRNP K protein is implicated in multiple steps 
of gene expression including transcription, RNA splicing and translation (Matunis, 
Matunis  et  al.  1992;  Dejgaard,  Leffers  et  al.  1994;  Bomsztyk,  Denisenko  et  al. 
2004). hnRNP K co-immunoprecipitated with anti-ICP27 antibody and interaction of 
ICP27 with this protein was confirmed by yeast-two hybrid system (Y2-H) (Wadd, 
Bryant et al. 1999). The SADET sequence is perfectly conserved between KNS 
and ICP27 suggesting the possibility of utilisation of the same transport pathway 
and direct interaction with nucleoprotein complexes (Michael, Eder et al. 1997). 
1.5.2  RNA export adaptor protein (REF) 
REF is a part of the exon junction complex (EJC) laid down on mRNAs during 
splicing and involved in nonsense-mediated decay (NMD) (Gatfield, Le Hir et al. 
2001).  This  protein  shuttles  between  the  nucleus  and  the  cytoplasm  and  binds 
directly to both mRNA and TAP (Rodrigues, Rode et al. 2001). REF interacts with 
ICP27 (Chen, Sciabica et al. 2002). ICP27 recruits REF to intronless viral RNAs, 
indirectly  recruits  TAP  and  stimulates  viral  mRNAs  nuclear  export  through  a 
cellular mRNA export pathway (Koffa, Clements et al. 2001). 
1.5.3  RNA export receptor protein TAP/NXF1  
TAP  is  a  619-aa
  cellular  protein  that  is  a  potential  export  receptor  for  cellular 
mRNA. It shuttles between nucleus and cytoplasm and associates with p15 as a 
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nucleoporins with TAP has been identified. TAP interacts with NUP 62, NUP 98, 
NUP  153  and  NUP  214/CAN.  It  has  been  demonstrated  TAP  interacts  with  a 
constitutive  transport  element  (CTE)  that  is  present  in  the  RNAs  of  type  D 
retroviruses and has a role in mRNA export (Gruter, Tabernero et al. 1998; Bear, 
Tan  et  al.  1999;  Bachi,  Braun  et  al.  2000;  Tan,  Zolotukhin  et  al.  2000;  Braun, 
Herold et al. 2001; Katahira, Straesser et al. 2002; Herold, Teixeira et al. 2003). 
TAP interacts with ICP27 and the C-terminus of ICP27 is required for this binding 
(Chen, Li et al. 2005). ICP27 recruits TAP to viral mRNAs and utilises the TAP 
pathway to export viral mRNAs (Koffa, Clements et al. 2001). 
1.5.4  Casein kinase 2 (CK2) 
CK2  is  known  to  phosphorylate  more  than  200  proteins  and  is  involved  in 
processes  such  as  transcriptional  control,  apoptosis  and  cell  cycle  regulation 
(Dobrowolska,  Lozeman  et  al.  1999).  ICP27  has  been  shown  bind  to  CK2  b 
subunit by the C-terminus zinc finger and the arginine rich part of ICP27 using 
immunoprecipitation  and  Y2-H  assay  (Wadd,  Bryant  et  al.  1999).  Interaction  of 
ICP27  with  CK2  stimulates  activity  of  ICP27  at  early  times  of  infection  and 
redistributes the CK2 from the nucleus to the cytoplasm (Koffa, Kean et al. 2003).  
1.5.5  Spliceosomal associated protein 145 (SAP 145) 
SAP145 is one of the essential components of the spliceosome that binds to pre-
mRNA. SAP145 interacts with ICP27 and causes host cell shut off by inhibiting 
splicing (Champion-Arnaud and Reed 1994; Bryant, Wadd et al. 2001). 
1.5.6  p32 
p32 was first isolated as a protein tightly associated with ASF/SF2 purified from 
HeLa cells (Krainer, Conway et al. 1990). p32 regulates RNA splicing by inhibiting 
ASF/SF2 RNA binding and phosphorylation (Petersen-Mahrt, Estmer et al. 1999). 
The p32 that co-immunoprecipitated with ICP27 is phosphorylated by CK2, which 
is precipitated with ICP27. Immunofluorescence studies showed that colocalisation 
of ICP27 with p32 alters the distribution of p32 to the nucleus. It seems ICP27 can 
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1.5.7  Cellular RNA polymerase II (RNAP II) and ICP8 
Cellular  RNAP  II  transcribes  all  viral  genes  and  ICP8  is  a  single  strand  DNA 
binding protein that down regulates transcription from the parental viral genome 
(Godowski and Knipe 1986).Complex formation of ICP27, ICP8 and RNAP II has 
been  demonstrated  (Zhou  and  Knipe  2002).The  direct  ICP27-ICP8  interaction 
plays a role in the stimulation of late gene transcription (Olesky, McNamee et al. 
2005). Herpes simplex virus 1 (HSV-1) ICP27 has been shown to interact with the 
C-terminal domain (CTD) of RNAP II and  ICP27 mutants that cannot interact fail to 
relocalise RNAP II to viral transcription sites, suggesting a role for ICP27 in RNAP 
II recruitment (Dai-Ju, Li et al. 2006). 
 
1.6  Nucleocytoplasmic transport 
1.6.1  General feature 
All nucleocytoplasmic transport of macromolecules between the cytoplasm and the 
nucleus  is  mediated  by  at  least  three  different  classes  of  soluble  transport 
receptors. These include members of the importin-β protein family (the importins 
and exportins, also termed karyopherins), the TAP/Mex67 family that contribute in 
export of mRNA and the small nuclear transport factor 2 (NFT2), which imports the 
small GTPase Ran into the nucleus. Cargoes shuttle between the cytoplasm and 
the nucleus via the nuclear pore complex (NPC).  All nuclear transport factors can 
bidirectionally  traffick  through  the  nuclear  pore  complex  by  specific  interactions 
with  phenylalanine/glycine  (FG)-rich  nuclear  pore  complex  components  called 
nucleoporins  (NUPs)  (Conti  and  Izaurralde  2001;  Kuersten,  Ohno  et  al.  2001; 
Macara  2001;  Weis  2002).  Trafficking  of  cargos  via  the  NPC  is  carried  out  by 
mobile transport machinery. These interaction with the NPC components which is 
highly selective and consume energy, could be regulated by signalling pathways 
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1.6.2  Protein transport 
In general proteins containing nuclear localisation signal (NLS) or nuclear export 
signal  (NES)  bind  to  transport  receptors  termed  karyopherins  (kaps,  importins, 
exportins or transportins) and make a complex of transporter and cargo that dock 
to  nucleoporins  and  translocates  from  the  nuclear  or  cytoplasmic  side  of 
nucleopore  complex  (NPC).  Then  a  small  GTPase,  Ran,  plays  a  main  role  to 
interact  with  karyopherins  and  triggers  the  dissociation  of  import  complexes  or 
stabilises the assembly of export complexes to exit the nucleus (Figure 1.9) (Cole 
and Hammell 1998; Suntharalingam and Wente 2003; Weis 2003).  
1.6.3  RNA export 
mRNAs are transcribed from DNA in eukaryotic cells as pre-mRNA which is then 
processed to mature mRNA before being translated into protein in the cytoplasm. 
RNA polymerase
 II is the enzyme that is involved in pre-mRNA synthesis in the 
nucleus.  Pre  mRNA  is  processed  by  capping  at  the  5’  end  cleavage  and 
polyadenylation  to  form  the  3’  end.  Concomitant  with  these  processes,  splicing 
action  place  to  remove  non-coding  intervening  sequences.  For  translation  and 
protein  synthesis  in  the  cytoplasm  the  processed  mRNAs  should
  be  exported 
through  the  nuclear  pore  complex  (NPC).  In  fact,  traffick  of  mRNAs  from  the 
nucleus to the cytoplasm requires different steps including processing, packaging, 
recognition by export factors and accomodation through the
 NPC (Chen, Sciabica 
et al. 2002). Biochemical and genetic approaches have shown that three classes of 
factors are implicated for mRNA
 export: the adapter proteins, which bind to the 
mRNA directly, receptor
 proteins that recognise and interact to adapter proteins, 
and  nucleoporins  (NUPs)  that  mediate  translocation  and  shuttling  across  the
 
nuclear membrane (Komeili and O'Shea 2001; Zenklusen and Stutz 2001). There 
are  two  main  export  pathways  identified  for  mRNA  transport,  CRM1  and  TAP. 
CRM1 export receptor (exportin 1) is involved in export by recognition of the NES, 
however it is not the major contributor to mRNA export in metazoans or yeast and 
exports  only  a  small  subset  of  mRNA.  CRM1  also  mediates  nuclear  export  of 
proteins, snRNAs and rRNAs (Fischer, Huber et al. 1995; Fornerod, Ohno et al. 
1997; Cullen 2000; Weis 2003). The best candidate for mRNA export could  be                                                                                                                    Chapter 1, Introduction                 
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TAP, a cellular receptor protein that shuttles between the nucleus and cytoplasm. It 
can be cross-linked to poly (A) RNA, is localised at the nuclear pores, and interacts 
directly with the nucleoporins. It has been shown to have a direct role in mRNA 
export  (Figure  1.10  and  table  1.6)  (Segref,  Sharma  et  al.  1997;  Santos-Rosa, 
Moreno et al. 1998; Kang and Cullen 1999; Herold, Suyama et al. 2000; Braun, 
Herold et al. 2001).  
1.6.4  Viral interaction with the nuclear transport machinery  
Use  of  viruses  is  an  invaluable  tool  in  discovery  of  nuclear  transport  routes. 
Viruses,  especially  RNA  viruses,  need  to  control  the  transport  machinery  for 
successful  replication in hosts. Disruption of the transport system is part of the 
cytopathogenic ability of viruses to prevent the host antiviral response (Fontoura, 
Faria et al. 2005). Poliovirus infection inhibits nuclear import of cellular proteins by 
targeting  the  karyopherina/b1  and  karyopherinb2  pathways  which  are  usually 
utilised for protein import. Thus poliovirus infection acts by degradation of certain 
nucleoporins such as NUP 153 and NUP 62 that result in disruption of the nuclear 
pore  complex  structure  (Gustin  and  Sarnow  2001).  The  next  example  is  the 
Vesiculoviral matrix protein M (VSV M) that induces a disruption in cellular mRNA 
export  by  interacting  with  the  Rae1.  Rae1  is  the  mRNA  export  factor  that  is 
essential  for  successful  export  of  cellular  mRNA  via  binding  to  nucleoporin  98 
(Faria, Chakraborty et al. 2005). In hepatitis C, disruption of the karyopherin b3  
pathway is a target for protein 5A that is suggested to interact with karyopherin b3 
and inhibits host gene expression (Chung, Lee et al. 2000). In the case of DNA 
viruses, in human subgroup C adenovirus, two important proteins E1B and E4 Orf6 
function at least in the selective export of viral mRNAs. They could block the export 
of cellular mRNAs and induce of viral mRNA export (Flint and Gonzalez 2003). 
Finally, ICP27 and its homologues in some herpesviruses cellular pathway TAP 
that  interacts  with  Aly/REF  and  recruits  viral  mRNA  to  translocate  in  NPC  and 
export it to cytoplasm. It has been shown that ICP27 does not interfere with export 
of  cellular  mRNAs,  UsnRNAs  or  tRNAs  (Koffa,  Clements  et  al.  2001;  Chen, 
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1.6.5  ICP27 and viral mRNA export 
Most of HSV-1 transcripts are intronless and multifunctional ICP27 is involved in 
the export of viral mRNAs. At later time during infection, ICP27 shuttles between 
the nucleus and cytoplasm. The RGG box domain is involved with viral intronless 
mRNA binding and the three KH-like domains are involved in RNA binding affinity 
and specificity (Mears and Rice 1996; Sandri-Goldin 1998; Soliman and Silverstein 
2000). ICP27 binds to splicing related (SR) proteins as well as showing a direct 
interaction  with  other  spliceosomal  components  including  Aly/REF  as  a  RNA 
export  adaptor  (Bryant,  Wadd  et  al.  2001;  Koffa,  Clements  et  al.  2001;  Chen, 
Sciabica et al. 2002; Sciabica, Dai et al. 2003). Amino acids 104-138 of ICP27 that 
have  an  overlap  with  the  NLS  are  involved  with  REF  interaction  showing  this 
domain is important for import of ICP27 to the nucleus and export of ICP27-bound 
viral RNAs to the cytoplasm. A direct role of Aly/REF in HSV-1 RNA export and 
and its stimulation by ICP27 has been demonstrated (Koffa, Clements et al. 2001; 
Chen, Sciabica et al. 2002). Recent experiments showed Aly/REF is dispensable 
for  mRNA  export  in  some  organisms  (Gatfield  and  Izaurralde  2002;  Longman, 
Johnstone et al. 2003) and it is certainly possible that there is involvement of other 
adaptor  proteins  in  HSV-1  RNA  export  (Sandri-Goldin  2004).  Although  the  C-
terminal  domain  of ICP27  has been  shown to  interact  with  TAP/NXF1  and this 
protein  is  required  for  ICP27  export,  ICP27  does  not  facilitate  export  of  viral 
intronless RNAs directly via TAP/NXF1 (Chen, Sciabica et al. 2002; Chen, Li et al. 
2005).  In  contrast  ICP27  interacts  with  REF,  recruits  TAP  to  viral  mRNAs  and 
stimulates  their  nuclear  export  via  a  cellular  mRNA  export  pathway  (Koffa, 
Clements et al. 2001). The TAP transport pathway is the major route for HSV-1 
mRNA export to the cytoplasm but some recent evidence indicates the possibility 
of ICP27 independent HSV-1 RNA export and other export factors may have a role 
to play (Sandri-Goldin 2004) (Figure 1.11).     
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1.7  Nuclear pore complex (NPC) 
1.7.1  General features and function   
NPCs are very large protein complexes; surrounded by the two membranes of the 
nuclear envelope and stably anchored in the nuclear envelope. This structure is 
conserved  in  all  eukaryotes  (Figure  1.12).  Each  vertebrate  NPC  is  an 
approximately 120 MDa structure consisting of about 30 different proteins termed 
nucleoporins (NUPs) (Table 1.5). It serves as gateways of communication between 
the nucleus and cytoplasm. Most NUPs are present in multiple copies per NPC 
and are located symmetrically on both faces and a few are on either the nuclear or 
cytoplasmic faces asymmetrically (Fahrenkrog and Aebi 2003; Rout, Aitchison et 
al. 2003; Fahrenkrog, Koser et al. 2004). The essential role of NUPs is providing 
docking sites for soluble transport receptors, which mediate the translocation of 
proteins and RNA cargoes through the nuclear pore complex. It has been shown 
that  the  central  gated  channel  of  the  NPC  is  very  stable,  whereas  most  of 
peripheral  components  in  the  nuclear  and  cytoplasmic  faces  exhibited  more 
dynamic behaviour that are consistent with their function as a structural scaffold, 
and adaptor as well as certain regulatory functions (Figure 1.13) (Rabut, Doye et 
al.  2004).  Typically  NUPs  are  organised  in  distinct  subcomplexes  (Lim  and 
Fahrenkrog 2006). One-third of the identified vertebrate and yeast nucleoporins 
termed FG-repeats NUPs, are directly associated in binding to transport receptors 
(Stewart, Baker et al. 2001). The FG-repeats often are part of larger motifs, such 
as GLFG or FxFG. The FG-repeats usually are clustered in FG-rich regions, in 
which  the  individual  hydrophobic  repeats  are  separated  by  a  hydrophilic  linker 
(Figure  1.14).  It  has  been  shown  that  the  FG-rich  regions  of  some  bacterially 
expressed recombinant nucleoporins are flexible and largely unstructured (Bayliss, 
Littlewood et al. 2000; Denning, Uversky et al. 2002). In addition to binding assay 
studies, X-ray crystallography has shown interactions between nuclear transport 
factors and FG repeat nucleoporins. Involvement of FG-rich nucleoporin fragments 
in complex with the N-terminal fragment of importin-β (Bayliss, Littlewood et al. 
2000; Bayliss, Littlewood et al. 2002), the Ran nuclear import factor NTF2 (Bayliss, 
Leung  et  al.  2002),  and  the  NTF2  like  domain  of  TAP/NXT1  has  been 
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appear  to  be  primarily  hydrophobic.  These  interactions  are  mediated  by  the 
phenylalanine of the FG-repeat, which is inserted into a hydrophobic pocket. In the 
case  of  TAP,  the  interaction  of  NUPs  with  TAP/NXT1  is  mediated  by  a  single 
phenylalanine of the FG sequence inside a hydrophobic pocket of the NTF2 like 
domain of TAP. Interestingly, both importin-β and TAP have a second nucleoporin 
binding region in their C-terminal part that is important for their transport activity 
(Bednenko, Cingolani et al. 2003). FG-repeat NUPs are natively unfolded and this 
property may be vital for fast transport rates through the NPCs. This form of the 
FG-NUP structure is postulated to pose a substantial barrier to nonreceptor cargo 
while providing for a high FG-density interaction zone for receptor-mediated cargo 
(Lim,  Aebi  et  al.  2006;  Lim  and  Fahrenkrog  2006).  Indeed,  FG-repeat  regions 
exhibit a high degree of flexibility and mobility (Paulillo, Phillips et al. 2005), with on 
ability to simultaneous interact with several binding partners (Allen, Huang et al. 
2001).  They  also  promote  fast  molecular  association  and  dissociation  rates  to 
facilitate transport of the proteins and RNAs via NPCs (Gilchrist, Mykytka et al. 
2002). (Figure 1.14 & 1.15). 
1.7.2  Nucleoporin 214/CAN 
The vertebrate nucleoporin 214/CAN is a FG-repeat NUP that is located in the 
cytoplasmic face of the NPC (Figure 1.13). This putative oncogene NUP has three 
domains: the N-terminal domain of NUP 214/CAN localises to the cytoplasmic face 
of the NPC, the central domain associate with NUP 88 that binds to NUP 98, a 
mobile NUP that shuttles between nucleus and cytoplasm, and is located at the 
nuclear ring of the NPC near the entry to the central pore, and the C-terminal FG-
repeat domain that localises in both the nuclear and cytoplasmic faces of the NPC. 
The multiple location of the C-terminus indicates a flexible property of the NUP 
214/CAN FG-repeat domain (Paulillo, Phillips et al. 2005).The C-terminal domain 
of NUP 214 interacts with various transport factors and has  been shown to  be 
involved in both nuclear import and export. The importance of this NUP is shown 
by genetic depletion of NUP 214 in mice that causes early embryonic death. In 
fact, reduction in NLS-mediated protein import, and strong nuclear poly (A) RNA 
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Deursen,  Boer  et  al.  1996;  Fornerod,  van  Deursen  et  al.  1997;  Rollenhagen, 
Muhlhausser et al. 2003) (Figures 1.15 and 1.14). 
1.7.3  Nucleoporin 153 
NUP  153  is  one  of  the  large,  1476  amino  acid  FG-repeat  nucleoporins  that  is 
located at the nuclear basket (Figure 1.13) (Pante, Bastos et al. 1994) and has a 
high degree of mobility and flexibility in its FG-repeat domain. It is subdivided into 
three distinct domains: an N-terminal domain that is anchored to the nuclear ring 
(Walther,  Fornerod  et  al.  2001;  Fahrenkrog,  Maco  et  al.  2002),  a  zinc  finger 
domain  in  centre  that  resides  at  the  distal  ring  and  a  C-terminal  domain  with 
approximately  700  amino  acids  that  contain  about  40  FG-repeats  with  high 
flexibility within the NPC. This C-terminus domain can be detected at the nuclear 
basket  and  even  at  the  cytoplasmic  periphery  of  the  central  pore  (Fahrenkrog, 
Maco  et  al.  2002).  NUP  153  interacts  with  nucleic  acids  and  several  proteins. 
These  interactions  are  related  to  transport,  nuclear  envelope  assembly  and 
disassembly, and cellular regulation. Also interaction of the C-terminus domain of 
NUP 153 with several receptor proteins has been shown (Walther, Fornerod et al. 
2001). It has been demostrated that NUP 153 plays a critical role in both nuclear 
export and import (Ullman, Shah et al. 1999) (figures 1.16 & 1.17 & table 1.7). 
1.7.4  Nucleoporin 98 
NUP 98 is a member of the FG-repeat containing nucleoporins that are located on 
both faces of the NPC and shuttle between the nucleus and the cytoplasm (Figure 
1.13)  (Griffis,  Altan  et  al.  2002).  Similar  to  NUP  153,  NUP  98  is  composed  of 
multiple domains and the N-terminal half consists of two domains of FG and GLFG 
repeat separated by a Rae1/Gle2 binding site. Rae1/Gle2 binds to NUP 98 at the 
NPC and plays a role in mRNA transport and seems to be a shuttling transport 
factor involved in translocation of mRNA (Pritchard, Fornerod et al. 1999). Also, 
Rae1/Gle2 aids in delivery of TAP to NUP 98 and the NPC (Blevins, Smith et al. 
2003).  NUP  98  interacts  with  importin-β  that  participates  in  nuclear  trafficking 
(Griffis, Altan  et  al.  2002).  NUP  98  is  an  essential  component  of multiple  RNA 
export  pathways  and  is  unlikely  to  be  involved  in  the  nuclear  import  of  protein 
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NUP 98 bound to NUP 96 in complex with other NUPs that play a role in RNA 
export and in  tethering NUP 98  and NUP  153 in the  nucleus (Griffis, Xu et al. 
2003).  NUP 98, like  NUP  214/CAN participates in  nuclear  export of  HIV-1  Rev 
protein (Zolotukhin and Felber 1999) (Figure 1.17).   
1.7.5  Nucleoporin 62 (p62) 
NUP 62 (p62) is a major component of the NPC and directly interacts with various 
nuclear transport factors, importin-β, NTF2 and TAP (Paschal and Gerace 1995; 
Percipalle,  Clarkson  et  al.  1997;  Levesque,  Bor  et  al.  2006).  However  the 
mechanism of involvement of these interactions in nucleocytoplasmic transport is 
not clear (Fukuhara, Sakaguchi et al. 2006). This FG-repeat NUP is located in the 
central  channel  near  both  the  nucleoplasmic  and  cytoplasmic  faces  of  NPCs 
(Figure 1.13) (Guan, Muller et al. 1995) and is implicated in transport (Finlay, Meier 
et  al.  1991).  It  forms  a  complex  with  other  NUPs  and  is  constructed  from  two 
domains,  a  C-terminus  α-helical  coiled-coil  domain  that  is  probably  involved  in 
protein-protein  interaction  and  may  anchor  p62  to  the  NPC  and  an  N-terminal 
domain  of  xFxFG  repeats,  which  is  probably  implicated  in  nucleocytoplasmic 
transport  (Buss,  Kent  et  al.  1994;  Guan,  Muller  et  al.  1995;  Wiemann,  Kolb-
Kokocinski et al. 2005) (figure 1.15). 
1.7.6  Translocation in the nuclear pore complex 
Transport  of  shuttling  proteins  and  RNAs  is  dependent  on  their  own  physical 
properties  and  the  ability  of  them  to  interact  with  transport  receptor  and/or  the 
NPC. This situation stimulates the NPC properties to suit the efficient shuttling of 
these  molecules.  Three  major  translocation  waies  are  proposed  for 
accommodation  of  the  broad  range  of  shuttling  molecules  with  very  different 
properties. First, that termed the affinity gradient model where transport receptors 
bind with variable affinities to  different FG-containing NUPs, of which some are 
located at both faces of the NPC. It is based on shuttling complexes which bind to 
NUPs with progressively increasing affinity through the translocation route (Ben-
Efraim and Gerace 2001). The virtual gating model is the second method that is 
based on an enzymatic event, which can be catalysed by the NPC. A Brownian 
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reaction of cargo  is then favoured  by  shuttling interactions  with the FG-repeats 
themselves  or  by  removing  the  products  of  the  enzymatic  reaction  which  is 
achieved by the accessory components of the transport machinery (Rout, Aitchison 
et al. 2003). Finally, in the hydrophobic exclusion model, the kinetics of nuclear 
trafficking and the structure of NPC are integrated to accommodate molecules. FG-
repeats  domains  can  form  a  hydrophobic  meshwork  through  weak  interactions. 
Transport  of  receptors  and  cargos  is  achieved  through  structure  recognition  of 
NUP FG-repeat that allows passage through the hydrophobic environment created. 
melting  elements  with  high  surface  hydrophobicity.  Also  the  NPC  as  a  flexible 
solution can be adapted to the translocating factors (Ribbeck and Gorlich 2002). 
Recent studies showed some unsolved questions about these models and some of 
them point to other directions (Strawn, Shen et al. 2004; Yang, Gelles et al. 2004; 
Zeitler and Weis 2004; Paulillo, Phillips et al. 2005). New mathematical modelling 
has  been  defined  nuclear  transport  in  a  quantitative  manner  that  could  be 
equivalent to the previous models based on some experimental evidence (Becskei 
and Mattaj 2005) ( figures 1.18 & 1.19).    
 
1.8  Aims of this study 
The aim of this progect was to investigate interaction of HSV-1 ICP27 with cellular 
nucleoporins. As reported previously, ICP27 is a multifunctional regulatory protein  
that has a role in transport of viral RNA using cellular components and pathways 
(Smith, Malik et al. 2005). ICP27 has already been implicated in nuclear export of 
viral  RNAs.  It  binds  to  ALY/REF  and  is  recruited  to  TAP  and  its  partner  NXT. 
TAP/NXT is essential for export of cargo because it is this heterodimer that directly 
interacts with components of the NPC at high affinity. However, there is another 
possibility that I wished to consider: ICP27 could traffic RNA and proteins through 
the nuclear pore complex directly by interaction with NUPs in the NPC (Mattaj and 
Englmeier  1998;  Zenklusen  and  Stutz  2001;  Weis  2002;  Sandri-Goldin  2004; 
Hetzer, Walther et al. 2005).  
Studies  in various  eukaryotic organisms suggest there must be  other pathways 
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elegans  (Longman,  Johnstone  et  al.  2003)  and  D.  melanogaster  (Gatfield  and 
Izaurralde 2002). For virus infection, HSV-1 ICP27 deletion d3-4 mutant virus that 
lacks the REF interaction domain is fully replication-competent (Lengyel, Guy et al. 
2002).  Although Koffa, et  al,  showed the HSV-1 ICP27  deletion  d3-4 mutant is 
defective in its export ability (Koffa, Clements et al. 2001). As export of viral mRNA 
is  necessary  for  viral  replication  this  reveals  an  alternative  pathway  for  mRNA 
export by the mutant virus. Previous studies in our laboratory on the ICP27 SADET 
mutant,  the  shuttling  motif  conserved  between  ICP27  and  cellular  hnRNP  K 
protein, showed that SADET mutated ICP27 may still shuttle but was no longer 
able to interact with cellular nucleocytoplasmic transport proteins REF and hnRNP 
K. So it was proposed ICP27 could shuttle through pathways distinct from those 
mediated  by  REF  and  hnRNP  K,  possibly  the  CRM1  export  route  or  via  direct 
interaction with nucleoporins (Leiper 2004). 
 
The main NUP in the NPC that I was interested in testing in terms of its interaction 
with ICP27 was NUP 62 (p62). This is because it is located in the central gated 
channel, directly interacts with various nuclear transport factors, importin-β, NTF2 
and TAP as well as other NUPs (Paschal and Gerace 1995; Percipalle, Clarkson et 
al. 1997; Levesque, Bor et al. 2006) and has role in transport. However, I was also 
interested in testing any interaction of ICP27 with a range of NUPs. As NUPs can 
be  divided  into  FG  and  non-FG  repeat  NUPS  (Stewart,  Baker  et  al.  2001),  I 
decided to test NUPs in both categories. For the FG-repeat NUPs I selected NUPs 
with different locations in the NPC. As mentioned above NUP 62 is located in the 
central pore. However, NUP 153 has a complex localisation pattern. NUP 153 is 
located mostly at the nuclear pore basket but is mobile (Fahrenkrog, Maco et al. 
2002).  NUP  98  is  also  highly  mobile  (Griffis,  Altan  et  al.  2002).  In  contrast, 
NUP214/CAN is found at a steady state level on the cytoplasmic face (Paulillo, 
Phillips et al. 2005). For the non-FG repeat NUPs I decided to use Rae 1 and NUP 
107. Rae 1 is on the nuclear basket and there is evidence that it interacts with 
NUP98 (Blevins, Smith et al. 2003). NUP107 however, is located on the nuclear 
side of the nuclear membrane in complex with NUP160, NUP133, NUP 107 and 
NUP  96  (Fahrenkrog  and  Aebi  2003;  Rout,  Aitchison  et  al.  2003;  Fahrenkrog, 
Koser et al. 2004). My choice of NUPs was constrained by the availability of good 
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interaction studies.  By choosing to study a range of NUPs located throughout the 
NPC, I hoped to try to determine whether ICP27 trafficked through the NPC by 
sequential interaction with NUPs lining the pore. That is, my hypothesis was that 
ICP27 would act as a viral cargo loader that would be handed from NUP to NUP to 
facilitate direct transport through the NPC. 
I also aimed to relate times of infection, production levels of ICP27 and expression, 
and possibly function, of the NUPs. Finally, our group had already demonstrated 
interaction of ICP27  with hnRNP K,  a nucleocytoplasmic shuttling, RNA-binding 
protein.  ICP27  binds  hnRNP  K  through  the  SADET  sequence  of  both  proteins. 
hnRNP K's SADET sequence is essential for its transport between the nucleus and 
cytoplasm. I aimed to determine if this SADET sequence has any role in interaction 
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2 Materials and Methods   
2.1  Materials 
2.1.1  Plasmids 
The acknowledged investigators provided the following plasmids: 
pGEX-27: (Mears & Rice, 1996) Provided by S. Rice, Calgary University, USA. 
Expresses the fusion protein GST-ICP27 
pGEX-27-HIS:  provided  by  Dr.  Margy  D.  Koffa,  Laboratory  of  Molecular  Cell 
Biology,  Cell  Cycle  and  Proteomics,  Greece. Inserted  HIS  tag  at  C-terminus, 
expresses the fusion protein HIS-ICP27 
pGEX-ORF57: provided by Dr P. Malik, Edinburgh University, UK. Expresses the 
fusion protein GST-ORF57 
pCMV-27:  The plasmid pCMV-27 consists of full length ICP27 cloned downstream 
of a HCMV IE promoter in the pCMV10 vector, constructed by Dr N. Rethmeier, 
Institute of Virology, University of Glasgow, UK (Bryant et al., 2000). 
pEYFP-27:  N terminal fusion of ICP27 ORF to EYFP coding sequence, provided 
by J. Scott, FBLS infection and immunity, University of Glasgow. 
pGEX: Amersham Ltd 
pGEX6p1-RAE  1:  Provided  by  Prof  S.  A.  Wilson,  University  of  Sheffield  ,  UK. 
Expresses the fusion protein GST-RAE 1 
pGEX6p1-p62:  Provided  by  Prof  S.  A.  Wilson,  University  of  Sheffield,  UK. 
Expresses the fusion protein GST-NUP 62 
pGEX-3X-h NUP 107: Full length human  NUP  107 provided  by Dr. Ian  Mattaj, 
EMBL, Germany. Expresses the fusion protein GST-NUP 107.                                                                                                  Chapter 2, Matherials and Methods               
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pTRC 2C- h NUP 153: Full length human NUP 153 provided by Dr Katie Ullman, 
University of Utah. Expresses the fusion protein GST-h NUP 153-6H. 
GST-NUP  98  (66-515):  N-terminal  FG-repeat-containing  domain  of  NUP  98 
provided by Dr. Elisa Izaurralde, EMBL, Germany. Expresses the fusion protein 
GST-NUP 98 (66-515). 
pGEX4T-CAN (1690-1894): A fragment of FG-repeat-containing domain of NUP 
214/CAN provided by Dr. Elisa Izaurralde, EMBL, Germany. Expresses the fusion 
protein GST- NUP 214/CAN (1690-1894). 
pGEX4T-CAN (1690-2090) GST-NUP 214 (1690-2090): A fragment of FG-repeat-
containing  domain  of  NUP  214/CAN  provided  by  Dr.  Elisa  Izaurralde,  EMBL, 
Germany. Expresses the fusion protein GST- NUP 214/CAN (1690-2090). 
pGEXCS-NXF1/TAP: A full length TAP provided by Dr. Elisa Izaurralde, EMBL, 
Germany. Expresses the fusion protein GST-TAP. 
pQETAP-NUP 98 (531-782): C-terminus fragment of aa 531-782 tagged with HIS 
in N-terminus provided by Dr. Ian Mattaj , EMBL, Germany. Expresses the fusion 
protein HIS-NUP 98 (531-782). 
pRN3zz-CAN (1690-1894): Provided by Dr. Elisa Izaurralde, EMBL, Germany. 
pRN3zz-CAN (1893-2090): Provided by Dr. Elisa Izaurralde, EMBL, Germany.  
pRN3zz-hNUP 98: Provided by Dr. Elisa Izaurralde, EMBL, Germany. 
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2.1.2  Bacteria 
The E.coli strain DH5a was used with transformation efficiency for maintenance 
and propagation of plasmid DNAs.  For fusion protein expression from prokaryotic 
vectors I utilised E.coli strain BL21 (DE3) pLysS and has the advantage of being 
deficient in lon and ompT proteases and BL21 RP codon plus has the advantage 
of expression of mammalian proteins by codon usage (Stratagene). 
2.1.3  Bacterial culture media 
All strains were grown in L-broth (LB) (10 g NaCl, 10 g Bactopeptone, 5 g yeast 
extract in 1litre water, pH 7.5).  Agar plates were 1.5% (w/v) agar in LB.  Generally, 
media and LB agar plates were supplemented with antibiotic. 50 mg/ml kanamycin 
was used for kanamycin resistance transformed cells and 100 mg/ml ampicillin was 
used for all other ampicillin resistance plasmid containing bacteria. 
2.1.4  Cells and Tissue culture 
All cell culture media for growing cell lines were obtained from Invitrogen-Gibco. 
Antibiotics were added only before virus propagation (100 units/ml penicillin and 
100mg/ml  streptomycin)  and  cell  lines  were  subcultured  for  less  than  twenty 
passages.  HeLa  cells  used  for  transfection  experiments  were  not  treated  with 
antibiotics at any stage. 
2.1.4.1  BHK-21 (C13) cells 
BHK is a fibroblastic cell line derived from baby hamster kidney cells (Macpherson 
and Stoker, 1962).  BHK-21 cells were grown in Glasgow Modified Eagles Medium 
(GMEM) supplemented with 10% newborn or foetal calf serum (NBCS, FCS), 10% 
tryptose phosphate broth, 100 U/ml penicillin and 0.01% streptomycin. 
2.1.4.2  M49 cells 
A BHK derived ICP27 complementing cell line that expresses ICP27 (Lilley et al., 
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(DMEM) supplemented with 10% foetal calf serum (FCS), 10% tryptose phosphate 
broth, 1% L-glutamine, 500mg/ml of G418 (Gibco BRL) and 500mg/ml of Zeocin.   
2.1.4.3  HeLa cells 
An epithelial cell line derived from a human cervical carcinoma, HeLa cells were 
grown in Minimum Essential Medium (MEM) with Earle’s salts supplemented with 
10%  FCS,  1%  L-glutamine,  1%  non  essential  amino  acids  solution,  100  U/ml 
penicillin and 100 mg/ml streptomycin. 
2.1.4.4  Vero cells 
Derived  from  African  green  monkey  kidney,  Vero  cells  were  grown  in  DMEM 
supplemented with 10% FCS and 100 U/ml penicillin and 100 mg/ml streptomycin. 
2.1.5  Viruses 
HSV-1 strain 17
+:
 HSV-1 wild type strain 17
+ virus was as described (Brown et al., 
1973). Referred to as wt or wt 17
+ virus. 
HSV-1 vEYFP-ICP27: Recombinant HSV-1 that expresses an EYFP-ICP27 fusion 
protein  from  the
  IE-2  promoter  was  supplied  by  J.  Scott,  FBLS  infection  and 
immunity, University of Glasgow. 
HSV-1 ICP27 mutants: Characteristics of ICP27 mutants used in this study are 
shown in Table 2.1. Mutants were provided by the acknowledged investigator.  
2.1.6  Antibodies            
Primary and secondary antibodies used during this investigation, the dilution used 
and their sources are listed in Tables 2.2 and 2.3. 
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2.1.7  Common solutions 
30% acrylamide mix                                 29% w/v) acrylamide, 1% (w/v)  
                                                                 N, N’-methylene bis-acrylamide 
5X agarose gel loading buffer                  1X TAE, 1% SDS (w/v), 50%  
                                                                 Glycerol (v/v),1mg/ml bromophenol blue  
Bradford’s reagent                                   0.01% (w/v) Coomassie Brilliant Blue, 
                                                                 0.0003%(w/v)SDS, 4.75% (v/v) ethanol,                   
                                                                 8.5% (v/v) phosphoric acid     
Blocking buffer                                         5% (w/v) nonfat dry milk in PBS-T 
Buffer E                                                   100mM Tris-HCl pH 7.4, 100 mM NaCl                                                        
                                                                2mM EDTA, 1% NP40, 0.5% (w/v) Na-     
                                                                deoxycholate. Protease inhibitor tablets 
                                                                (Roche) were added before use. 
Coomassie stain                                     0.02% (w/v) Coomassie Brilliant Blue 50%  
                                                                (v/v)methanol, 43%(v/v) water, 7% (v/v)  
                                                                acetic acid    
Coomassie Destain                                 5% (v/v) methanol, 7% (v/v) acetic acid, 
                                                                88% (v/v) water     
HEPES extract buffer                              50 mM HEPES pH 7.5, 50 mM NaCl,                                                                                                   Chapter 2, Matherials and Methods               
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                                                                0.1% (v/v) Nonidet P40. Protease inhibitor 
                                                                tablets (Roche) were added before use. 
HIS elution buffer                                    20 mM Tris-HCl pH 8, 100 mM NaCl, 
                                                                300 mM imidazole 
HIS lysis buffer                                        20 mM Tris-HCl pH 8, 100 mM NaCl, 
                                                                20mM imidazole,0.5% NP-40. Protease               
                                                                inhibitor tablets (Roche) were 
                                                                added before use.   
HIS wash buffer                                      HIS lysis buffer. HIS lysis buffer without  
                                                               NP-40. HIS lysis buffer with 1M NaCl 
Lysozyme                                               10 mg/ml lysozyme in 25 mM Tris-HCl  
                                                               pH 8,0 
NETN buffer                                           20mM Tris-HCl pH 8.0, 100 mM NaCl                                                        
                                                               1mM EDTA, 0.5% NP40, Protease              
                                                               inhibitor tablets (Roche) were added 
                                                               before use. 
Giemsa stain                                          1.5% (w/v) suspension of Giemsa in  
                                                               glycerol, heated at 56
oC for 2 h and              
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PBSA                                                     170 mM NaCl, 3.4 mM KCl, 10 mM   
                                                              Na2HPO4, 1.8 mM KH2PO4, pH 7.2  
PBS-T                                                   PBSA with 0.05% (v/v) Tween 20. 
3X protein gel loading buffer                 150 mM Tris HCl, 300 mM dithiothreitol,  
                                                             6%(w/v)SDS,0.3%(w/v)  bromophenol  
                                                             blue, 30% (v/v) glycerol, pH 6.8  
Protein gel running buffer                     0.05 M Tris base, 0.05 M glycine, 0.1%  
                                                             (w/v) SDS 
Pull down binding buffer                      50mM Tris-HCl pH 8, 100 mM NaCl                                                        
                                                            0.1% NP40, Protease inhibitor tablets 
                                                            (Roche) were added before use. 
Pull down wash buffer                         50mM Tris-HCl pH 8, 150 mM NaCl                                                        
                                                            0.1% NP40. Protease inhibitor tablets  
                                                            (Roche) were added before use. 
0.5 x TBE                                            0.5 x TBE (45 mM Tris base, 45 mM boric                                 
                                                            acid, 1 mM EDTA pH 8.0) 
TE buffer                                             10 mM Tris HCl, 1 mM EDTA, pH 8.0 
Towbin (blotting buffer)                      25 mM Tris base, 192mM glycine, 20%  
                                                           (v/v) methanol                                                                                                    Chapter 2, Matherials and Methods               
  48 
Transfer tank buffer                           50 mM Tris base, 50 mM glycine, 20%   
                                                          (v/v) methanol, 0.01% (w/v) SDS 
Trypsin                                              0.25% (w/v) trypsin in Tris-saline  
                                                          Containing phenol red, adjusted to pH  
                                                          7.5  with NaHCO3  
Versene                                            0.6 mM EDTA in PBSA, 0.002% phenol  
                                                         red  
Water                                               Obtained from a Ro 60 plus deioniser                 
                                                        (Millipore, USA) and sterilised by           
                                                        autoclaving  
 
2.1.8  Chemicals and Reagents   
All  chemicals  and  reagents  were  purchased  from  BDH  Chemicals  UK  or  from 
Sigma unless otherwise stated in this thesis. 
 
Amersham                         ECL western blotting reagents, Rainbow molecular  
                                          weight  markers, Hybond C nitrocellulose membrane,  
                                          Glutathione Sepharose beads 
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Bio-Rad                            Ammonium persulphate (APS), Coomassie brilliant blue,  
                                         TEMED 
Cayla (France)                 Zeocin (phleomycin derivative) 
Fluka                                Formaldehyde, formamide 
Invitrogen                         1kb DNA ladder  
Joseph Mills Ltd              Ultra pure ethanol, methanol 
Kodak                              X- Omat film 
Prolabo                            Butanol, glacial acetic acid, glycerol, isopropanol 
Roche                              Protease inhibitor cocktail          
Qiagen                             Midi and mini prep plasmid isolation kits         
Active motif                      Nuclear and cytoplasmic cell extract kit  
2.1.9  Autoclaving and glassware sterilisation 
Equipment  and  solutions  were  sterilised  at  15  psi  for  20  min  by  staff  in  the 
washroom,  Institute  of  Virology,  Glasgow  or  the  Glasgow  Biomedical  Research 
Centre (GBRC). Glassware was sterilised by baking in an oven at 180°C for at 
least  12  h.  Heat-labile  solutions  were  sterilised  by  filtration  though  a Whatman 
syringe filter (diameter 0.2 µm) into a sterile tube. 
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2.2  Methods 
2.2.1  Bacteria and plasmid transformation 
2.2.1.1  Making competent E.coli 
E.coli strain DH5α, was used for general plasmid transformation. E.coli strain BL21 
(DE3) plysS or RP codon plus was used for plasmids incorporating GST or His 
expression systems. A 1 ml overnight culture was inoculated into 100 ml LB and 
grown  for  about  3  h  at  37°C  in  a  shaking  incubator  until  the  OD630  was 
approximately  0.4.  The  culture  was  then  cooled  on  ice  and  cells  pelleted  by 
centrifugation at 5000 rpm for 10 min at 4°C in a Sorvall RT 6000B refrigerated 
centrifuge. The cells were resuspended in 50 ml ice cold 50 mM CaCl2 and left on 
ice for 30 min. Cells were then pelleted as before, and resuspended in 10 ml cold 
50  mM  CaCl2,  15%  glycerol.  200  µl  aliquots  were  snap  frozen  in  dry  ice  with 
ethanol and stored at –70
oC. 
2.2.1.2  Transformation of plasmids 
Plasmid  DNA  was  transformed  into  a  200  µl  aliquot  of  competent  E.coli,  cells 
which  were  thawed  on  ice.  The  DNA  was  added  to  the  cells  and  the  mixture 
incubated on ice for 30 min prior to heat shock in a 42°C water bath for 2 min. 800 
µl of LB was added to the cells, which were shaken for 60 min at 37°C before 
plating onto LB agar plates containing appropriate antibiotic selection.  Plates were 
incubated overnight at 37
oC.  
2.2.1.3  Plasmid DNA extraction from transformed bacteria 
A  single  colony  from  a  bacterial  plate  or  approximately  1  ml  of  liquid  bacterial 
culture was used to inoculate 100 ml of LB containing the appropriate antibiotic.  
This was then incubated  at 37
oC at 200 rpm.  The overnight culture was spun 
down  at  3000  rpm  for  20  min  in  a  Sorvall  RT  6000B  refrigerated  centrifuge.  
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manufacturer’s instructions.  A typical yield of DNA using this method was 100 mg 
which was resuspended in 100 ml buffer E. 
2.2.1.4  Electrophoretic separation and purification of DNA fragments 
DNA  was  resolved  in  a  horizontal  slab  gel  of  1%  (w/v)  agarose  in  1X  TBE 
containing 1 mg/ml ethidium bromide and electrophoresed in a buffer of 1X TBE.  
Samples  were  loaded  following  addition  of  5X  agarose  gel  loading  buffer.  
Electrophoresis was performed at 70 – 120V and DNA was visualised under UV 
illumination at 205 nm and photography was carried out using a camera linked to a 
computer running UV Products gel documentation system store 7500, version 7.12 
(UV Products Ltd, Cambridge). 
2.2.2  Cell culture 
2.2.2.1  Passaging cells 
Mammalian  cells,  HeLa,  Vero,  BHK-21  or  M49  were  sub  cultured  at  90% 
confluence.  Trypsin solution 0.25% (w/v) in Tris-saline containing phenol red pH 
7.5 was thawed from –20
oC and mixed with versene to yield 0.06% (v/v) trypsin 
/EDTA  solution.    T-175  flasks  or  roller  bottles  with  confluent  monolayers  were 
opened  in  a  Category  2  hood.  The  supernatant  decanted  and  10  ml  or  20  ml, 
respectively,  of  versene  was  poured  over  the  monolayer  and  decanted.    The 
monolayer was then washed with a versene/trypsin solution and left for 2-3 min at 
RT.  The cells were shaken into 10 ml (for a T-175 flask) or 20 ml (for roller bottle) 
media for further use. Cells were grown at 37
 oC in humidified incubator under 5% 
CO2. For continual passage, cells were split in a 1:10 ratio every 4-5 days. 
2.2.2.2  Cryopreservation of cells 
Confluent cell monolayers were harvested from T-175 flasks as described above 
and resuspended in 10 ml media. Cells were centrifuged at 2000 rpm at 4
oC for 5 
min in a Heraeus multifuge 3 S/R refrigerated centrifuge, the media decanted and 
cells  resuspended  in  5  ml  PBSA  and  again  centrifuged  for  5  min.    Cells  were 
resuspended in 4 ml of media, with 10% DMSO.  Aliquots of 1 ml were transferred                                                                                                  Chapter 2, Matherials and Methods               
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into 1.5 ml cryo-vials.  These were frozen overnight at –70
oC and moved to a liquid 
nitrogen freezer for long term storage. 
2.2.2.3  Thawing cells 
Above frozen cells were thawed quickly in a 37
oC water bath and resuspended in 
10 ml of pre-warmed medium and centrifuged at 1000 rpm for 3 min in Heraeus 
multifuge 3 S/R refrigerated centrifuge and resuspended again in 25 ml of medium 
to seed a culture flask. This medium was changed after 6-8 h.  
2.2.2.4  Transfection of cells with plasmid DNA 
Cells  in  35  and  60  mm  dishes  were  transfected  with  ICP27  and  nucleoporin 
expression plasmids.  The day before transfection cells were plated so they were 
80-90%  confluent,  on  the  day  of  transfection.  The  plasmid  DNA  was  diluted  in 
Optimem  and  in  a  separate  Eppendorf,  Lipofectamine  2000  (Invitrogen)  was 
diluted into Optimem and incubated at RT for 5 min. The diluted plasmid DNA was 
then combined with the diluted Lipofectamine and incubated at RT for 20 min to 
allow DNA-Lipofectamine complexes to form. Medium was removed from the cells 
and 2 ml or 4 ml of growth medium (without serum) was added for 35 and 60 mm 
dishes, respectively. The DNA-Lipofectamine mix was then added directly to each 
plate and mixed gently. The cells were incubated at 37
oC for 4-5 h, after which the 
medium was removed and replaced with standard growth medium. The cells were 
incubated for 24 h post transfection. 
2.2.2.5  Viral infection of cells 
Almost  confluent  monolayers  were  grown  on  plates  or  flasks  and  infected  with 
various viruses or left uninfected. With all viruses and in all cell types, infection was 
at a m.o.i of 10 unless otherwise stated for longer infection times. 80% confluent 
cells were incubated with virus in 100 ml per T175 flask and after 1 h adsorption 20 
ml of an appropriate growth medium was added. From these infectious, soluble 
protein  extracts  were  made  and  used  in  different  pull  down  and 
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2.2.3  Production of virus stock  
2.2.3.1  Growth of virus stock  
BHK cells were grown in roller bottles to a confluency of 85% and infected with 
0.003 pfu/cell of wt 17
+ virus in 20 ml of media. ICP27 complementing cell line BHK 
M49 was used for the growth of HSV-1 ICP27 viral mutants.These were incubated 
at 31
oC for 3-5 days until CPE was complete when the cells were shaken into the 
medium.  The cell suspension was poured into a 250 ml plastic Falcon tube and 
the  cells  pelleted  by  centrifugation  at  2000  rpm  for  30  min  at  4
oC  in  Heraeus 
multifuge 3 S/R refrigerated centrifuge. The supernatant and cell pellet was divided 
into 2 individual stocks: cell associated virus and cell-released virus. 
2.2.3.2  Cell associated (CA) virus 
The cell pellet was resuspended in 0.5 ml medium/roller bottle, pipetted into sterile 
bijoux,  thoroughly  sonicated  and  centrifuged  at  2000  rpm  for  10  min  at  4
oC  in 
Heraeus  multifuge  3  S/R  refrigerated  centrifuge  to  remove  cell  debris.  The 
supernatant  was  kept  on  ice  while  the  pellet  was  treated  as  above.  Both 
supernatants were pooled to give the CA virus stock. 1 ml of this was aliquoted into 
1.5 ml sterile cryo-vials and stored at –70
oC. 
2.2.3.3  Cell released (CR) virus 
The  supernatant  was  poured  into  250  ml  sterile  centrifuge  bottles  and  spun  at 
12000 rpm (Sorvall GSA rotor) for 2 h at 4
oC.  The supernatant was discarded and 
the virus pellet resuspended in 1 ml medium/roller bottle. The pellet was sonicated 
until homogenous and 500 ml CR aliquots transferred to 1.5 ml sterile cryo-vials 
and stored at –70
oC.  
2.2.3.4  Sterility check on virus stocks 
Brain  heart  infusion  agar  (BHI)  plates  containing  10%  (v/v)  horse  blood  (blood 
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aliquot of viral stocks and incubating at 37
oC for 7 days. If there was no growth by 
48 h, stocks were considered sterile. 
2.2.3.5  Virus titration 
Wild type and mutant HSV-1 ICP27 virus stocks were serially diluted 10 fold in 
PBSA/5% CS and 0.1 ml aliquots added to fresh monolayers of either BHK-21 or 
M49 cells on 60 mm plates from which the media had been removed. The plates 
were incubated at 37
oC with 5% CO2 for 1 h to allow adsorption to the cells, before 
overlaying with 4 ml medium supplemented with 1% carboxymethyl cellulose. The 
plates  were incubated at 37
oC for 2-3  days. The media  was  decanted  and the 
monolayers fixed and stained with Giemsa/X-gal at RT for 2-24 h. After rinsing the 
plates with dH2O, plaques were counted using a dissection microscope and virus 
titres calculated as plaque forming unit per ml (pfu/ml). 
2.2.4  Protein extraction and analysis 
2.2.4.1  Whole cell extract preparation 
Soluble  proteins extracts  were made from cells infected  with various viruses or 
uninfected  for  immunoprecipitations  and  pull  down  assays.  Cells  were  washed 
twice in ice cold PBS A and harvested in 10ml PBS A by scraping. Cells from a 
175 cm
2 flask were pelleted by centrifugation at 1000 rpm for 5min at 4°C in a 
Heraeus multifuge 3 S/R refrigerated centrifuge and resuspended in 800ml HEPES 
extract buffer. The cells were lysed by passing 5 times through a syringe with a 26-
gauge needle and sonication for 30-60sec in a soni-bath and left rotating at 4°C for 
30 min for solubilisation. Debris was pelleted by micro-centrifugation at 12000 rpm 
for 10min at 4°C in a Sorvall RT 6000B refrigerated centrifuge. The soluble protein 
extracts were either used directly or stored at -70°C. In order to standardise the 
amount of protein added to immunoprecipitations or pull downs the total protein 
content of soluble protein extracts was determined by standard Bradford’s assay 
and  electrophoresed  on  SDS-PAGE  and  western  blotted  to  examine  proteins 
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2.2.4.2  Nuclear and cytoplasmic cell extracts 
For some immunoprecipitations and pull down assays a nuclear and cytoplasmic 
extract  was  prepared.  After  infection  at  different  time  points,  nuclear  and 
cytoplasmic extracts were made by the Active Motif nuclear extract kit (catalogue 
number 40010) using the manufacturer’s protocol. 
2.2.4.3  Estimation of protein concentration 
Estimation of protein concentration was performed using the method of Bradford 
protein assay from Bio-Rad. 10 ml of protein sample was diluted in 90 ml dH2O and 
mixed with 1ml Bradford reagent. After 10 min at RT the absorbency of the solution 
was  measured  at  595  nm,  and  converted  to  mg  protein  by  comparison  to  a 
standard curve produced using known quantities of bovine serum albumin (BSA). 
2.2.4.4  SDS polyacrylamide gel electrophoresis (SDS-PAGE) of proteins 
Proteins were resolved by electrophoresis through SDS-PAGE using Bio-Rad mini 
gel electrophoresis tanks. Gel mixes were as follows:  
For 10ml                  10% resolving gel  6% resolving gel  2ml stacking gel 
dH2O     4 ml      5.3 ml          1.4 ml   
30% acrylamide mix              3.3 ml              2.0 ml          0.33 ml 
1.5 M Tris (pH 8.8)             2.5 ml               2.5 ml          0.25 ml 
                                                                                                             (pH 6.8) 
10% SDS     0.1 ml     0.1 ml          0.02 ml 
10% APS     0.1 ml     0.1 ml          0.02 ml 
TEMED     0.004 ml    0.008 ml                0.002 ml 
 
Resolving  gel  mixes  were  poured  into  glass  plate  sandwiches,  overlaid  with 
butanol and allowed to set.  The butanol was washed away with dH2O, stacking gel 
mixture  was  overlaid  and  a  comb  inserted.  Protein  samples  were  mixed  with 
protein  gel  loading  buffer  and  placed  in  a  boiling  water  bath  for  3  min  prior  to 
loading.  Along  with samples,  10  µl Rainbow marker  (Amersham) was  also  run. 
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Gels were either stained with Coomassie Blue solution for 30 min and destained in 
protein gel destain or transferred to nitrocellulose membrane for Western blotting. 
 
2.2.4.5  Western  blotting  and  transfer  of  proteins  to  nitrocellulose 
membrane 
To  detect specific  protein,  proteins resolved on SDS-PAGE  were transferred to 
nitrocellulose using a Bio-Rad Transblot cell.  A blotting sandwich was set up such 
that the gel was in contact with a sheet of nitrocellulose (Hybond-ECL Amersham) 
and  both were sandwiched between Whatman 3 mm papers of the appropriate 
size.  This  was  in  turn  sandwiched  between  sponges  provided  by  Bio-Rad  and 
transfer carried out at 250 mA for 1 h. 
2.2.4.6  Immunodetection of proteins 
After transfer to nitrocellulose, the presence of specific proteins was detected using 
antisera.  Incubation  in  PBSA,  5%  dried  milk  overnight  at  4°C  blocked  the 
nitrocellulose membranes. They were then washed for three 10 min at RT in PBSA 
0.05% Tween (PBS-T), before incubation for 1-2 h at RT on a shaker in 20 ml of 
appropriately  diluted  primary  antibody  in  PBS-T  5%  dried  milk  (Table  2.2). 
Following this, blots were washed for three 10 min at RT in PBS-T, and appropriate 
secondary antibody added at a 1/1000 dilution in PBS-T 5% dried milk (Table 2.3). 
After 60 min incubation at RT, blots were washed as previously and proteins were 
detected using the Amersham Enhanced Chemiluminescence (ECL) system. The 
two reagents were mixed in equal volumes and a total volume poured onto the 
filter,  which  was  agitated  for  1  min.  The  blots  were  wrapped  in  cling  film  and 
exposed to Kodak X-OMAT S film. 
 
2.2.5  Co-immunoprecipitations (CO-IP) 
2.2.5.1  Immunoprecipitation and preparation of cell extracts 
To investigate protein: protein interactions and their ability to detect an interaction 
between an antibody and its partner protein, co-immunoprecipitations were carried 
out  with  several  antisera  and  conditions  were  optimised  for  each  antibody.  A                                                                                                  Chapter 2, Matherials and Methods               
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complex of antigen and antibody can be precipitated using Staphylococcus aureus 
protein A/G which interacts with IgG, coupled to Sepharose beads (Figure 2.2). 
Identification of the immunoprecipitated antigen and proteins, which co-purify with 
the target antigen, can be achieved by separation of the complex on SDS-PAGE, 
followed by detection of proteins by Western blotting. Both polyclonal antisera and 
Mabs  can  be  used  for  such  co-immunoprecipitation  experiments,  however  it  is 
important to be aware of certain limitations, for example an antibody may mask an 
interaction site or a protein: protein interaction may mask the antibody binding site. 
In this respect, polyclonal antisera are better but Mabs often give a cleaner result. 
Salt  and  detergent  concentrations  in  buffers  used  to  immunoprecipitate  and  to 
wash will affect the ability of proteins to interact and so determine the stringency of 
the immunoprecipitation. Generally, cells at 90% confluence were infected with wt 
HSV-1 and its ICP27 mutants at MOI of 10 or left uninfected as a control sample 
(MI). At different time points after infection cells were washed twice in PBS and 
harvested in 10 ml of PBS by scraping and pelleted at 1000 rpm for 5 min in a 
Heraeus multifuge 3 S/R refrigerated centrifuge at 4°C. HEPES extract buffer was 
used to lyse the cells by passing 5 times through a syringe with a 26-gauge needle 
and sonication for 30-60 sec in a soni-bath and left rotating at 4°C for 30 min for 
solubilisation. Cellular debris was removed by spinning at 12000 rpm for 10 min in 
a  Eppendorf  5415R  refrigerated  centrifuge  at  4°C.  Protein  concentration  and 
expression profiles were measured by Bradford protein assay and fractionated on 
SDS-PAGE. Soluble protein extracts were either used directly or stored at -70°C.    
2.2.5.2  Co-immunoprecipitation using ICP27 monoclonal antibody 
Various infected and non-infected cell extracts (~100µg) were mixed with 2 µl of 
Mab 1113 and 2 ml of Mab 1119 or 2 ml NMS and NRS in 700 ml modified buffer E 
(100mM  Tris  HCl,  100mM  NaCl,  2mM  EDTA,  2mM  EGTA,  1%  NP40,  1%  Na 
deoxycholate, protease inhibitor, pH 7.4) for 3h at 4°C. 100 ml protein A-Sepharose 
(made up at 50% (w/v) and washed 2X in buffer E) was then added and mixed for 
1h. After pelleting the beads and 5X washes in buffer E at 12000 rpm 30 sec in an 
Eppendorf  5415R  refrigerated  centrifuge  at  4°C,  60ml  protein  gel  loading  buffer 
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proteins separated by SDS-PAGE. After separation gels were subject to Western 
blot analysis. 
2.2.5.3  Co-immunoprecipitation using NUP antibodies 
The  same  protocol  as  described  in  the  above  section  was  used  for  co-
immunoprecipitation  of  nucleoporins  but  different  amounts  of  antibodies  were 
added instead. In this investigation 10 µl of anti NUP 153, 12 µl of anti NUPs 414, 
12 µl of anti NUP 62 and 15 µl of anti NUP 98 were used. As a control 2 µl of NMS, 
NRS or NGS mixed with cell extracts depending on the type of NUP antibody. 
2.2.6  Expression  and  purification  of  fusion  proteins  and  pull 
down assays 
2.2.6.1  Expression and purification of GST fusion proteins 
The Glutathione S-transferase (GST) gene fusion system can be used to identify 
new protein: protein interactions, or to confirm and investigate those identified in 
other  systems.  Fusion  proteins  are  expressed  in  E.coli  cells  containing  the 
recombinant pGEX plasmid and BL21 (DE3) and BL21 RP codon plus are used.  
Protein expression from a pGEX plasmid is under the control of the tac promoter, 
which is induced using the lactose analogue isopropyl β-D-thiogalactoside (IPTG).  
Induced cultures are allowed to express GST fusion proteins for several hours, 
after which cells are harvested and lysed. Cell debris was cleared by centrifugation 
and fusion protein purified and immobilised by binding to Glutathione attached to 
Sepharose  4B.  After  binding  the  matrix  is  washed  with  buffer  to  remove  non-
specifically bound bacterial proteins and mixed with cellular extracts. The beads 
serve  as  an  affinity  matrix  allowing  proteins,  which  interact  to  bind  to  the 
immobilised  target  fusion  protein.  Bound  proteins  can  be  partially  purified  by  a 
simple centrifugation step, hence the name “pull down” assay. Beads are washed 
again to remove non-specifically bound cellular proteins and proteins analysed by 
SDS-PAGE. 
GST alone, GST-ICP27, GST-ORF57, GST-TAP and different GST-NUP plasmids 
were transformed either into  E.coli BL21 or BL21 RP codon plus and grown on LB 
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LB ampicilin and incubated at 37°C overnight. The culture was diluted 1:50 and 
grown in 100 ml LB plus ampicillin at 37°C until OD600 of 0.6-1 was reached. Then 
fusion protein expression was induced by adding 0.5-1 mM IPTG for 3 h at 37°C 
for GST alone and GST-ICP27 and 16 h at 29°C for other GST fusion proteins. 
Bacteria were harvested by centrifugation at 4000 rpm for 15 minutes in a Sorvall 
RT  6000B  refrigerated  centrifuge.  Pellets  were  resuspended  in  10  ml  of  NETN 
(modified  NETN  buffer  for  GST-ORF57  and  GST-NUPs)  with  0.1  volume  of 
lysozyme and protease inhibitor and sonicated on ice using a soniprobe. Soluble 
protein was separated from cell debris by 40 min centrifugation at 9000 rpm in a 
Sorvall RT 6000B refrigerated centrifuge. The affinity chromatography system used 
for  purification  of  the  fusion  protein  from  bacterial  lysates  involved  adding  pre-
swollen Glutathion-Sepharose 4B beads to lysates (10 ml lysate/ 500µl), rocking 
for 2-4 h at 4°C to mix protein lysates and beads, followed by washing 3 times with 
cold PBS and once with cold PBS-T using 30 sec centrifugation at 12000 rpm in an 
Eppendorf  5415R  refrigerated  centrifuge  at  4°C.  Purified  fusion  protein  was 
resuspended in PBS, and aliquots were stored at -20°C or -70°C. Small amounts 
of different stages of expression and purification, including culture before and after 
induction, and sonication, unbound and purified fractions were analysed on SDS-
PAGE  followed  with  either  western  blotting  or  Coomassie  stain  to  monitor 
expression, concentration and purity of the fusion proteins.   
2.2.6.2  Expression and purification of His tagged proteins 
For expression and purification of His-ICP27 and His-NUP 98 (531-782), plasmids 
were  transformed  into  E.coli  BL21  and  grown  on  LB  and  plates  containing 
100mg/ml  kanamycin.  Single  colonies  were  inoculated  into  10  ml  LB  with 
kanamycin  and  incubated  at  37°C  overnight.  The  culture  was  diluted  1:50  and 
grown in 100 ml LB with kanamycin at 37°C until OD600 of 0.6-1 was reached. Then 
fusion protein expression was induced by adding 0.5 mM IPTG for 3 h at 37°C. 
Bacteria were harvested by centrifugation at 4000 rpm for 15 minutes in a Sorvall 
RT  6000B  refrigerated  centrifuge.  Pellets  were  resuspended  in  10  ml  His  lysis 
buffer and sonicated on ice using a soniprobe. Soluble protein was separated from 
cell  debris  by  a  40  min  centrifugation  at  9000  rpm  in  a  Sorvall  RT  6000B 
refrigerated  centrifuge.  The  affinity  chromatography  system  was  used  for                                                                                                  Chapter 2, Matherials and Methods               
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purification of the fusion protein from bacterial lysates by adding Ni-NTA agarose, 
rocking for 2-4 h at 4°C to mix protein lysates and beads, followed by 2 times wash 
with His wash buffer (Lysis buffer), once with His wash buffer without NP-40, once 
His wash buffer with 1M NaCl and once again with HIS wash buffer using 30 sec 
centrifugation at 12000 rpm in an Eppendorf 5415R refrigerated centrifuge at 4°C. 
Purified fusion protein was eluted by loading on to a column and eluted with His 
elution buffer in 4-5 fractions which were then aliquoted and stored at -70°C. Small 
amounts of different stages of expression and purification including culture before 
and after induction and sonication, unbound and purified fractions were analysed 
on  SDS-PAGE  followed  with  either  western  blotting  or  Coomassie  staining  to 
monitor expression, concentration and purity of the fusion proteins. 
2.2.6.3  GST pull down assay 
An equal amount of each GST fusion protein-bound beads was mixed with 100 µg 
cell extracts or 1 µg of purified His tagged protein. The mix was rocked in 700 µl of 
pull down binding buffer for 3 h at 4°C. Beads were washed 4 times in pull down 
wash  buffer,  by  spinning  at  12000  rpm  for  30  sec  in  an  Eppendorf  5415R 
refrigerated centrifuge at 4°C. After this, bound proteins were eluted in SDS protein 
gel loading buffer.  Samples were placed in a boiling bath for 3 min and pulled 
down proteins separated by SDS-PAGE and visualised by western blotting (Figure 
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3 Interaction of ICP27 with nucleoporin 62  
3.1  Introduction 
The  NPC  is  a  huge  macromolecular  structure  that  extends  across  the  nuclear 
envelope,  forming  an  entry,  which  regulates  the  flow  of  messenger  RNA  and 
proteins  between  the  nucleus  and  the  cytoplasm  (Fahrenkrog  and  Aebi  2003; 
Rout, Aitchison et al. 2003; Fahrenkrog, Koser et al. 2004). Nucleoporin 62 (NUP 
62) is one of the best- characterised nucleoporins localised to the nuclear pore 
central plug. This protein is a member of the phenylalanine-glycine (FG) repeats 
containing nucleoporins associated with the importin alpha/beta complex, which is 
involved  in  the  import  of  proteins  containing  nuclear  localization  signals 
(Fahrenkrog and Aebi 2003; Rout, Aitchison et al. 2003; Fahrenkrog, Koser et al. 
2004). Its N-terminus is believed to be involved in nucleocytoplasmic transport and 
binds  to  nuclear  transfer  factor  2  (NTF2)  and  Ran.  The  C-terminal  end,  which 
shows  a  hydrophobic  heptad  repeat,  contains  a  coiled-coil  structure  aiding  in 
protein–protein  interactions  and  associates  with  importin-β1,  transcription  factor 
Sp1,  the  signaling  component  TRAF-3  and  heat  shock  factor  2  (Gamper,  van 
Eyndhoven et al. 2000). Recent studies have shown interaction of the N-terminal 
domain of mammalian NUP 62 with other nucleoporins of the FXFG family such as 
NUP 358, NUP 214 and NUP 153 and it has been proposed that some of these 
interactions  may  contribute  to  the  movement  of  cargo  across  the  nuclear  pore 
complex (Stochaj, Banski et al. 2006). Also the functional involvement of viruses 
with  nucleoporins  has  been  shown  in  that  poliovirus  infection  can  destroy  the 
structure of the NPC by degradation of NUP 62 (Gustin and Sarnow 2001). Work 
on ICP27 demonstrated its role at transcriptional and post-transcriptional levels as 
well as in shuttling and transport of viral mRNAs. ICP27 binds to partner proteins 
TAP  and  REF  and  contributes  to  nuclear  export  (Smith,  Malik  et  al.  2005). 
Consequently, we were interested in seeking for interaction of ICP27 with cellular 
nucleoporins involved in the transport machinery. First I looked at NUP 62 and this 
chapter presents data that shows HSV-1 ICP27 protein interacts with NUP 62 in 
vivo in virus infected cells and in vitro.  
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3.1.1   Expression of fusion proteins and pull down assay 
The  study  of  protein  interactions  has  been  vital  to  the  understanding  of  how 
proteins  function  within  the  cell.  There  are  many  ways  to  investigate  protein- 
protein  interactions.  In  this  study  GST-fusion  protein  pull  down  assays  and  co-
immunoprecipitations were used to reveal interacting proteins. Details of the theory 
of GST fusion protein pull down assays and experimental conditions that can be 
varied are found in Materials and Methods. 
3.1.2  GST-ICP27 fusion protein expression 
To  produce  ICP27  as  a  GST  fusion  protein  I  used  an  optimised  expression 
procedure that was established in our lab. Expression of protein from the pGEX 
vector is under control of the tac promoter and the E.coli BL21 strain with protease 
deficiency was used to minimise proteolytic degradation. Expression of some full 
length  GST-ICP27  and  various  truncations  was  achieved.  The  protein  was 
visualised by Coomassie blue staining. Figure 3.1 Panel I shows Coomassie blue 
stain of bound and unbound expressed GST-ICP27 (lanes 1 and 2 respectively) 
and  purified  bound  fraction  using  a  protein  200  plus  LabChip  kit  (Agilent 
technologies),  in  order  to  monitor  expression,  concentration  and  purity  of  GST-
ICP27 (lane 3). This fast protein analysis with the bioanalyser system is used allow 
to monitor and optimise each step of recombinant protein purification via affinity 
chromatography. Also Panel II demonstrates western blot of similar gels by using 
specific  antibodies  against GST (lane 1) and ICP27  (lane  2).  GST-ICP27 is  an 
unstable protein and it is difficult to obtain high yields of uncleaved fusion protein. 
A major cleavage product of around 50-60 kDa is always seen together with some 
smaller products. Regarding the specifity of antibodies using here there are more 
truncates of protein seen in lane 1 of Panel II Figure 3.1 because western blotting 
with  the  α-  GST  antibody  detects  fusion  protein  and  truncated/degraded  fusion 
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3.1.3    Expression of HIS-ICP27  
 Expression of His-ICP27 has already been optimised in our lab and I have used 
the same procedure at 37°C to express this protein  for direct interaction assay of 
ICP27 with different GST-NUP fusion proteins. Figure 3.2 shows expression of His-
ICP27 fractions by Coomassie blue staining and western blotting with His mAb and 
anti ICP27 mAb (H1113). These purified proteins were used in pull down assays to 
show direct interaction of ICP27 with nucleoporins. 
3.1.4  GST-NUP 62 fusion protein expression 
I attempted to produce significant expression of nucleoporin 62 as a GST fusion 
protein (gifted to us and listed in Material and Method section). An objective
 with 
this  part  of  the  study  was  to  compare  the  effects  of  different
  factors  upon 
expression of a set of human
 nucleoporin fusion products in E.coli
 and establish an 
optimised method for expression of these proteins that can be used in interaction 
experiment studies. Various factors might be the cause of lack of good expression 
of GST fusion proteins.To optimise their expression and obtain sufficient amount of 
purified proteins, effects of temperature, method of lysis, as well as use of protease 
deficient BL21-Codon plus-RP competent E.coli cells that enables efficient high-
level expression of heterologous proteins, were also investigated. An expression 
plasmids of nucleoporin GST-NUP 62 was an FG-repeat human nucleoporin that is 
involved in protein and mRNA export, were used in optimisation experiments and 
the initial and final improved level of expression obtained can be seen in the next 
sections. 
3.1.4.1  The effect of temperature on expression of the GST-NUP 62 
 There  are  numerous  single  case  studies  showing  increased  solubility
  of 
recombinant proteins at lower cultivation temperatures. I have seen this effect on 
my  nucleoporin  GST  fusion  proteins  at
  29°C,  and  prefer  to  carry  out  solubility
 
screening at the lower temperature. Bacterial cultures were grown in 100 ml LB 
containing  ampicillin  and  were  induced  at  OD600  of  0.6  by  1.0  mM  IPTG  and 
incubated at 37° C (as used usually for GST-ICP27 in  our laboratory) and 29° C 
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work)  and  harvested  after  3  and  16  hrs  respectively.  Pellets  were  lysed  by 
sonication  in  lysis  buffer  and  incubated  with  Gluthatione  beads.  Samples  were 
analysed on 10% SDS-PAGE and stained by Coomassie blue. Results shown in 
Figure  3.3  demonstrated  at  29° C  temperature  level  of  full-length  GST-NUP  62 
expression  was  highest  and  the  level  and  number  of  truncations  were  reduced 
(Panel I) in comparison with a higher cultivation temperature of 37° C (Panel II). 
Thus protein expression continued to be at 29° C. GS T-NUP 62 band was identified 
on the basis of correct molecular mass (90 KDa). 
3.1.4.2  The effects of E.coli strain on expression of the GST-NUPs 
To  produce  nucleoporins  as  GST  fusion  proteins,  a  protease  deficient  strain  of 
E.coli (BL21) was used in usual to minimise proteolytic degradation. But because I 
was  using  human  nucleoporins  fused  to  GST  and  wanted  to  obtain  significant 
expression of full-length GST-NUPs the strain of E.coli competent cell was altered 
to  increase  the  amount  of  full-length  product.  Expression  tests  as  described  in 
Material and Methods were carried out on the strain BL-21 (DE3) Codon
 Plus RP 
(Stratagene),  which  has  a  plasmid  that  supplies  extra
  tRNAs  corresponding  to 
codons that are rare in E. coli but common
 in humans. Figure 3.4 demonstrates 
significant efficiency of BL-21 Codon Plus RP in expression of GST-NUP62 (Panel 
I, lane 1 and panel II, lane 4) in comparison to the usual strain BL21 (Panel I, lane2 
and  panel  II,  lane  3).  Expressed  protein  was  western  blotted  against  specific 
antibodies  as  shown  in  Panel  III.  Enhanced  level  of  protein  expression  and 
reduction  of  truncates  and  degraded  bands  are  the  advantage  of  E.coli  BL-21 
(DE3) Codon
 Plus RP (Stratagene), which was used mostly in this study. 
3.1.4.3  The effect of sonication and bug buster reagent on expression of 
GST-NUP 62 
As part of my investigation to find out which method of lysis is the best to open 
bacterial cells to obtain efficient protein expression I have used the soni-probe and 
bug buster reagent master mix as detected in the Material and Method section. 
The expressed GST-NUP 62 bacterial pellet was lysed either by sonication or bug 
buster  reagent.  Lysates  were  pelleted  and  bound  to  glutathione  beads  and 
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antibody. Results show the sonication method may lyse the bacteria better and 
make  available  more  GST-NUP  62  to  bind  to  glutathione  beads.  Figure  3.5 
demonstrates significant difference in the level of GST-NUP 62 expression in lane 
1  in  contrast  to  lane  2  where  cells  were  lysed  by  bug  buster  reagent.  Further 
experiments to make the lysates were based on the sonication method. 
3.1.4.4  The optimised method used for GST-NUPs expression 
GST fusion nucleoporin plasmids were transformed into BL-21 (DE3) Codon
 Plus 
RP  (Stratagene)  and  grown  on  LB  plates  containing  ampicillin.  Single  colonies 
were picked and inoculated into 10 ml LB broth plus ampicilin and grown overnight. 
1:50  dilution  of  culture  was  made  into  100  ml  LB  broth  containing  ampicilin. 
Expression of nucleoporin fusion proteins was induced by adding 1.0 mM IPTG at 
28
oC for about 16 h after obtaining OD600 of 0.4-0.6. Bacteria were pelleted and 
resuspended in modified NETN lysis buffer and solubilised. Fusion proteins were 
purified and bound to beads and eluted off the beads using reduced glutathione 
solution.  Significant  full-length  fusion  expression  was  obtained  for  several 
nucleoporins (NUP 62, Rae 1, NUP 98 and 214/CAN) and used in pull down assay 
experiments (Figure 3.6). 
3.1.5  ICP27 interacts with NUP 62 in a GST pull down assay 
Purified GST-ICP27 fusion protein and its homologue  from KSHV GST-ORF57 
purified protein and as a negative control, purified GST alone bound to glutathione 
beads  were  used  to test whether ICP27  and its homologue  ORF57  pulls down 
nucleoporin 62 from HeLa infected cell extracts. The input fusion proteins used 
were visualised by Coomassie blue staining and bands of approximately 90 kDa 
(lane 2), 80 kDa (lane 1) and 28 kDa (lane 3) were detected corresponding to 
purified  fusion  proteins  GST-ICP27,  GST-ORF57  and  GST  alone  respectively 
(Figure 3.7 Panel I). Lower MW bands were observed showing truncations and 
degradation of full-length proteins. A GST pull down assay experiment was carried 
out using the above fusion proteins and HeLa mock infected cell extract followed 
by western blotting with anti NUP 62 polyclonal antiserum (N-19) that detects the 
N-terminus domain of nucleoporin 62 of human origin. Results showed nucleoporin 
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with GST alone (lane 4). Lane 1 indicates the input control band of the NUP 62 
from HSV-1 17+ infected cell extract at approximately 62 kDa (Figure 3.7 Panel II).   
3.1.6  NUP 62 interacts with ICP27 in a GST pull down assay 
I carried out a pull down assay by using GST-NUP 62 and GST alone bound to 
glutathione beads and HeLa infected cell extracts with wt HSV-1 17+, ICP27 null 
mutant  D27  HSV-1,  CMV  27  (ICP27)  lysate  (which  is  HeLa  cells  transiently 
transfected with an ICP27 expression plasmid) and mock infected. Pulled down 
proteins  were  fractionated  on  SDS-PAGE  and  transferred  to  nitrocellulose 
membrane  followed  by  immunoblotting  by  using  anti-ICP27  (1113)  monoclonal 
antibody (Figure 3.8 Panel I). In wild type (wt) HSV-1 infected cells (lane 2) and 
CMV 27 (lane 4) transfected HeLa samples ICP27 was pulled down by GST-NUP 
62 because an approximately 63 kDa sized band was observed similar in size to 
the input band of ICP27 in infected wt HSV-1 cell extract (lane 1). In contrast, there 
was no band of this size in mock (lane 5) and D27 infected cell extracts (lane 3) nor 
in the GST alone lanes (lane 6). Roughly equivalent amounts of a 40 kDa band of 
GAPDH in each lane in the pull down assay was detected in Panel II. The fusion 
protein GST-NUP 62 and GST alone used were visualised by western blotting with 
anti-GST antibody and showed approximately equal protein amounts were used in 
this experiment (Figure 3.8 Panel III). 
3.1.7  NUP 62 interacts directly with ICP27 in a GST pull down 
assay 
Recent protein interaction studies showed interference from RNAs in some protein-
protein  interactions  cause  indirect  interaction  between  proteins.  Use  of  purified 
fusion protein in both sides of the pull down assay or RNase I treatment of samples 
(Material  and  Method)  can  remove  interference  of  the  RNAs  in  the  pull  down 
assay. To find out more abut a direct or indirect interaction between NUP 62 and 
ICP27, GST fusion NUP 62 and His tagged ICP27 were expressed and purified 
and pull down assays carried out. In order to assess the possible role of RNAs in 
any interaction mediated between ICP27 and nucleoporins I have used RNase I to 
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proteins  GST-NUP  62  and  GST  alone  were  incubated  with  purified  His-ICP27 
followed  with  fractionation  on  SDS-PAGE  and  western  blotting  with  anti-His 
antibody. As shown in Figure 3.9 Panel I ICP27 bound to GST-NUP 62 (lane 2) but 
did not bind to GST alone (lane 3). Nucleoporin 62 directly interacted and pulled 
down His-ICP27. However the percentage of His-ICP27 interacting with NUP 62 is 
low in comparison with input His-ICP27. Image quantification showed only around 
0.1% of ICP27 was pulled down. Very transient interaction of nucleoporins with 
NUP proteins in the transport system in the NPC could result in low efficiency of 
apparent  protein-protein  interactions  in  vitro.  Although  the  interaction  in  vitro 
seems low, in vivo other protein-protein or protein-RNA interaction may stabilise 
the interaction. Therefore, recombinant GST-NUP 62 full-length protein and GST 
alone were used in a pull down assay with HeLa cell lysates in the presence or 
absence of RNase I. Fusion proteins were incubated with wt HSV-1 17+ infected 
HeLa cell extracts and treated with and without RNase I. A western blot of the 
pulled down proteins was carried out with anti-ICP27 monoclonal antibody (1113). 
Results  showed  (Figure  3.9  Panel  II)  NUP  62  interacted  with  ICP27  in  the 
presence (lane 2) and absence (lane 1) of RNase I and reveals that interaction 
between ICP27 and  nucleoporin  62 is not RNA-mediated and they can  interact 
directly with each other in the presence of HeLa extracts. Unbound samples of 
Panel II were western blotted with anti GAPDH antibody (Panel III) to demonstrate 
similar amount of input protein in each reaction.     
 
3.2  Co-immunoprecipitation assays of ICP27 and NUP 
62 
3.2.1  Introduction 
Immunoprecipitation is a frequently used method to purify specific proteins from 
complex samples such as cell lysates or extracts. An important characteristic of IP 
reactions  is  their  potential  to  deliver  not  only  the  target  protein  but  also  other 
molecules that interact with the target. An antibody forms an immune complex with 
a specific target antigen such as in a lysate. It is then captured on either protein A                                                                                                                           Chapter 3, Results               
  68 
or  G  sepharose  beeds.  Components  of  the  bound  immune  complex  are  eluted 
from beads and analysed by SDS-PAGE and often detected by western blot. 
3.2.2  Using  anti-ICP27  and  nucleoporin  62  antibodies  for  co-
immunoprecipitation  
Western blot and immunoprecipitation assays have demonstrated the efficiency of 
anti-ICP27 mAbs 1113 and 1119 to detect ICP27 in different cell extracts in our 
laboratory.  The  use  of  various  monoclonal  and  polyclonal  antibodies  against 
different nucleoporins was also tested and optimised to apply them for each co-
immunoprecipitation  assay.  Profiles  of  protein  bands,  which  interact  either  with 
ICP27  or  nucleoporins,  were  established.  The  heavy  chain  of  the 
immunoprecipitating  antibodies  and  ICP27  and  some  nucleoporins  migrated 
around the same point on the SDS-PAGE gel, however, visualisation of the heavy 
chain  (due  to  cross  reactivity  of  immunoprecipitating  antibodies  with  secondary 
antibody or protein A used in Western blotting) provided a convenient control to 
show  that  similar  amounts  of  antibody  were  added  to  each  reaction.  Previous 
studies in our laboratory showed profiles of cell proteins, which interact with ICP27, 
using radiolabelled cell extracts of HSV-1 infected HeLa, Vero or BHK cell lines. 
The pattern of immunoprecipitating bands was broadly the same in all cell types. 
Many  laboratories  routinely  use  infected  HeLa  cells  to  study  virus  proteins. 
Repetition  of  the  co-immunoprecipitations  often  gave  profiles  with  somewhat 
different  relative  intensities,  but  always  the  same  pattern  of  bands,  further  the 
immunoprecipitated  bands  within  a  particular  profile  showed  the  same  relative 
intensity compared to each other. HeLa cells were chosen for the rest of the study, 
they are routinely used in our laboratory to examine HSV-1 protein interactions and 
as  they  were  routinely  passaged  in  our  laboratory,  were  easy  to  obtain.  To 
optimise  this  method  for  further  experiments  a  control  immunoprecipitation  with 
beads  alone  was  performed  and  ICP27  precipitated  with  anti  ICP27  antibody 
(1113). Figure 3.10, lane 6 shows that beads alone, incubated in the presence of 
HSV-1 wild type infected cell extracts did not precipitate any ICP27. In contrast, 
beads with 1113 ICP27 antibody efficiently precipitated ICP27 (lane 1) while beads 
with  anti-NUP  antibody  414  did  not  precipitate  ICP27.  This  demonstrates  the 
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pelleting the α-414 beads as expected. Not all ICP27 was precipitated by 1113 
antibody beads because some can still be detected in the supernatant. There are 
two  ICP27  bands  detected.  These  probably  represent  phosphorylated  forms  of 
ICP27. Because I never detected ICP27 precipitating with beads alone, I did not 
routinely preclear my HeLa extracts before immunoprecipitation. I understand that 
it  is  important  to  do  this  for  all  experiments.  The  following  data  are  therefore 
subject to question.  
 
3.2.3  Stringency  of  interaction  between  ICP27  and  its  co-
immunoprecipitating nucleoporin 62 
Previous  studies  on  co-immunoprecipitation  in  our  laboratory  showed  the  initial 
profile of proteins, which interacted with ICP27, by using buffer containing 100mM 
NaCl, a salt concentration close to the physiological salt concentration of ~90mM. 
The  strength  of  protein-protein  (NUP  62/  ICP27)  interactions  in  co-
immunoprecipitations  was  tested  substituting  the  100mM  buffer  with  washes  of 
increasing salt concentration up to 500 mM. The resultant profile of bands was 
then  inspected.  Bands  representing  specific  interactions  were  most  obvious  at 
100mM but at higher salt concentrations bands remained (Figure 3.11). In Panel I 
the 63 KDa band represents ICP27 that was precipitated by its antibody at various 
salt concentrations in contrast normal mouse serum (NMS) that could not bring 
down ICP27. However NMS is not the best control to use but it is the only control I 
have used in this study. A better control would be to use an irrelevant antibody of 
the same isotope for example anti-GAPDH antibody. The 62 KDa band in Panel II 
showed the interaction of NUP 62 with ICP27 and it was still clearly visible after a 
500mM salt wash. 
3.3  RNase treatment 
3.3.1  RNase  I  activity  and  use  of  that  in  protein  interaction 
assay 
It  has  been  shown  that  some  ICP27  interactions  with  its  partner  proteins  are 
completely  or  partially  RNA  mediated.  Each  RNase  has  different  cleavage                                                                                                                           Chapter 3, Results               
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specificity.  RNase I efficiently cleave after all four bases of single-stranded RNA, 
in  contrast  to  RNase  A,  which  only  cleaves  after  C  and  U  residues.  RNase  I 
degrades  all  RNA  dinucleotide  bonds  leaving  a  5'  hydroxyl  and  2',  3'  cyclic 
monophosphate.  It  will  degrade  any  RNA  to  a  mixture  of  mono-,  di-,  and 
trinucleotides. It has a marked preference for single-stranded RNA over double-
stranded  RNA,  which  allows  it  to  work  well  in  ribonuclease  protection  assays. 
Regarding my aims to find direct interaction of ICP27 with nucleoporins I carried 
out  the  control  experiments  of  RNase  I  activity  to  remove  all  RNAs  and 
immunoprecipitation assays. In order to test achievement of RNase I activity, 100 
µg  of  wt  infected  HeLa  cell  protein  extract  and  mock  infected  cell  extract  was 
treated with RNase I at 37° C as described in Materi al and Methods. Samples were 
run on an agarose gel with untreated HeLa mock infected cell extract as a control 
and  visualised  with  ethidum  bromide  staining.  Figure  3.12  Panel  1  shows  the 
presence of RNA in lane 1 that is not treated with RNase I and remove of RNA in 
lanes 2 and 3 in wt and mock infected cell extracts which were treated with RNase 
I.  Immunoprecipitation  of  RNase  I  treated  cell  extracts,  with  ICP27  antibody  is 
shown (Figure 3.12). ICP27 from cell extracts was still bound by ICP27 antibody in 
the presence of RNAse I (Panel II, lane 1), while binding to normal mouse serum 
(NMS)  was  not  observed  (Panel  II  lane  2).  Panel  III  shows  that  NUP  62  from 
RNase I treated cell extracts (input) co-precipitated with ICP27 while binding to 
normal  mouse  serum  (NMS)  was  significantly  reduced.  The  apparent  residual 
binding to NMS may be nonspecific or may be the result of alteration in mobility of 
the  antibody  heavy  chain  band  due  to  loading  dye  concentration  (Figure  3.12 
Panel  III,  lane  2).  RNA  residues  may  have  no  contribution  to  the  ICP27-NUPs 
interaction in vivo. In confirmation, RNase I treatment in the pull down assay of 
GST fusion proteins with HeLa  cell infected wt HSV-1 showed the interaction of 
ICP27 with nucleoporins are not RNA mediated. Figure 3.12, panel IV shows GST-
NUP 62 pulled down ICP27 in the presence (Panel IV lane 2) and absence (Panel 
IV lane 3) of RNase I. 
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3.4  ICP27  and  nucleoporin  interactions  in  virus 
infected cells 
3.4.1  ICP27 and NUP 62 co-immunoprecipitate from cell extracts 
Further evidence for an interaction between ICP27 and NUP 62 in vivo came from 
western  blotting  of  the  ICP27  and  NUP  62  co-immunoprecipitation  experiments 
with various antisera. Different antibodies were used in these experiments after 
optimisation of the test using specific antibody and normal control serums. Results 
confirmed that ICP27 and NUP 62 were precipitated by each other.  
3.4.1.1  ICP27  monoclonal  antibodies  (1113  and  1119)  used  to  co-
immunoprecipitate NUP 62 from extracts of HeLa cells 
ICP27  monoclonal  antibodies  (mAb)  1113  and  1119  were  used  to  co-
immunoprecipitate  nucleoporin  62  from  wild  type  (wt)  HSV-1,   27  HSV-1  and 
mock-infected HeLa cell extracts. I used as a control wt HSV-1 HeLa cell lysate 
incubated with normal mouse serum (NMS). Again, I note that this was not the best 
control to use in this experiment. An irrelevant antibody of same isotope (IgG) as 
1113 and 1119 should have been used. Antibody, lysates and protein A beads 
were incubated in IP buffer at 4
°C. Proteins were separated by SDS-PAGE and 
visualised by transfer to nitrocellulose membrane, probed with antibody and X-ray 
film  exposure  analysis.  Samples  were  also  western  blotted  with  ICP27  Mab  to 
show anti-ICP27 antibody pulled down ICP27 and NMS did not bring down ICP27. 
Figure 3.13 Panels I, II and III shows the profile of the immunoprecipitation results 
based on cell extracts used. As it seen in Panel I lane 1 and Panel II lane 1 anti-
ICP27  antibody  precipitated  ICP27  and  co-precipitated  nucleoporin  62 
respectively. Whereas ICP27 null virus infected cell extracts  27 (Panel I lane 2) 
and mock infected cell extracts (Panel I lane 3) did not precipitate with anti-ICP27 
antibodies.  Also  ICP27  null   27  (Panel  II  lane  2)  and  mock-infected  samples 
(Panel II lane 3) did not precipitate nucleoporin 62. ICP27 and NUP 62 was not 
precipitated by the normal mouse serum in HSV-1 17+ infected cell extract (Panels 
I and II lane 4). The intense lower band (about 50 KDa) is due to background from 
the  heavy  chain  of  the  antibodies  used  for  the  immunoprecipitation.  Unbound                                                                                                                           Chapter 3, Results               
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samples and were tested by separation of the above samples on SDS-PAGE gel 
and western blotting with anti-FG repeat NUPs 414 antibody. The last panel of this 
figure (Panel III) reveals roughly equal amounts of the control unbound NUP 62 in 
each band in this experiment. 
3.4.1.2  Monoclonal anti-FG-repeat NUPs  414  and anti NUP 62 antibodies 
(N-19,  D-20  and  H-122)  used  to  co-immunoprecipitate  HSV-1  ICP27  from 
extracts of HeLa cells and BHK cell infected and uninfected with HSV-1 
Immunoprecipitation  of  wild  type  (wt)  infected  HeLa  cell  extract  with  antibodies 
against NUP 62 precipitated a band of about 62 kDa corresponding with NUP 62. 
Three  anti-NUP  62  antibodies  N-19,  D-20  and  H-122  were  incubated  with  wt 
infected HeLa cell extracts and precipitated complexes were separated on SDS-
PAGE and visualised by western blotting with anti-FG-repeat Nups 414 antibody. 
Figure 3.14 Panel I shows NUP 62 was precipitated by all of these antibodies but 
using anti-NUP 62 (H-122) gives the best level of NUP 62 band in this experiment 
in  presence  but not  absence  of the  RNase I  (Figure  3.14 lanes  3  and  7). The 
lowest level of NUP 62 band was achieved with anti-NUP 62 (D-20) and its binding 
was reduced after RNase I treatment (lanes 1 and 5). Levels of proteins in different 
lysates were indicated by western blotting of unbound samples with anti GAPDH 
antibody  (Panel  II).  Reduction  of  interaction  in  lanes  5  and  6  in  comparison  of 
increased  interaction  in  lane  7  could  be  due  to  configuration  of  protein  and 
antibody binding and the position of RNAs in the complex formed.  
Interaction  of  nucleoporin  62  with  ICP27  was  first  investigated  by  co-
immunoprecipitation  with  anti-NUP  62  (N-19)  antibody  due  to  avalibility  of  that 
during my project and ability of that to show NUP 62 in different lysates. Lysates of 
HeLa cells infected with wt, D27, M15 (a defective C-terminus point mutant, Table 
2.1)  virus  and  mock  infected  were  incubated  with  this  antibody  and  complexes 
separated  on  SDS-PAGE  and  analysed  by  western  blotting  with  anti-ICP27 
antibody (1113) and anti-NUP 62 (N-19). As a control, normal goat serum (NGS) 
was used with wt cell lysates. I note again that this was not the best control to use 
in this experiment. An irrelevant antibody of same isotope (IgG) as N-19 should 
have been used.  Figure 3.15 Panel I shows ICP27 co-precipitated from wt and 
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While ICP27 null mutant (D27), did not show the corresponding band (Panel I lane 
4). Also normal goat serum (NGS) did not co-precipitate ICP27 from wt infected 
cell extract (Panel I lane 6). In Figure 3.15 Panel II Western blotting with anti-NUP 
62  (N-19)  showed  precipitation  of  NUP  62  from  wt,  D27  and  M15  cell  extracts 
incubated with anti-NUP 62 (N-19) antibody (Panel II lanes 3,4 and 5) but not with 
normal goat serum (Panel II lane 6). A band of 63 KDa corresponding to ICP27 is 
seen in lane 2 in panel I but not in the mock infected cell extract, as expected. A 
band of 62 KDa is seen in both the mock and 17+ infected cell extract indicating a 
similar amount of p62 in each. 
This antibody was used for co-immunoprecipitation of ICP27 in BHK cell extracts 
infected with wt, D27 and mock infected. Figure 3.16 shows NUP 62 precipitated 
ICP27 in both wt infected and CMV-27 transfected BHK cells and not in D27 and 
mock infected cell extracts nor with normal goat serum (NGS). Because the NUP 
fusion  proteins  used  in  this  project  were  of  human  origin,  experiments  were 
continued in HeLa cells. BHK cell is a standard and most commonly used cell line 
for growing HSV-1. 
The next antibody used in co-immunoprecipitation experiments was anti-NUP 62 
(H-122). Lysates of HeLa cells infected with HSV-1 wt, and mutant HSV-1 M16 
(Table 2.1), D27 HSV-1 and mock infected were mixed with antibody. Wild type 
infected  cell  extract  with  normal  rabbit  serum  (NRS)  was  used  as  a  negative 
control. Again, I note that this was not the best control to use in this experiment. An 
irrelevant antibody of same isotope (IgG) as H-122 should have been used. RNase 
I  treatment  was  used  in  addition  to  untreated  samples.  The  samples  were 
visualised with western blotting with anti-ICP27 antibody (1113) and anti-NUP 62 
(H-122)  to  show  interacting  proteins.  Figure  3.17  Panel  I  shows  ICP27  co-
precipitated  in  wt  and  M16  mutant  infected  cell  extracts  in  the  presence  and 
absence  of  RNase  I  (Panel  I)  whilst  ICP27  was  not  precipitated  from  the  null 
mutant (D27) and mock infected cell extracts (lanes 3, 4, 8 and 9) nor from wt-
infected  lysate  incubated  with  normal  rabbit  serum  (lane  10).  Western  blot  for 
nucleoporin 62 with anti-NUP 62 (H-122) antibody showed that anti-NUP 62 (H-
122) antibody precipitated nucleoporin 62 from wt, M16 and D27 samples in RNase 
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(NRS) did not precipitate NUP 62 from wt infected cell extract (Lane10). However 
H-122 antibody did not precipitate NUP 62 from mock infected cell extracts. A faint 
band can be seen in lane 4 but no band is present in lane 9. This is very surprising 
because H-122 antibody should recognise NUP 62 against which it was raised. To 
confirm that NUP 62 was able to be precipitated from mock infected cell samples a 
new western blot was prepared and blotted with α- 414 antibody that detects all 
FG-repeats nucleoporins. In this case  a strong band was detected in the mock 
infected cell lysates. It is clear that H-122 antibody is not suitable for use in co-
immunoprecipitation experiments. Fortunately the anti NUP 62 antibody N-19 was 
able to precipitate both NUP 62 and ICP27 from cell extracts (Figure 3.15, Panel 
II).    
Another antibody that detects a range of FG-repeat nucleoporins was used to co-
immunoprecipitate ICP27 in complex with nucleoporin 62. The anti-414 monoclonal 
antibody was mixed with HSV-1 wt, D27 and mock infected HeLa cell extracts and 
its ability to precipitate ICP27 was tested in the presence and absence of RNase I. 
Samples  were  analysed  by  western  blotting  with  anti-ICP27  antibody  (1113). 
Figure  3.18  Panel  I  shows  a  band  of  approximately  63  kDa  corresponding  to 
protein ICP27, which co-precipitated in wt infected samples even when treated with 
RNase I (lanes 1 and 6) while lanes containing the controls, mock infected (MI) 
and ICP27 null mutant (D27) infected cell lysates, did not show the corresponding 
band (Figure 3.18 Panel I). A partial band was detected in lane 7 where the D27 
infected cell lysate was co-immunoprecipitated with anti 414 antibody. It was not 
seen in lane 2 without RNase I digestion. It is likely that this is due to spill-over 
from lane 6. Also normal mouse serum (NMS) did not co-precipitate ICP27 from wt 
infected  cell  extract  (lane  4).  Then  samples  were  immunoblotted  with  anti-FG 
repeat NUPs 414 antibody and showed nucleoporin 62 as well as other tested FG 
repeat NUPs were precipitated by this antibody in wt, D27 and mock infected HeLa 
cell  extracts  (Figure  3.18  Panel  II)  while  normal  mouse  serum  (NMS)  did  not 
precipitated NUPs (lane 4). The additional bands are other FG-repeat nucleoporins 
that are detected with 414 antibody and the heavy chain of the antibody is seen at 
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3.5  Mapping the interacting regions of ICP27 with NUP 
62 using GST pull down assay 
GST pull down assays of GST-NUP 62 were carried out and the expressed fusion 
protein bound to beads was mixed with HeLa cells extracts in the presence and 
absence of RNase I. Viral infections were carried out with the panel of the wt and 
ICP27 N-terminus and C-terminus mutants (Table 2.1). Samples were separated 
on SDS-PAGE and visualised by western blotting with anti ICP27 1113 (detects 
amino  acids  109-138  for  d3-4  mutant)  and  1119  (detects  amino  acids  6-19  for 
dLeu  mutant)  monoclonal  antibodies  to  detect  all  mutants.  Anti-ICP27  1113 
antibody  detects  all  wt  and  mutant  ICP27  proteins  except  d3-4  mutant  in  this 
experiment.  Anti-ICP27  1119  antibody  detects  wt  and  all  other  mutants  except 
dLeu. Results showed wt ICP27 and most of the mutants except ICP27 null D27, 
N-terminal  mutant  dLeu  and  C-terminal  mutants  M15  and  M16  interacted  with 
nucleoporin 62. Control mock-infected cell extract did not interact with GST-NUP 
62 (lane 6) as well as GST alone that did not pull down ICP27 from wt infected 
HeLa cell extract (Figure 3.19 Panel I lane 15). Unbound samples fractionated on 
SDS-PAGE and western blotted with anti ICP27 antibodies showed ICP27 protein 
corresponding to the expected size in all wt and mutant cell extracts except D27 
and mock infected as expected (Figure 3.19 Panel II). These data indicated that 
the interactive regions of ICP27 are in the  initial N-terminus amino acids (dLeu 
mutant) and almost at the end of the C-terminus (M15 and M16 mutants) domain 
of ICP27. However, contrary to these data with GST pull downs I detected binding 
of  M15  and  M16  mutants  to  NUP  62  in  immunoprecipitation  experiments.  This 
means that I cannot conclude that the ICP27 C-terminus is involved in the NUP 62 
interaction. Further experiments are required to elucidate this problem. 
3.6  Interaction of TAP with ICP27 and NUPs 
3.6.1  Interaction of TAP with ICP27 
TAP is a good control for ICP27 pull down because it interacts with both ICP27 and 
NUP 62. TAP/NXF1 is the most important nuclear export receptor
 for mRNAs in 
metazoans  that  is  involved  in
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cytoplasm.
  ICP27  was  shown  to  interact  with  TAP/NXF1  both  in  vitro  and
  in 
infected cells. It has been shown that ICP27 shuttles between the nucleus and 
cytoplasm  via  TAP  and  exports  viral  intronless  mRNA.  The  C-terminus  from 
residues 406 to 508 of TAP is required for the
 interaction with ICP27, but the N-
terminal  leucine-rich  region  from  amino
  acids  6  to  12  also  contribute  in  this 
interaction. In fact, ICP27
 interacts directly with TAP/NXF1 in vitro. The association 
of ICP27
 with TAP/NXF1 occurs after ICP27 has left sites of viral transcription. 
Therefore,
  ICP27  mediates  viral
  RNA  export  through  the  TAP/NXF1  pathway 
(Sandri-Goldin  1998;  Koffa,  Clements  et  al.  2001;  Chen,  Sciabica  et  al.  2002; 
Ellison, Maranchuk et al. 2005). To confirm interaction of ICP27 with TAP, GST-
TAP  pull-down  assays  were  performed  with  His-ICP27  and  as  a  control  GST 
alone. Bound samples were analyzed on SDS-PAGE followed by western blotting 
with anti ICP27 mAb (1113). Figure 3.20 Panel I shown GST-TAP pulled down 
ICP27 (lane 4) but GST alone did not interact with ICP27 (lane 3). Lane 2 shows 
interaction of NUP 62 with ICP27. Image quantification showed only around 0.1% 
of ICP27 was pulled down as before. Also the GST-TAP pull down assay test was 
carried out with HeLa cells infected with wt HSV-1 and its mutant D27. Cell extracts 
were incubated with GST-TAP and GST alone and were analysed on SDS-PAGE 
followed by western blot with anti ICP27 mAb (1113). Figure 3.20 Panel II shows 
ICP27  pulled  down  by  GST-TAP  (lane  3)  but  not  with  GST  alone  (lane  2).  In 
comparison, ICP27 mutant D27 did not interact with GST-TAP (lane 4). Panel III 
shows expression of GST-TAP western blotted with anti-GST antibody. In Panel IV 
I have blotted against anti NUP 62 showing association of TAP with NUP 62. 
Co-immunoprecipitation assays of TAP with ICP27 were also performed by using 
the anti-ICP27 antibodies 1113 and 1119 with a range of HeLa cell infected lysates 
and  western  blotted  against  TAP  and  ICP27.  Results  determined  TAP  co-
precipitated with ICP27 from wt infected HeLa cells but not with the other lysates 
(Figure  3.21  Panel  I).  When  membranes  were  western  blotted  against  ICP27, 
precipitation of ICP27 with ICP27 antibody in wt and M15 infected cell extracts was 
observed (Figure 3.21 Panel II). This confirms previously published data from our 
laboratory and from the Sandri-Goldin laboratory. 
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4 Testing Interaction of ICP27 with nucleoporin 98, 
153 and 214 
4.1.1  Interaction of ICP27 with nucleoporin 98 
Nucleoporin 98 is one of the best characterised FG repeat mobile nucleoporins 
that is placed on both sides of the nuclear pore complex and has been shown to 
shuttle between the nucleus and cytoplasm (Griffis, Altan et al. 2002). The ability of 
NUP 98 to export RNA through different pathways has been revealed (Powers, 
Forbes et al. 1997). It can bind to various proteins involved in nuclear transport 
such as HIV-1 Rev protein (Zolotukhin and Felber 1999) and importin β (Griffis, 
Altan  et  al.  2002).  The  N-terminal  domain  NUP  98  is  FG-repeat  rich  and  this 
contributes to protein interaction. Studies using Vesiculoviral matrix protein M (VSV 
M) showed that this protein binds to Rae1 and forms a complex with Rae1 and 
inhibits mRNA export. Rae1 is important to provide delivery of TAP to NUP 98 and 
also has a role in mRNA export by interaction with NUP 98 (Faria, Chakraborty et 
al. 2005). The  ability  of ICP27 in shuttling  and export of viral mRNA has  been 
shown in our laboratory and in this section I present data examining interaction of 
ICP27 with nucleoporin 98 in infected cells and in vitro. 
4.1.2  ICP27 interacts with NUP 98 in a GST pull down assay 
Fusion proteins GST-ICP27 and its homologue GST-ORF57 and negative control 
GST alone were purified, bound to glutathione beads and used to test whether 
ICP27 and ORF57 pulled down nucleoporin 98 from infected HeLa cell extracts. 
The input fusion proteins used were visualised by coomassie blue staining and  
bands of approximately 90 KDa (Figure 3.7 Panel I lane 2), 80KDa (lane 1) and 
28KDa  (lane  3)  corresponding  to  full  length  purified  fusion  protein  GST-ICP27, 
GST-ORF57 and GST alone respectively were observed as well as a number of 
degradation products. A GST pull down assay experiment was carried out using 
the above fusion proteins and infected HeLa cell extracts. HeLa cell nuclear and 
cytoplasmic  extracts  were  prepared  (Figure  5.8).  Both  nuclear  and  cytoplasmic 
extracts were incubated with the above fusion proteins and complexes separated 
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(L-20)  that  detects  the  N-terminus  domain  of  nucleoporin  98  of  human  origin. 
Results  showed  (Figure  4.1)  nucleoporin  98  in  both  nuclear  and  cytoplasmic 
extracts interacted with ICP27 (lanes 2 and 7) and ORF57 (lanes 4 and 8) whereas 
NUP 98 did not interact with GST alone (lane 3). Also lanes 1 and 6 indicate the 
input  control  band  of  about  98  KDa  that  corresponded  to  NUP  98  from  HeLa 
infected cell extracts. We expect the main position of nucleoporin 98 to be in the 
nuclear  side  of  the  NPC.  NUP  98  was  observed  to  be  present  in  the  nuclear 
fraction  and  interacted  with  ICP27  and  ORF57  in  nuclear  extracts.  Some 
interaction  was  also  observed  with  NUP  98  in  cytoplasmic  extracts.  The  lower 
molecular weight bands in lanes 2 and 7 may be a cross ractivity of the NUP 98 
antibody with a cellular protein. However, this band was detected only in the GST-
ICP27 lanes and not in the other lanes so this is difficult to explain. I should have 
used an irrevelent GST fusion protein to rule out nonspecific binding. In addition I 
should have examined binding of cytoplasmic extract to the control GST protein.  
4.1.3  NUP 98 may interact with ICP27 in the pull down assay 
Truncated  GST-NUP  98  fusion  protein  containing  amino  acids  66-515  was 
expressed and purified and bound to glutathione beads (Figure 3.6 Panel II). Pull 
down assays were carried out using GST-NUP 98 and GST alone. These fusion 
proteins were interacted with HeLa cell extracts infected with wt HSV-1 17+, ICP27 
null D27 HSV-1 and mock infected. Pulled down proteins were separated by SDS-
PAGE  and  transferred  to  nitrocellulose  membrane  followed  by  immunoblotting 
using anti-ICP27 (1113) monoclonal antibody (Figure 4.2 Panel I). In wild type (wt) 
(lane 2) infected samples ICP27 was pulled down by GST-NUP 98 (66-515) as 
shown by the approximately 63 KDa sized band (lane 1). In contrast, there was not 
any protein pulled down in mock (lane 4) and D27 HSV-1 infected cell extracts 
(lane 3) as well as GST alone with HSV-1 17+ infected extract (lane 5). The profile 
of unbound ICP27 protein in the pull down assay is shown by western blotting with 
anti-ICP27 antibody (Figure 4.2 Panel II). Also GAPDH levels in the lysates were 
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4.1.3.1  Anti-NUP  98  antibodies  (L-20  and  H-300)  used  to  try  to  co-
immunoprecipitate ICP27 from extracts of HeLa cells infected and uninfected 
with HSV-1 
Co-immunoprecipitation studies to find out in vivo any interaction between ICP27 
and NUP 98 in infected cells were carried out. Co-immunoprecipitation of wild type 
(wt) and mutant HSV-1 infected HeLa cell extracts with antibodies against NUP 98 
was tested. Two anti-NUP 98 antibodies (L-20 and H-300) were incubated with 
HSV-1 wt infected HeLa cell extract, M15 and M16 mutant as well as  27 and 
mock infected HeLa cell extracts. Figure 4.3 Panel I shows ICP27 was precipitated 
with anti-NUP 98 antibody L-20 in the presence of RNaseI. However, I was not 
able to compare this to precipitation in the absence of RNase I so I cannot say 
whether RNase reduces NUP 98 interaction with ICP27 with this antibody. Control 
preimmune normal goat serum did not precipitate ICP27. However, as I mentioned 
before in chapter 3, this is not the best control to use for the immunoprecipitation 
experiment. A small amount of ICP27 also co-precipitated from M15 infected cell 
extracts  in  presence  of  RNase  I  (Panel  I  lane  5).  The  significant  reduction  in 
interaction of M15 ICP27 protein with NUP 98 may reflect its reduced ability to take 
part in nuclear export of virus RNAs. However I did not include an input lane for 
M15 infected HeLa cells and it is known that M15 is replication defective. So this 
may explain the low level of precipitated ICP27 in this lane. As expected, ICP27 
null mutant and mock infected cell extracts did not show the corresponding band 
(Panel I lanes 4 and 6). A band of around 63 KDa in the HSV-1 wild type infected 
cell extract input (lane 2) corresponds to ICP27 and acts as a positive control.  
The next antibody used in a co-immunoprecipitation experiment was anti-NUP 98 
(H-300). It was mixed with HeLa cell lysates infected with HSV-1 wt and HSV-1 
mutants M16 and D27 and mock infected as well as HSV-1 wt infected cell extracts 
with normal rabbit serum (NRS). Also RNase I treatment was used in addition to 
untreated  samples. Western  blotting  with  anti-ICP27  antibody  (1113)  showed  a 
possible  interaction  of  the  proteins.  Figure  4.3  Panel  II  shows  ICP27  co-
precipitated in wt infected cell extracts in the presence and absence of RNase I 
and the approximately 63 KDa band in lanes 2 and 7 corresponded to the ICP27 
protein. ICP27 also co-precipitated in M16 mutant infected cell extracts but only in 
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(I do not have a control for this) in this sample or reduction of interaction by RNase 
I. Whilst NUP 98 H-300 antibody in the presence of  ICP27 null mutant (D27) and 
mock infected cell extracts could not precipitate ICP27 (lanes 4, 5, 9 and 10). Wild 
type HSV-1 infected cell lysate ICP27 did not co-precipitate with pre immune rabbit 
serum (lane 11).  
However Panel III shows that NUP 98 was not pulled down from mock infected and 
infected cell extracts using antibody L-20 (this was also the case for H-300). This 
was an unexpected result. However there is no record in the literature of these 
antibodies  being  used  successfully  to  precipitate  NUP  98.  As  I  could  not  see 
precipitation of NUP 98 with the antibodies, this calls into question the ICP27 pull 
down data in Panels I and II. To explain the co-precipitation of ICP27 and NUP 98 
in Panels I and II, it is possible that protein/ protein interactions such as NUP 98 
and  cargo  like  ICP27  may  expose  epitopes  that  could  be  hidden  in  the  native 
protein. My results do not conclusively demonstrate an interaction between NUP 
98 and ICP27.      
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4.1.4  Interaction of ICP27 with nucleoporin 153 
One of the large, important FG repeat nucleoporins that is positioned in the nuclear 
basket is NUP 153. This 1476 amino acid nucleoporin is a structural component of 
the nuclear pore complex and the NPC transport system. The critical role of NUP 
153 during nuclear export and import has been demonstrated (Ullman, Shah et al. 
1999) and interaction of this nucleoporin with other NUPs such as NUP 62 and its 
contribution of them in nuclear transport has been suggested (Stochaj, Banski et 
al. 2006). Similar to NUP 214, the C-terminus domain of NUP 153 with many FG 
repeat residues is involved in interactions with various proteins that are related to 
the  transport  machinery  (Walther,  Fornerod  et  al.  2001).  Since  the  aim  of  this 
project is to identify cellular nucleoporins which can interact with the HSV-1 ICP27, 
protein NUP 153 was next considered among the large subset of nucleoporins
 that 
contains long phenylalanine-glycine dipeptide-containing domains
 (FG repeats). It 
has  been  suggested  these  form  a  kinetic  meshwork  and  allow  transport  of 
complexes by creating a barrier (Ribbeck and Gorlich 2001; Rout and Aitchison 
2001).  Also  to  achieve  nuclear  transport,
  proteins  and  RNAs  bind  transport-
competent receptors either
 directly or indirectly via adaptor proteins (Mattaj and 
Englmeier  1998)  and  studies  on  cells  infected  with  poliovirus  have  shown 
degradation of NUP 153 after infection with this virus in disruption of NPC (Gustin 
and Sarnow 2001). In this section my data suggest interaction of nucleoporin 153 
with ICP27 by using protein interaction assay methods. 
 
4.1.5  Recombinant GST-NUP 153 interacts with ICP27 in a pull 
down assay 
Full length GST-NUP 153 fusion protein was expressed in bacteria and purified 
(Figure 4.4 Panel IV and V). Unfortunately many degradation products can be seen 
in the Coomassie-stained gel. However it is likely that the band with the lowest 
mobility is NUP 153 due to the correct apparent size. Western blotting of a similar 
gel with anti NUP 153 antibody revealed that the most upper band was indeed 
NUP 153. Although there  is a  bubble or space on the  autoradiograph  over the 
bound fraction between 70-180 KDa, the unbound fraction clearly shows a GST-
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assay  to  test  whether  it  is  possible  to  bring  down  ICP27  from  wt  HSV-1  HeLa 
infected  cell  extract.  RNase  I  treatment  was  used  to  remove  the  RNAs  in  the 
samples and as a control I interacted HSV-1 wt infected lysate with GST alone. 
SDS-PAGE  followed  by  western  blotting  with  anti-ICP27  antibody  showed  that 
ICP27  interacted  with  GST-NUP  153  but  did  not  bind  to  GST  alone.  An 
approximately 63 kDa band corresponding to ICP27 was observed in the input lane 
(Figure 4.4 Panel I lane 3). Panel II shows unbound protein lysate used in this 
western  blot  experiment  and  panel  III  shows  levels  of  GAPDH  in  the  unbound 
samples. 
4.1.5.1  Anti-NUP  153  antibody  co-immunoprecipitated  ICP27  from  cell 
extracts 
Specific  monoclonal  antibody  against  nucleoporin  153  was  used  to  co-
immunoprecipitate ICP27 from infected HeLa cell lysates. Antibody was mixed with 
wt  HSV-1,  ICP27  null  mutant  27lac  Z  and  D27  infected  HeLa  cell  extracts  and 
mock infected cell extracts. Samples were fractionated on 6% SDS-PAGE followed 
by western blotting with anti-ICP27 (1113) and anti-NUP 153 antibodies. Results 
indicated that anti-NUP 153 precipitated NUP 153 in all samples. Normal mouse 
serum did not precipitate any NUP 153 (Figure 4.5 Panel II). Western blotting with 
anti-ICP27  antibody  showed  nucleoporin  153  co-precipitated  ICP27  from  wt 
infected cell extract but not from its null mutants 27lac Z and D27 nor from mock 
infected cell extracts. Also co-immunoprecipitation with NMS did not bring down 
ICP27 from wt infected cell extract (Figure 4.5 Panel I) as expected. 
 
4.1.6  Mapping the interacting regions  of  ICP27 with NUP 153 
using GST pull down assay 
Fusion protein full length GST-NUP153 was expressed and purified as described 
previously and HeLa cells were infected with wild type HSV-1 and ICP27 mutants 
representing several functional domains of ICP27 (Figure 4.6). To map the regions 
of ICP27 involved in the interaction with nucleoporin 153, GST-NUP 153 was used 
to pull down ICP27 from HSV-1 wt and ICP27 mutant-infected cell extracts. Pull 
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antibodies1113 and 1119. The observed pattern showed GST-NUP 153 brought 
down ICP27 in wt infected cell extract and interacted with both N and C terminus 
domain mutants of ICP27.  Exceptions were dLeu a nuclear export signal mutant at 
very N-terminus part of ICP27 and M15 point mutation at the C terminus of ICP27. 
ICP27 null mutant D27 and mock-infected samples did not show the corresponding 
bands  as  expected  (Figure  4.6  Panel  I).  The  unbound  sample  membrane  was 
stripped and western blotted with GAPDH to show the amounts of protein in the 
lysates (Figure 4.6 Panel III). It can be seen from the control western blot in Panel 
III that the amount of GAPDH is not equal in all lanes. This means that there is 
probably less extract loaded in lanes 5, 8 and 13. d2-3 (lane 5) showed strong 
interaction with NUP 153. However the weaker interaction of d6-7 may be due to 
lower levels of ICP27 in the reaction. Results suggest the partial contribution of 
some mutants that have significantly reduced interaction with NUP 153 such as d1-
2 in the N-terminal domain and M16 in C-terminal part of ICP27. Unbound samples 
were  western  blotted  with anti-ICP27  antibodies  1113  or  1119  and showed the 
levels of ICP27 protein in each sample (Figure 4.6 Panel II).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                         Chapter 4, Results               
  84 
4.1.7  Interaction of ICP27 with nucleoporin 214/CAN 
Nucleoporin 214/CAN is one of the cytoplasmic side FG repeat NUPs that interact 
with various cellular and viral factors to facilitate their transport through the nuclear 
pore  complex.  This  2090  amino  acid  NUP  consists  of  three  major  domains 
including  the N-terminal domain that localises to the cytoplasmic face of the NPC, 
the central domain associated with NUP 88 that binds to NUP 98, and is located at 
the  cytoplasmic  ring  of  the  NPC  near  the  entry  to  the  central  pore  and  the  C-
terminal FG-repeat domain that localises at both the nuclear and cytoplasmic face 
of the NPC. Multiple locations of the C-terminus indicates a flexible property of the 
NUP 214/CAN FG-repeat domain (Paulillo, Phillips et al. 2005).These C-terminal 
~800 amino acid residues interact with various transport factors as well as with 
other FG repeat nucleoporins such as NUP 62 and has been shown to be involved 
in both nuclear import and  export (Stochaj, Banski et al. 2006). The  profiles of 
interaction between ICP27 and NUP 214/CAN proteins are presented in this part.  
4.1.8  NUP 214/CAN interacts with ICP27 in the pull down assay 
To  test  the  interaction  of  the  cytoplasmic  nucleoporin  214/CAN  with  ICP27,  I 
expressed and purified 2 recombinant GST fusion proteins of NUP 214 gifted by 
Dr. Elisa Izaurralde (Chapter 2). Both of these fusion proteins contained the C-
terminal domain of NUP 214 that is FG-repeat rich. Amino acid truncation 1690-
2090 was the bigger fusion protein that was observed in western blotting with an 
anti-GST  antibody  as  well  as  anti  FG-repeat  NUP  414  antibody  yielding  an 
approximately 67 KDa band (Figure 3.6 Panel II). The second recombinant protein 
was a truncation of amino acids 1690-1894 that was used in some experiments 
yielding  a  band  of  an  approximately  50  KDa  (Figure  3.6  Panel  III).  Pull  down 
assays  were  carried  out  using  these  GST  fusion  proteins  and  GST  alone  and 
incubated with HSV-1 wt, D27 and mock infected HeLa cell extracts. Samples were 
separated  by  running  on  SDS-PAGE  and  western  blotted  with  anti-ICP27 
antibody(1113). Results showed both GST-NUP 214 (1690-1894) and GST-NUP 
214  (1690-2090)  (Figure  4.7)  interacted  with  ICP27  in  HSV-1  wt  infected  cell 
extract samples but did not interact in D27 and mock infected HeLa cell extract 
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with wt infected HeLa cell extract. This experiment also demonstrated GST-NUP 
214 (1690-2090) gives a stronger band in comparison with its smaller truncation of 
GST-NUP 214 (1690-1894). The unbound samples of this pull down assay were 
analysed by running the samples and western blotting with anti-ICP27 antibody. 
These show the absence of ICP27 in D27 and mock infected HeLa cell extracts 
and presence of ICP27 in wt infected HeLa cell extract samples (Panel II). No band 
was observed in lane 6 with wild type HSV-1 infection. This was very surprising. It 
is possible that all the ICP27 had interacted with NUP 214 and precipitated from 
the extract or ICP27 had become degraded in this fraction. Western blotting with 
anti-GAPDH antibody showed similar levels of GAPDH in Panel III of Figures 4.7. I 
did  not  carry  out  the  reverce  experiment,  using  GST-ICP27  to  pull  down  NUP 
214/CAN. 
4.1.8.1  ICP27 and NUP 214 co-immunoprecipitate from cell extracts 
The antibody that I used in this study to co-precipitate ICP27 from cell extracts was 
anti-NUP 214 (N-15). Immunoprecipitation tests were carried out by mixing anti-
NUP 214 (N-15) antibody with HSV-1 wt, M16 point mutant, ICP27 null D27 and 
mock infected HeLa cell extracts. Wild type HSV-1 infected cell extracts incubated 
with normal goat serum (NGS) was used as a control for the immunoprecipitation 
test.  Samples  were  separated  on  SDS-PAGE  followed  by  western  blotting  with 
anti-ICP27 (1113) antibody. As shown in Figure 4.8, ICP27 was co-precipitated by 
nucleoporin  214  in  wt  infected  and  M16  point  mutant  extract  samples  in  the 
presence and absence of RNase I (lanes 1, 2, 7 and 8). The stronger band of 
ICP27 in M16 infected cell lysates (lane 2) in comparison to the band in HeLa cell 
lysates infected with wt virus is due to accidently loading of more M16 cell extract 
(2X) in this lane. Six lanes of Panel I were stripped and western blotted with anti 
FG-repeat NUP 414 antibody and showed precipitation of NUP 214 in all lanes 
except lane 6 where immunoprecipitation was carried out with normal goat serum. 
(Figure 4.8 Panel II). I did not carry out a GAPDH loading control on the unbound 
fraction. This should have been doen to confirm the increased loading in lane 2 
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4.1.9  Mapping the interacting regions  of  ICP27 with NUP 214 
using a GST pull down assay 
GST pull down assay was used to identify regions of ICP27 that are involved in 
interaction with nucleoporin 214/CAN. A truncation of GST-NUP 214 (1690-2090) 
that encompasses the other truncation of GST-NUP 214 (1690-1984) described 
previously,  was  used  to  pull  down  ICP27  from  the  panel  of  the  ICP27  wt  and 
mutant virus-infected cell extracts. Western blot of the membrane with anti-ICP27 
antibody showed (Figure  4.9 Panel I) some of the mutant ICP27 proteins were 
pulled down by GST-NUP 214 (1690-2090) and there was no interaction with GST 
alone (Panel I lane 15). Data showed there was no binding between GST-NUP 214 
(1690-2090)  and  ICP27  null  mutant  (D27)  and  mock  infected  HeLa  cell  extract 
(Panel I lane 2 and 3). C-terminus point mutants M15 and M16 (Panel I lane 5 and 
6) and the N-terminus mutant dLeu (Panel I lane 7) were unable to interact with 
GST-NUP  214  (1690-2090).  Other  N-terminal  and  C-terminal  mutants  that 
interacted with GST-NUP 214 (1690-2090) gave ICP27 protein bands with different 
molecular  weight  corresponding  to  their  mutation  (Panel  I).  A  GAPDH  loading 
control is missing from this experiment. So I can only conclude whether a mutant 
interacts with NUP 214, not to what extent they may interact. Panel II shows ICP27 
detected  in  all  the  lysates  of  HSV-1  infected  cells,  but  not  in  the  HSV-1  D27 
infected, nor in mock infected cells. The Panels in Panel II are taken from different 
gels and gels that are differents to that on Panel I. This means that levels of ICP27 
cannot be compared between the lanes. These results suggested that both the N-
terminal and C-terminal part of ICP27 are involved in interaction with nucleoporin 
214/CAN. The input sample of some GST-NUP 214 (1690-2090) that was used in 
this experiment is shown (Figure 4.9 Panel III). 
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5  Further  study  of  ICP27  and  nucleoporin 
interaction  
5.1  ICP27 does not interact with non FG-repeat NUPs 
5.1.1  GST-Rae 1 fusion protein expression 
To  optimise  GST-Rae1  expression  and  obtain  sufficient  amounts  of  purified 
protein,  effects  of  temperature  and  protease  deficient  BL21-Codon  plus-RP 
competent E.coli cells that enables efficient high-level expression of heterologous 
proteins,  were  investigated.  A  GST-Rae1  expression  plasmid  (a  non  FG-repeat 
nucleoporin  that  is  involved  in  mRNA  export)  was  used  in  an  optimisation 
experiment and the initial and final improved level of expression obtained can be 
seen in the next section. 
5.1.1.1  The effect of temperature on expression of the GST-NUP Rae1 
There  are  numerous  single  case  studies  showing  increased  solubility
  of 
recombinant proteins at lower cultivation temperatures. I have seen this effect on 
my nucleoporin GST fusion proteins at
 29° C. Bacterial cultures were grown in 100 
ml LB containing ampicillin and were induced at OD600 of 0.6 by 1.0 mM IPTG and 
incubated at 37° C and 29° C and harvested after 3 an d 16 hrs respectively. Pellets 
were  lysed  by  sonication  in  lysis  buffer  and  incubated  with  gluthatione  beads. 
Samples  were  analysed  on  10%  SDS-PAGE  and  stained  by  Coomassie  blue. 
Results shown in Figure 5.1 demonstrated at 29° C te mperature that level of full-
length GST-Rae1 expression was highest and the level and number of truncations 
were  reduced  (Panel  I,  lanes  1  &  2)  in  comparison  with  a  higher  cultivation 
temperature of 37° C (Panel II, lanes 3 & 4). Thus protein expression continued to 
be at 29° C.  
5.1.1.2  The effects of E.coli strain on expression of GST-Rae 1 
To  produce  nucleoporins  as  GST  fusion  proteins,  a  protease  deficient  strain  of 
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human nucleoporins fused to GST and wanted to obtain significant expression of 
full-length GST-NUPs the strain of E.coli competent cells was altered to increase 
the amount of full-length product. Expression tests as described in Material and 
Methods were carried out on the strain BL-21 (DE3) Codon
 Plus RP (Stratagene), 
which has a plasmid that supplies extra
 tRNAs corresponding to codons that are 
rare  in  E.  coli  but  common
  in  humans.  Figure  5.2  demonstrates  significant 
efficiency of BL-21 Codon Plus RP in expression of GST-Rae 1 (Panel I, lane 1) in 
comparison to the usual strain BL21 (Panel I, lane 2). Enhanced level of protein 
expression and reduction of truncates and degraded bands are the advantage of 
E.coli BL-21 (DE3) Codon
 Plus RP (Stratagene), which was mostly used in this 
study.  Optimised  purified  GST-Rae1  was  analysed  using  a  Protein  200  Plus 
LabChip  kit  (Agilent  technologies)  (Panel  II,  lane  1),  and  blotted  with  anti-GST 
antibody  (Panel  II  lanes  2  &  3).  This  fast  protein  analysis  with  the  bioanalyser 
system  is  used  allow  monitoring  and  optimisation  of  each  step  of  recombinant 
protein purification via affinity chromatography. A similar approach was taken to 
purify another non FG-repeat NUP, NUP 107 (Figure 5.3, Panel I).   
5.1.2  ICP27  does  not  interact  with  nucleoporin  Rae1  and 
nucleoporin 107 
Rae1 is an mRNA export factor that has a homologue Gle2 in Saccharomyces 
cerevisiae.  Rae1  interacts  with  RNPs  and  mutation  in  the  Rae1/Gle2  genes 
disrupts poly (A) RNA export, NPC, and nuclear envelope structure. This 41 KDa 
nuclear pore complex protein is a shuttling mRNA export factor that interacts with 
NUP 98 at an amino terminal region named the GLEBS motif or Rae1 binding site. 
Rae1 also binds TAP/NXF1 and a role is proposed for Rae1 in recruiting TAP to 
NUP  98,  possibly  representing  the  first  step  for  interaction  of  mRNP  export 
complexes  to  Nups  (Blevins,  Smith  et  al.  2003).  It  has  been  shown  Vesicular 
stomatitis virus (VSV) M protein binds the mRNA export factor Rae1 and blocks 
mRNA export by disrupting Rae1 function (Faria, Chakraborty et al. 2005).  
Nucleoporin 107 is localized to the nuclear rim and is an essential component of 
the nuclear pore complex (NPC). NUP 107 does not contain FG repeats that serve
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that depletion of mammalian NUP 107 resulted in the failure of a subset
 of NUPs to 
assemble into NPCs followed by degradation of these
 proteins (Ben-Efraim and 
Gerace 2001). To determine interaction between ICP27 and Rae1 and NUP107 
pull down assays were carried out. GST-NUP107, GST-TAP (Figure 3.20, Panel 
III), GST-Rae 1 and GST alone were incubated with His-ICP27. Bound proteins 
were  visualised  by  running  on  10%  SDS-PAGE  and  western  blotting  with  anti-
ICP27 antibody (1113). Figure 5.3 shows ICP27 was not pulled down with GST-
NUP107 nor with GST-Rae 1 (Panel II, lanes 4 and 3) while GST-TAP had the 
ability to bring down ICP27 as expected (Panel II, lane 5). Two bands seen in lane 
3 (GST-Rae 1) could be nonspecific detection of cellular proteins by the ICP27 
antibody.  
 
5.2  HSV-1  infection  does  not  affect  expression  of 
nucleoporin  
5.2.1  Introduction 
Generally,  transport  of  macromolecules  through  the  nuclear  pore  complex  is 
dependent  upon  interactions  with  the  NPC,  which  is  regulated  by  signalling 
pathways  and  viruses.  In  fact  our  understanding  about  virus-host  interactions 
seems  to  supply  insights  into  the  key  regulatory  steps  of  nucleocytoplasmic 
shuttling, which could also provide possible targets for viral and cancer therapies 
(Fontoura, Faria et al. 2005). Certain RNA viruses that replicate in the cytoplasm 
disrupt nucleocytoplasmic trafficking. It may benefit them to inhibit cellular mRNA 
export and reduce the competition with the cellular machinery for replication and 
translation  (Gustin  2003).  It  has  been  shown  that  poliovirus  infection  induces 
disruption of the NPC by inhibiting nuclear import of cellular proteins, which likely is 
due to the degradation of NUP 153, NUP 62 and probably of other nucleoporins 
(Gustin and Sarnow 2001). On the other hand it was demonstrated that Vesicular 
stomatitis virus (VSV) induces  a major blockage in mRNA export by interaction 
between VSV M protein and the mRNA export factor Rae1 (Faria, Chakraborty et 
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The protein 5A (NS5A) of HCV is involved in interaction with Kapb3 and disruption 
of nuclear import of ribosomal proteins (Chung, Lee et al. 2000). Also the potential 
ability  of  adenovirus  in  disruption  of  the  mRNA  export  pathway  has  been 
demonstrated (Flint and Gonzalez 2003). HSV-1 is a DNA virus that replicates in 
the nucleus and its regulatory protein ICP27 can interact directly with REF/Aly that 
then recruits TAP to induce viral mRNA export (Koffa, Clements et al. 2001; Chen, 
Sciabica et al. 2002). It has been shown that HSV-1 infection of HeLa cells did not 
affect the nucleocytoplasmic transport of several cellular shuttling proteins but this 
study did not presented any data about nucleoporins (Chen, Li et al. 2005). In this 
project  I  have  shown  evidence  to  suggest  direct  interaction  of  shuttling  HSV-1 
protein, ICP27 with some FG-repeat nucleoporins. It was interested to examine the 
ability  of  ICP27  in  interference  with  nucleoporins  and  any  possible  change  in 
expression of NUPs.  
5.2.2  Expression of ICP27 and mutated ICP27 in HSV-1 infected 
HeLa cells 
A time course study of HeLa cell infection with wild type HSV-1 17+, ICP27 null 
(D27)  mutant  and  mock  infected  cell  extract  was  carried  out  at  various  times. 
Equivalent amounts of proteins were fractionated on 10% SDS-PAGE and western 
blotted  with  monoclonal  anti  ICP27  antibody  (1113).  Results  showed  ICP27  is 
expressed as early as 2 hours post infection (Figure 5.4, Panel II). It appears that 
expression of ICP27 increases after 2 hours and a high level of expression is seen 
at 8 h post infection at MOI=10 (lane 14), at 16 hpi with MOI=1 (lane 20) ICP27 
levels eventually reduced due to cell lysis (e.g lane 29 MOI=0.1). The idea behind 
carrying  out  infections  at  different  MOI  until  48  hpi  was  to  show  expression  of 
ICP27 in low MOI infected cells. A 63 KDa ICP27 band was detected in HSV-1 17+ 
infected cell extracts (lanes 2, 5, 8, 11, 14, 17, 20, 23, 26, 29). However no similar 
sized  bands  were  seen  in  the  mock  infected  and  ICP27  null  HSV-1  infected 
extracts (lanes 1, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25, 27, 28, 
30). The weak upper bands could be due to some cellular proteins that cross react 
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5.2.3  Expression of nucleoporins in mock, wt and HSV-1 ICP27 
null mutant infected HeLa cells 
A time course study of HeLa cell infection with wild type HSV-1 17+ , ICP27 null 
(D27)  and  mock  infected  cells  was  carried  out,  proteins  were  fractionated  by 
running on a 6% SDS-PAGE and western blotted with monoclonal anti FG-repeat 
nucleoporin  414  antibody.  Results  showed  various  nucleoporins  are  expressed 
well at different MOI and at different times post infection (Figure 5.5). There is no 
significant difference in expression of nucleoporins in any of the cell extracts at any 
MOI or time post infection except at MOI=0.1 at 36 and 48 hpi (Panel III). There 
appears to be lower levels of FG repeat nucleoporins in lanes 22-27 but this may 
be due to reduced numbers of live cells even in the uninfected cell populations. 
The  FG-repeat  nucleoporins  I  worked  on  are  marked.  The  additional  bands 
detected could be some other cellular nucleoporins proteins that are recognised 
with anti FG-repeat NUPs 414 antibody but are not in my study. Infecting HeLa 
cells with the various HSV-1 ICP27 mutants I have used in my study and harvested 
and  western  blotted  with  anti  FG-repeat  NUPs  414  antibody  showed  a  similar 
profile  as  above.  This  experiment  shows  that  virus  infection  does  not  regulate 
NUPs.   
5.2.4  Transient  transfection  study  of  ICP27  showed  no  change  in 
expression level of endogenous nucleoporins 
In  addition  to  the  previous  studies  on  levels  of  expression  of  endogenous 
nucleoporins by infection with HSV-1 ICP27, I carried out transient transfection of 
enhanced  yellow  fluorescent  protein  ICP27  (EYFP-ICP27)  plasmid,  which 
expresses  ICP27.  After  24  h,  transfected  lysates  and  other  control  infected 
samples  including  mock,  mock  with  optimem  and  lipofectamine  and  also  GFP 
alone (because YFP was not available) were fractionated on 6% SDS-PAGE and 
western blotted with anti FG-repeat NUPs 414 antibody. Results did not show any 
effect of YFP-ICP27 on levels of expression of nucleoporins in tested samples in 
comparison  with  the  controls  seen  in  this  experiment  (Figure  5.6,  Panel  I).  So 
ICP27 cannot regulate expression of nucleoporins. Also to show the presence of 
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PAGE and western blotted with anti GFP antibody. Figure 5.6, Panel II shows the 
presence of ICP27 in the YFP-ICP27 transfected sample but not in the controls. 
   
5.3  Nuclear and cytoplasmic expression of ICP27 and 
nucleoporins in mock, wt HSV-1 and mutated ICP27 HSV-
1 infected HeLa cells 
To  examine  the  profile  of  nucleo-cytoplasmic  expression  of  ICP27  and 
nucleoporins,  infection  of  HeLa  cells  with  HSV-1  wt,  mutated  ICP27  and  mock 
infected cell extracts was carried out by MOI=10 at 6 and 12 hpi. Nuclear and 
cytoplasmic fractions were made as described by the manufacturer (Active Motif) 
and protein concentration estimated by Bradford assay. Samples were fractionated 
on 6% SDS-PAGE followed by western blotting against ICP27, NUP 98, NUP 62 
and ICP4. Figure 5.7, Panel I shows ICP27  was expressed in the nucleus and 
cytoplasm  in  cells  infected  with  wild  type  HSV-1.  ICP27  mutant  M15  was  only 
examined  at 12 hpi. It  was  also  present  in both  compartments. ICP27  was  not 
detected in mock and HSV-1  27 infected cells. Expression levels of mutant M15 
were reduced significantly in comparison with wild type. It has been shown that 
viral infection of cells with the M15 ICP27 mutant completely abrogates replication 
(Mears and Rice 1998) but the ability of this mutant to infect cells, express shuttling 
of protein and replicate DNA is similar to that of wild type HSV-1 (Mears and Rice 
1998). This indicates more investigation is required to fully understand its role. The 
overexposed lanes 5-8 do not allow a clear comparison between ICP27 level in 
these experiments. Panel II shows expression levels of NUP 98 in nuclear and 
cytoplasmic fractions in infected and non-infected lysates. It could be seen that 
more nuclear expression of NUP 98 was present in most infections. Blotting with 
anti-NUP 62 antibody demonstrated significant nuclear expression of NUP 62 in 
comparison  with its cytoplasmic profile (Panel III). The above membranes were 
stripped  and  western  blotted  against  ICP4  to  test  expression  of  a  viral  nuclear 
protein (Panel IV). Unfortunately I was not able to probe for a cytoplasmic protein 
to  verify  the  fractions.  This  experiment  suggests  that  virus  infection  does  not 
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5.4  Involvement of ICP27 SADET sequence mutants in 
interaction of ICP27 and nucleoporins 
5.4.1  Introduction 
Similar  to  ICP27,  heterogeneous  nuclear
  ribonucleoprotein  K  (hnRNP  K)  is  a 
multifunctional  protein  that  is  able  to  shuttle  between  the  nucleus  and  the 
cytoplasm  and  with suggested  role in transcription,  export of mRNA as  well as 
translation  (Matunis,  Matunis  et  al.  1992;  Michael,  Eder  et  al.  1997).  An 
involvement of the SADET amino acid sequence that is conserved between the 
KNS  residues  of  hnRNP  K  and  the  C  terminus  region  of  ICP27  has  been 
suggested (Leiper 2004) (Figures 1.7 and 1.8). ICP27 contains a region (aa 338-
378) homologous to the hnRNP K bi-directional shuttling domain KNS (Michael, 
Eder et al. 1997) and KNS mediated export is postulated via direct nucleoporin 
interaction.  The  HSV-1  M15  ICP27  replication  defective  mutant  showed  the 
importance  of  the  positionally  conserved  amino  acids  within  ICP27  in  the  C 
terminal region (Rice and Lam 1994). Claire Leiper, previously in our laboratory, 
made an engineered set of mutant plasmids that contain nucleotide substitution 
mutations in the SADET region to further investigate the structure and functions of 
ICP27.  This  work  showed  that  certain  SADET  mutants  altered  the  localisation 
pattern of ICP27 and also they failed to interact with the cellular export factor REF 
and hnRNP K. These mutants were introduced into the pCMV-27 vector (Leiper 
2004). The aim of this section of the project was to evaluate involvement of ICP27 
SADET  mutants  in  interaction  with  nucleoporins  and  the  nucleo-cytoplasmic 
transport system. 
5.4.2  Expression  of  SADET  mutant  proteins  in  transfected 
HeLa cells  
To  test  the  protein  expression  of  the  ICP27  SADET  mutants  and  to  show  the 
predicted size of the proteins. Equal amounts of wt and ICP27 SADET mutants 
expression  plasmids  (6   g)  were  transfected  into  HeLa  cells.  Transfected  cells 
were  harvested  after  24  hours,  protein  lysates  prepared  and  Bradford  assay 
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fractionated on 10% SDS-PAGE and proteins were analysed by western blotting 
with the anti ICP27 1113 antibody (Figure 5.8, Panel I). All of the wt and mutant 
ICP27 expression constructs tested encoded a protein that migrated at a similar 
size to wt ICP27. The wt CMV-27 SADET showed the 63 KDa band corresponding 
to  ICP27  and  some  degradation/truncation  products  (Panel  II  lane  7).  Mutant 
proteins were expressed at a significantly lower level in comparison with wt ICP27 
and the level seemed to vary among the mutants (Panel I lanes 2-7 and Panel II 
lanes  1-7).  As  a  control,  no  protein  was  detected  with  antibody  in  the  mock-
transfected lysate (Panel I lane 1). In Panels III and IV, the above membranes 
were  western  blotted  with  anti  GAPDH  antibody  and  demonstrated  the  level  of 
proteins used in this expression. Lanes 1-7 Panel III were exposed for a longer 
time than Panel IV. 
5.4.3  The  SADET  region  is  not  involved  in  the  interaction  of 
ICP27 and nucleoporins 
To  examine  involvement  of  SADET  mutants  in  interaction  of  ICP27  with 
nucleoporins,  immunoprecipitation  experiments  were  performed.  Lysates  from 
HeLa cells transfected with a range of ICP27 SADET mutants and ICP27 wild type 
expression plasmids were incubated with anti ICP27 1113 antibody and beads and 
treated  with  and  without  RNase  I.  Proteins  were  separated  by  SDS-PAGE  and 
transferred  to  nitrocellulose  membrane  and  western  blotted  with  anti  ICP27 
antibody 1113. RNase I untreated samples showed precipitation of ICP27 from all 
lysates as a 63 KDa band (Figure 5.9, Panel I). In RNase I treated samples, wt 
SADET  (CMV-63  in  Materials  and  Methods)  and  mutants  GADET  and  SADEG 
showed  a  strong  band  in  comparison  to  other  mutants  indicating  more  protein 
precipitation  (Figure  5.10,  Panel  I).  I  cannot  explain  why  SADET  mutants  have 
different mobilities in this experiment. Then membranes were stripped and western 
blotted  with  anti  FG  repeat  414  antibody  and  analysed  to  see  co-
immunoprecipitation of NUP 62 by ICP27 SADET mutants (Figure 5.9, Panel II). 
Results  were  difficult  to  interpret  because  of  variation  in  NUP  62  precipitation. 
While the wild type SADET (CMV-63) co-immunoprecipitated NUP 62, levels of 
precipitated  NUP  62  and  hnRNP  K  followed  those  of  ICP27  expression.  The 
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precipitated NUP 62 (Figure 5.10, Panel II). The AGAGA mutant lysate was limiting 
so it was used just in the RNase I treated experiment. RNase I treatment reduced 
interaction  of  ICP27  with  some  mutants  such  as  SAG  and  SAD  as  well  as 
interaction of them with NUP 62. However there was little change in level of the wt 
SADET and mutants GADET and SADEG after RNase I treatment (Figure 5.10, 
Panel I). To show presence of ICP27 expression in the lysates and to estimate the 
reactive amount of protein used for this experiment, unbound samples were run on 
SDS-PAGE,  transferred  and  western  blotted  against  anti  ICP27  antibody  and 
showed ICP27 was present in these samples (Figures 5.9 and 5.10, Panels IV). 
The  unbound  sample  membrane  was  stripped  and  western  blotted  with  anti 
GAPDH antibody and data confirmed roughly equal amounts of protein used in this 
experiment  (Figures  5.9  and  5.10,  Panels  V).  ICP27  protein  has  a  SADET 
sequence  is  partially  identical  to  the  sequence  of  the  hnRNP  K  bi-directional 
shuttling sequence (Michael, Eder et al. 1997). The next work was designed based 
on the idea that this sequence from ICP27 that is conserved in its homologues has 
been implicated in shuttling hnRNP  K. I  tested  whether  ICP27 SADET mutants 
may bind hnRNP K. It could show if mutations in this region result in the loss of 
interaction. The rest of the ICP27 immunoprecipitation samples were fractionated 
by  SDS-PAGE  gel  and  western  blotted  against  hnRNP  K  and  showed  the  co-
precipitation of hnRNP K by ICP27 in all wt and SADET mutants in the presence 
and absence of the RNase I treatment (Figures 5.9 and 5.10, Panels III). However 
it  seems  by  the  present  results  that  all  SADET  mutants  of  ICP27  bound  to 
hnRNPK.  This  is  different  to  what  was  found  previously  in  our  laboratory  and 
further work needs to be done to make it clear. 
5.5  Time course immunoprecipitation study of wt and 
mutant  HSV-1  infected  HeLa  cell  extracts  ICP27  and 
nucleoporin interaction 
5.5.1  Introduction 
ICP27 not only localises to the nucleus but also is capable of shuttling between the 
nucleus and cytoplasm, a feature that is consistent with a role in the RNA-based 
regulation of gene expression. Different studies have shown nuclear distribution of                                                                                                                           Chapter 5, Results               
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ICP27 at early times of infection and both nuclear and cytoplasmic localisation at 
later  times  of  infection  (Phelan  and  Clements  1997).  So  it  was  of  interest  to 
understand the timing of nucleoporin involvement with ICP27 in infected cells by 
using immunoprecipitation experiments. 
5.5.2   Profile of expression of ICP27 and nucleoporins in a time 
course immunoprecipitation study 
To examine a time course of immunoprecipitation, Hela cells were infected with 
HSV-1  wt,  ICP27  null   27,  C-terminus  mutant  M16  HSV-1  and  mock  infected. 
Cells were harvested at 3, 6.5 and 9.5 hpi at MOI=10 and 16 and 22 hpi at MOI=1 
and  protein  concentration  was  obtained  by  Bradford  assay.  Equal  amounts  of 
proteins  were  separated  on  6%  SDS-PAGE  and  transferred  to  nitrocellulose 
membrane  and  western  blotted  with  anti  ICP27  antibody  1113.  The  protein 
expression profile showed early expression of the wt ICP27 but not M16 mutant at 
3 hpi (Figure 5.11, Panel I). This difference in level of ICP27 expression at early 
times  of  infection  in  comparison  to  Figure  5.4  could  be  due  to  experimental 
variation. There was no expression of ICP27 in  27 and mock-infected extracts at 
all time post infection, as expected (Figure 5.11, Panels I and II). ICP27 expression 
was high at 9.5 in both wt and M16 mutant. At 22 hpi with MOI=1 strong bands of 
wt and M16 ICP27 were also detectable (Figure 5.11, Panel II). The membranes 
were stripped and western blotted for FG-repeat nucleoporins using anti FG-repeat 
NUPs 414 antibody. The results showed a similar level of nucleoporin expression 
at different times within the same experiment and there was no significant change 
in profile of NUP expression (Figure 5.11, Panel II). Also the expression pattern of 
nucleoporins  in  different  wt,   27,  M16  and  mock  infected  were  similar.  The 
disappearance of bands in some lanes is due to technical problems transferring 
the gel to membranes. 
5.5.3  Wild type and M16 mutant ICP27 co-precipitated with anti 
FG-repeat NUPs 414 antibody  
A range of immunoprecipitation and co-immunoprecipitation experiments with the 
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1119 antibodies, I performed a time course ICP27 immunoprecipitation test. Equal 
amounts of lysates of HSV-1 wt,  27, M16 and mock infected HeLa cells extracted 
at 3, 6.5 and 9.5 hpi at MOI=10 and 16 and 22 hpi at MOI=1 were incubated with 
antibodies and protein A beads and eluted in protein sample loading buffer and 
fractionated on 6% SDS-PAGE. Transferred membranes were western blotted with 
anti  ICP27  1113  antibody  and  exposed  to  X-ray  film.  As  shown  in  Figure  5.12 
panel I, at 3 hpi it is not clear whether ICP27 precipitated in any lysate, both RNase 
I treated and untreated. There are two reasons for this. Firstly, very little ICP27 is 
expressed  at  3  hpi  (Figure  5.11,  Panel  I).  Secondly,  the  separation  of  proteins 
around 60 KDa on this gel is poor so the antibody heavy chain migrated in the 
region of the ICP27 band. The input sample shown ICP27 band because this is 8 
hpi at MOI=10. At 6.5 hpi precipitation of wt and M16 ICP27 are visible under both 
RNase I treated and untreated condition and reveals RNA had no effect on the 
ICP27 precipitation (Figure 5.14, Panel II). Also 6.5 hpi samples fractionated by 
10%  SDS-PAGE  showed  clearer  bands  in  comparison  with  the  6%  gel  (Figure 
5.14, Panel III). Further infection at 9.5 hpi clearly detected wt and M16 ICP27 that 
precipitated  in  this  series  of  experiment  especially  in  the  case  of  M16  mutant 
ICP27(Figure 5.12, Panel IV ). At MOI=1 and 22 hours post infection however wt 
ICP27 was detected clearly but the M16 ICP27 band disappeared (Figure 5.12, 
Panel VI). However a repeated fractionation by 10% SDS-PAGE for 22 hpi again 
showed the M16 ICP27 band in this immunoprecipitation assay (Figure 5.12, Panel 
VII). Differences in mobility of ICP27 in IP samples and the input could be due to 
interference from the antibody heavy chain.  
After that I carried out a co-immunoprecipitation test of ICP27 using anti FG-repeat 
nucleoporin antibody 414 at early and late times of infection in HeLa cells. The 
samples were separated on 6% SDS-PAGE transferred and western blotted with 
anti 414 antibody. Figure 5.13 Panels I-III show precipitation of NUPs from 3 hpi to 
9.5 hpi at MOI=10 with 414 antibody. Panels IV and V show NUP precipitation at 
16 and 22 hpi at MOI=1. Unfortunately because of using less input sample and 
technical problems there are no clear bands of NUPs in some lanes of these gels 
(Figure 5.13). This problem could be seen in mock samples of lanes 9 in Panels IV 
and V of Figure 5.13 due to less loading samples. Also a transfer problem in the 
western blot of Panel III made the middle of the gel unclear (Figure 5.13, Panel III).                                                                                                                           Chapter 5, Results               
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Western  blot  of  the  above  membranes  with  anti-ICP27  antibody  showed  co-
immunoprecipitation  of  ICP27  at  later  times  of  infection  in  both  wt  ICP27  and 
mutant M16 (Figure 5.14, Panel I). All of these problems make this experiment 
very difficult to interpret. However, co-precipitation of the ICP27 in mutant M16 was 
significantly  reduced  in  comparison  with  wt  perhaps  due  to  the  inability  of  this 
mutant to complete the life cycle (Figure 5.14).  
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6 Discussion 
6.1  ICP27 is a multifunctional HSV-1 regulatory protein 
ICP27  is  a  multifunctional  regulatory  phosphoprotein,  which  functions  at 
transcriptional,  posttranscriptional  and  translational  levels  (Smith,  Malik  et  al. 
2005).    At  the  posttranscriptional
  level  ICP27  is  involved  in    RNA  processing, 
export and translation (McLauchlan, Phelan et al. 1992; Sciabica, Dai et al. 2003; 
Fontaine-Rodriguez, Taylor et al. 2004; Ellison, Maranchuk et al. 2005; Larralde, 
Smith  et  al.  2006).  At  late  times,  beginning  at  about  6  h  after  infection,  ICP27
 
begins  to  shuttle  between  the  nucleus  and  cytoplasm  using  cellular  transport 
machinery  proteins  such  as  Aly/REF,  TAP/NXF  (Sokolowski,  Scott  et  al.  2003; 
Chen,  Li  et  al.  2005)  and  CRM1  (Sandri-Goldin  2004).  The  nuclear  pore 
complexes (NPC) that consist of interacting proteins called nucleoporins is the sole 
gateway between the nucleus and the cytoplasm, and it mediates all trafficking 
between these two components (Mattaj and Englmeier 1998; Zenklusen and Stutz 
2001; Weis 2002; Sandri-Goldin 2004; Hetzer, Walther et al. 2005). This project 
aimed  to  investigate  the  interaction  of  ICP27  with  cellular  nucleoporins  and 
establish a new model of involvement of ICP27 with transport machinery. 
6.2  Summary of interaction of ICP27 with NUPs using 
pull down and immunoprecipitation assays 
Nuclear  pore  complexes  are  massive  and  comprise  approximately  30  different 
proteins,  called  nucleoporins  (NUPs).  NUPs  are  involved  both  in  transport  of 
proteins and RNAs and can be present in the central basket, the cytoplasmic side 
and the nuclear side of NPCs in the nuclear membrane (Weis 2002). They are 
grouped  into  two  main  families,  FG-repeat  nucleoporins  containing  repetitive 
elements of FXFG or GLFG and non FG-repeat NUPs (Poon and Jans 2005). 
There are a number of different methods that can be used to investigate protein-
protein interactions. These include pull down assays and co-immunoprecipitation 
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HSV-1 ICP27 protein with a range of NUPs. ICP27 interacted with NUP 62 in vitro 
and in vivo. My data also indicated a possible interaction of NUP153 and 214/CAN 
with ICP27, although the data were not so complete as that with NUP 62. I was 
unable to determine an interaction with NUP 98 because the NUP 98 antibodies 
available were unable to precipitate NUP 98 itself. NUP 62, NUP153, 214/CAN and 
NUP98  are  FG-repeat  NUPs  and  I  also  tested  ICP27  interaction  with  non-FG 
repeat NUPS, Rae 1 and NUP 107. It was clear that these NUPs did not interact 
with ICP27 indicating that this viral protein may associate specifically with certain 
FG repeat NUPs. 
 
6.3  ICP27 interacts with NUP 62 directly  
The mammalian protein NUP 62 is one of the best-characterised nucleoporins and 
there are16 copies of NUP 62 present in each NPC (Cronshaw, Krutchinsky et al. 
2002). NUP 62 is organized into two domains including: an N-terminal domain of 
about 15 FXFG-like repeat and the C-terminal portion that contains heptad repeat 
sequences (Buss, Kent et al. 1994).This FXFG-like repeat nucleoporin is located in 
the central basket of the nuclear pore complex. It is not mobile but physically and 
structurally it is able to access both the nuclear and cytoplasmic sides. NUP 62 is a 
protein involved in transport but it also has a structural function in the NPC. In vivo 
and in vitro investigations demonstrated association of NUP 62 in nuclear protein 
import  (Clarkson,  Kent  et  al.  1996;  Gamper,  van  Eyndhoven  et  al.  2000). 
Interaction  of  NUP  62  with  several  components  of  the  nuclear  protein  import 
machinery  has  been  reported.  NUP  62  interacts  with  nuclear  transport  factor  2 
(NTF2) and Ran (Paschal and Gerace 1995; Clarkson, Kent et al. 1996), importin-
β1 (Percipalle, Clarkson  et al.  1997), transcription factor Sp1 (Han, Roos et al. 
1998),  the  signalling  protein  TRAF-3  and  heat  shock  factor  2  (Gamper,  van 
Eyndhoven et al. 2000).  
In this thesis, I have defined a new interaction of ICP27 with mammalian protein 
NUP  62  in  vitro  and  in  infected  cells.  Immunoprecipitation  data  shows  that  the 
interaction  of  ICP27  with  NUP  62  is  not  limited  to  in  vitro  experiments  or 
overexpressing NUP 62 and can be detected in infected cells. Different lines of 
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First,  NUP  62  co-precipitates  with  ICP27  using  specific  anti  ICP27  monoclonal 
antibodies in immunoprecipitation assays. Second, similar results were obtained 
when  anti-NUP  62  antibodies  were  used  in  precipitation  assays  to  pull  down 
ICP27. Anti NUP 62 (N-19) and (H-122) antibodies that can detect the N-terminal 
and C-terminal regions of NUP 62 respectively co-precipitated ICP27 and NUP 62 
from cell extracts of HeLa and BHK cells. Third, anti FG-repeat nucleoporin 414 
antibody that detects a range of FG-repeat nucleoporins in the cell extracts, clearly 
co-precipitated ICP27 and the FG-repeat nucleoporins including NUP 62 against 
which  it  was  raised.  It  seems  the  interaction  of  ICP27  and  NUP  62  is  not 
dependent on RNA, because incubation of cell extracts with RNase I did not affect 
these interactions. 
In vitro evidence of association of ICP27 with NUP 62 relied on GST pull down 
assay data. Using purified GST-ICP27, NUP 62 was pulled down from HeLa cell 
extracts and using GST-NUP 62, ICP27 was pulled down from wild type HSV-1 
infected HeLa cell extracts. Interestingly, ORF57, a homologue of ICP27 in HHV-8 
that has a strong similarity in function including transport activities, also associates 
with NUP 62 in pull down assays. Using GST-ORF57, NUP 62 was pulled down 
from HeLa cell extracts but I was unable to carry out the reverse experiment.  
I have suggested in my study that ICP27 can interact directly with NUP 62. This is 
supported with a series of interaction experiments using RNase I treatment and 
purified proteins. In  a pull  down assay of GST-NUP  62  with HeLa  infected cell 
extracts ICP27 associates with NUP 62 in the presence and absence of RNase I 
so this interaction is not RNA mediated. Thereafter GST-NUP 62 pull down assays 
with purified His-ICP27 showed direct interaction between these two proteins. 
I attempted to  map the region  of ICP27 that interacted  with NUP 62. GST pull 
down indicated that three ICP27 mutants could no longer interact with NUP 62. 
These  were  dLeu  in  the  N-terminus  and  M15  and  M16,  in  the  C-terminus. 
However,  in  contrast,  co-immunoprecipitation  data  indicated  that  M15  and  M16 
mutants could interact with NUP 62 even in the presence of RNase I. Thus these 
C-terminal  interactions  could  not  be  confirmed.  I  did  not  carry  out  a  co-
immunoprecipitation experiment to test interaction of ICP27 dLeu with NUP 62 so I 
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differences  between  my GST pull  down and immunoprecipitation data could  be 
due to there being other proteins in the ICP27-NUP 62 complex in vivo that can 
bridge  an  interaction  between  the  two  proteins.  Future  work  to  explain  the 
differences I observed should focus on using co-immunoprecipitation with mutant 
virus infected cells. Biophysical methods such as Biacore could be used to check 
whether the wild type and mutated ICP27 proteins interacted directly with NUP 62. 
The work could be extended by high resolution immunofluorescence microscopy 
and electron microscopy using immuno-gold labelling of NUPs and ICP27.  
 
Although the data set I have accumulated for ICP27 interaction with NUP 62 is the 
most complete of the interaction I have examined, I would like to point out that 
there are several problems with this set of experiments. These problems exist in all 
my  thesis  work.  Firstly,  it  was  impossible  to  purify  GST-  or  His-ICP27  as 
completely  full  length  proteins.  There  were  always  a  large  number  of  protein 
truncates and deletions present. This may be because ICP27 has a central region 
that  is  predicted  to  be  very  disordered  in  structure  and  vulnerable  to  protease 
attack.  There  were  also  problems  obtaining  reasonable  quantities  of  full  length 
NUP proteins. This means that most of the experiments were not carried out under 
optimal  conditions.  For  the  GST  pull  down  experiments,  I  often  missed  out 
negative  and  positive  controls.  GST-TAP  would  have  been  a  good  control  for 
ICP27 binding throughout the thesis. Having demonstrated that Rae 1 could not 
interact  with  ICP27,  this  would  be  a  good  negative  control  in  future.  I  tested 
whether beads alone could pull down ICP27 and found no interaction. However, I 
did  not preclear all of the extracts I used in all the experiments. This calls into 
question the results I obtained. Other problems existed with the mutant ICP27 virus 
infection data. In some cases I was not able to complete a set of experiments on 
the one western blot. This means that I had to piece together blots from different 
experiments. Because a wild type HSV-1 infected control was not present on all of 
these  blots,  I  cannot  compare  between  panels  in  such  experiments.  Levels  of 
expression of mutant ICP27 proteins should have been compared with levels of 
expression of another wild type HSV-1 protein such as ICP0 or IPC4 to determine 
whether infections has been successful, or how much viral replication has been 
achieved in each case. Finally, I did not use appropriate negative controls for the 
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negative control. A much better control to have used in each case would be control 
antibodies of the same isotype as the antibody used in the immunoprecipitation 
experiments but against an irrelevant protein.  
 
If there is a direct interaction of ICP27 with NUP 62 I can propose the hypothesis 
that HSV-1 ICP27 protein and its HHV-8 homologue ORF57 may be involved with 
NUPs directly in nuclear import or export of protein and/or RNA. In the NPC, the 
position  of  NUP  62  on  both  the  nuclear  and  the  cytoplasmic  sides  and  in  the 
central  gated  channel  (Guan,  Muller  et  al.  1995),  suggests  it  may  be  a  good 
candidate  for  interaction  with  different  proteins  such  as  TAP  as  well  as  other 
nucleoporins (Stochaj, Banski et al. 2006). Interaction of the N-terminal portion of 
NUP 62 with NUP 153 and NUP 214 in growing cells can be dynamic and so it has 
been  proposed  that  NUP  62  is  closely  involved  with  NUPs  153  and  214  in 
nucleocytoplasmic shuttling of macromolecules. It is clear that NUP 62 is involved 
in many transient interactions in the nuclear pore complex (Stochaj, Banski et al. 
2006). I propose that complex formation between ICP27 and NUP 62 could provide 
an  important  structure  to  facilitate  movement  of  cargo  molecules  between  the 
nuclear  and  cytoplasmic  faces  of  the  NPC  through  the  central  gated  channel 
during both nuclear export and import. It has been suggested that interactions of 
NUP  214/NUP  62  and  NUP  62/NUP  153  could  provide  “stepping  stones”  to 
transport complexes to and from the gated channel (Stochaj, Banski et al. 2006).  
6.4  HSV-1  shuttling  protein  ICP27  interacts  with 
nuclear NUP 153 
Nucleoporin 153 is one of the essential NUPs that is associated with both nuclear 
export  and  nuclear  import  (Ball  and  Ullman  2005).  This  carboxy-terminus  FG-
repeat  nucleoporin  is  a  glycoprotein  that  is  enriched  in  amino  acids 
serine/threonine and that can be phosphorylated and glycosylated (Denning, Patel 
et al. 2003; Walther, Askjaer et al. 2003). NUP 153 is a high dynamic NUP that 
exchanges at the nuclear pore but some evidence shows that perhaps a subset of 
NUP 153 molecules is immobile in the NPC (Ball and Ullman 2005). Investigation 
on the mobility of NUP 153 showed distinct N-terminal functional domains mediate 
transcription-dependent mobility  (Griffis, Craige  et al. 2004). It has been shown                                                                                                                     Chapter 6, Discussion               
  104 
that the N-terminal domain of NUP 153 is anchored to the nuclear ring and the long 
C-terminus could be structurally flexible within the nuclear pore complex and can 
be  detectable  in  both  the  nuclear  and  cytoplasmic  side  of  NPC  as  well  as  the 
central  channel  (Fahrenkrog,  Maco  et  al.  2002).  A  list  of  various  proteins  and 
nucleic acids that interact with NUP 153 is shown in Table 1.7. The FG-repeat 
domain of NUP 153 interacts with importin-β (Shah, Tugendreich et al. 1998) and 
TAP  (Bachi,  Braun  et  al.  2000).  The  RNA  binding  domain  (RBD)  of  NUP  153 
interacts with mRNA and export of mRNA cargo through NPC could be due to 
direct  contact  or  protein-protein  contact  with  mRNA-associated  proteins  (Ball, 
Dimaano et al. 2007). 
Here I have investigated an interaction of HSV-1 ICP27 with NUP 153 in vitro and 
in infected cells using immunoprecipitation and pull down assays. Confirmation of 
the interaction between NUP 153 and ICP27 came from co-precipitation of ICP27 
with NUP 153. A complex of NUP 153 and its specific antibody, anti-NUP 153, co 
precipitated ICP27 from wt HSV-1 infected HeLa cell extract showing association 
of these two proteins in infected cells. In vitro corroboration of the participation of 
the ICP27 with NUP 153 relied on GST pull down assay data. Purified GST-NUP 
153  pulled  down  ICP27  from  wt  HSV-1  ICP27  infected  HeLa  cell  extracts  and 
established in vitro association of ICP27 and NUP 153. RNAse I treatment in the 
pull down assay of wtild type infected HeLa cell extracts with GST-NUP 153 did not 
change  the  level  of  interaction  and  revealed  that  this  interaction  is  not  RNA-
mediated.  However,  unfortunately  the  clone  for  NUP  153  was  the  last  that  I 
received and I did not have enough time to optimize experiments with this NUP. 
Optimisation of protein expression and the GST pull down and IP experiments in 
addition to other technique such as immunofluorescence and electron microscopy 
would improve the validity of this work.  
My investigation to map the regions of ICP27 that associated with NUP 153 using 
a pull down assay of GST-NUP 153 with a range of HeLa cell lysates infected with 
wt HSV-1, and HSV-1 mutated in the ICP27 gene, showed possible interaction with 
the region of the dLeu ( NES) mutation in the N-terminus. dLeu ICP27 is found 
only in the cell nucleus so the N-terminal leucine-rich sequence must act as NES 
during  viral  infection  (Lengyel,  Guy  et  al.  2002).  Another  important  N-terminal 
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interaction  with  NUP  153.  d1-2  shares  part  of,  but  not  the  whole  of,  the  NES 
sequence and this may explain why there appeared to be a partial interaction of 
d1-2 with NUP 153.  
In  the  C-terminal  region  of  ICP27  two  mutations  in  an  essential  region  of  the 
protein may participate in interaction with NUP 153. The M15 point mutation could 
not interact with NUP 153. However, the M16 mutation partially knocked out the 
ICP27-NUP 153 interaction. These data indicate that NUP 153 may also interact 
with the C-terminal region of ICP27. 
It has been suggested that NUP 153 might be involved in disassociating nuclear 
import cargo-receptor complexes (Shah, Tugendreich et al. 1998). It has also been 
suggested  that  NUP  153  may  play  a  role  in  receptor-independent  nuclear 
transport, as shown for the nuclear import of the transcription factor PU.1 and the 
signal transducer and activator of transcription, Stat (Gould, Martinez et al. 2000; 
Zhong, Takeda et al. 2005). However, NUP 153 can bind to RNAs and also has 
role  in  export  of  proteins  and  RNA  (Ullman,  Shah  et  al.  1999).  Very  recent 
investigations on the mechanism of trafficking through the NPC showed interaction 
of  NUP  153  and  NUP  62.  I  need  to  verify  this  interaction.  As  I  mentioned 
previously, NUP 62 could provide a structural mechanism for allowing sequential 
movement of cargo from the outside face through the central basket to the inside 
face of the NPC (and vice versa)  during both nuclear import and export (Stochaj, 
Banski et al. 2006). Export of viral mRNA takes place by utilising two main cellular 
pathways CRM1 and TAP (Sandri-Goldin 2004). However, different investigations 
on the transport of proteins and RNAs indicated that there had to be alternative 
pathways and this is why I investigated nucleoporin and HSV-1 ICP27 interaction. 
Data presented here suggest indeed that NUP 153 participates in interaction with 
ICP27 in the NPC. The C-terminal flexible and unfolded FG-repeat domain of NUP 
153 is involved in transient interaction with cargo as well as other FG-repeat NUPs 
(Lim, Aebi et al. 2006). Cooperation and interaction of this complex ( NUP 153/ 
ICP27) with other nucleoporins that are located in the nuclear and cytoplasmic face 
of NPC may allow FG-repeat domains of NUPs to accompany and guide cargo 
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6.5  Cytoplasmic  face  NUP  214/CAN  interacts  with 
ICP27  
The  cytoplasmic  filaments  of  the  NPC  have  been  proposed  to  have  a  role  in 
cytoplasmic release of nuclear export complexes and in assembly and docking of 
nuclear  import  complexes  (Gould,  Martinez  et  al.  2000).  NUP214/CAN  is  a 
member of the FG-repeat-containing nucleoporins in the cytoplasmic face of the 
NPC.  NUP  214  was  originally  known  as  a  putative  oncogene,  disrupted  by 
chromosomal  translocations  linked  with  myeloid  leukemias  (Fornerod,  van 
Deursen et al. 1997; Xylourgidis, Roth et al. 2006). Complex formation of NUP 214 
with other nucleoporins such as NUP 88, NUP 358 and NUP 62 was demonstrated 
(Xylourgidis, Roth et al. 2006). Direct interaction of NUP214 by its FG-motif rich 
domain with importin-β and CRM1 has been shown and also it was proposed to 
function as a CRM1 inhibitor (Xylourgidis, Roth et al. 2006). However, Bernad and 
colleagues  reported  that  a  NUP  214-NUP  88  complex  is  necessary  for  CRM1-
mediated export of a specific cargo, the 60 S preribosome, in a CRM1-FG repeat 
interaction-independent  mechansim  (Bernad,  Engelsma  et  al.  2006).  The  N-
terminal  region  of  NUP  214  is  positioned  in  the  cytoplasmic  side  of  NPC,  The 
central coiled coils are known to interact with NUP 88 and a long and flexible C-
terminal FG-repeat region localises in the nuclear and cytoplamic face of NPC and 
interacts with transport factors (Paulillo, Phillips et al. 2005). 
In this thesis, I have shown data that suggest a new interaction of the viral HSV-1 
protein  ICP27  with  NUP  214/CAN  in  vitro  and  in  infected  cells  using  co-
immunoprecipitation and pull down assays. Immunoprecipitation data shows that 
the  interaction  of  ICP27  with  NUP  214  is  not  limited  to  in  vitro  experiments  or 
overexpressing NUP 214 as it can be detected in infected cells. There are three 
lines  of  evidence  for  an  interaction.  First,  anti  NUP  214  (N-15)  antibody  that 
detects the N-terminal region of NUP 214 precipitated ICP27 and NUP 214 from wt 
HSV-1  infected  HeLa  cell  extracts.  Second,  in  the  immunoprecipitation  assay 
treatment of the complex formed with RNase I did not affect binding of these two 
proteins. This means the interaction of ICP27 and NUP 214 is not RNA-mediated. 
Third, GST pull down assays gave in vitro evidence of an involvement of ICP27 
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(aa  1690-2090)  pulled  down  ICP27  from  wild  type  HSV-1  infected  HeLa  cell 
extracts  and  established  an  in  vitro  association  of  ICP27  and  NUP  214. 
Interestingly,  the  longer  truncate  of  NUP  214  (aa  1690-2090)  showed  stronger 
association with ICP27 than the shorter NUP 214 (aa 1690-18940) suggesting the 
number of FG-repeat domains is important for the quality of interaction of ICP27 
with NUP 214. There was a problem in this experiment because ICP27 was not 
detected  in  the  unbound  fraction  although  it  was  clearly  detected  in  the  bound 
fraction.  This  means  this  experiment  would  have  to  be  repeated  before  firm 
conclusions can be drawn. Unfortunately we did not have any full length NUP 214 
recombinant  protein  to  compare  interaction  with  its  truncates  but  interaction  of 
ICP27 and full length NUP 214 was demonstrated in infected cells in this study. 
Altogether,  this  information  suggests  a  possible  involvement  of  FG  motif-rich 
domains of NUP 214 in interaction with ICP27. This FG repeat part of NUP 214 is 
also involved in interaction of two important transport factors importin-β and CRM1 
(Fornerod, van Deursen et al. 1997; Bayliss, Littlewood et al. 2000). 
Immunofluorescence studies of the flexible FG-repeat domain of NUP 214 showed  
that it was involved with the nucleo/cytoplasmic transport system suggesting that 
NUP  214  might  accompany  cargo-receptor  complexes  through  the  central  pore 
(Paulillo,  Phillips  et  al.  2005).  Because  it  has  an  FG-repeat  domain,  NUP  214 
appears to be involved with cargo import as well. It has been proposed that NUP 
214’s FG-repeat domain transiently accumulates at the nuclear NPC periphery in 
the presence of excess import cargo. Further work of this research group showed 
that in the case of RNA export the flexible FG-repeat region of NUP 214 is capable 
of accompanying the cargo through the central pore of the NPC (Paulillo, Phillips et 
al. 2005), underlying the importance of the FG-repeat domain. It means that during 
import,  cargoes  may  be  passed  from  an  asymmetric  FG-repeat  nucleoporin 
residing  NUP  214,  to  a  symmetric  FG-repeat  nucleoporin,  NUP  62,  to  an 
asymmetric FG-repeat nucleoporin residing on the nuclear side of the NPC, or vice 
versa in the context of export allowing delivery of proteins to their final destination 
(Paulillo, Phillips et al. 2005).  
It has been defined that NUP 214 is organized into three domains and that the C-
terminal domain is the FG repeat region. Consistent with interaction of NUP 214 
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I demonstrated a that C-terminal residues of 465-466 (M15) and residue 488 (M16) 
are required for the interaction with NUP 214. However, as the C-terminal segment 
of NUP 214 is phosphorylated and O-glycosylated the modifications could change 
the  binding  ability  of  these  proteins  (Miller,  Caracciolo  et  al.  1999).  The  longer 
truncate,  GST-NUP  214  (1690-2090),  pulled  down  ICP27.  However,  although  I 
could show association of the FG domain of NUP 214 in interaction with ICP27 I 
cannot conclude that non FG domains are not involved in this interaction. Future 
work will be required to fully map this interaction. Immunoprecipitation experiments 
where cellular NUP 214 is interacted with ICP27 will give improved data compared 
to the GST-NUP 214 pull down experiments. 
Due to the position of NUP 214 in the cytoplasmic face of NPC it could associate 
with ICP27 to provide it to other NUPs in central channel gate such as NUP 62 and 
then to nuclear NUPs such as NUP 153 and NUP 98 to dissociate in the nucleus. 
On the other hand, nuclear face NUPs may bind to ICP27 in nucleus and shuttle 
ICP27 alone or in a complex with RNA to the central basket and pass it through the 
NPC to NUP 214 to dissociate in cytoplasm.  
6.6  Non  FG-repeat  NUPs  Rae  1  and  NUP  107  did  not 
interact with ICP27 
In this study I was interested to search for an interaction of ICP27 with non FG-
repeat NUP Rae1 as a cellular shuttling protein that is involved with NUP 98 in 
transport activity. Result showed there may not be any association between ICP27 
and Rae1 in GST pull down assays. Rae1 acts as a shuttling mRNA export factor 
that interacts with NUP 98 at Rae1 binding sites in N-terminal domain of NUP 98 
(Pritchard,  Fornerod  et  al.  1999).  Power’s  group  demonstrated  that  Rae1  may 
function to deliver TAP to NUP 98. This report suggested a competition of TAP and 
NUP 98 in binding to Rae1 (Blevins, Smith et al. 2003).  
NUP 107 localises to the nuclear rim and is an essential component of the nuclear 
pore complex (NPC). NUP 107 does not contain FG repeats that serve
 as docking 
sites for karyopherins and other transport factors. It has been shown that depletion 
of mammalian NUP 107 resulted in the failure of a subset
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into  NPCs  followed  by  degradation  of  these
  proteins  (Ben-Efraim  and  Gerace 
2001).  GST  pull  down  assay  using  ICP27  and  NUP107  showed  no  interaction 
between  these  two  proteins  supporting  the  idea  that  the  FG-repeat  domain  of 
NUPs is essential for interaction with ICP27 and its shuttling activity.  . 
6.7  ICP27 and NUPs are in complex after 6hpi 
In this study I have shown possible interaction of ICP27 with certain NUPs in vitro 
and in infected cells. Different studies have shown nuclear distribution of ICP27 at 
early times of infection and both nuclear and cytoplasmic localisation at later times 
of  infection  (Phelan  and  Clements  1997).  Time  course  immunoprecipitation 
experiments  showed  involvement  of  ICP27  with  nucleoporins  at  6.5  hpi.  As 
expected the low amount of expression of ICP27 at early times of infection did not 
show involvement of ICP27 and NUPs in the immunoprecipitation assay. At later 
times  of  infection,  the  level  of  involvement  of  ICP27  and  FG-repeat  NUPs 
increased and also association of ICP27 mutant M16 with NUPs appeared at 9.5 
hpi. These data are consistent with the expression profile of ICP27 and NUPs and 
also reveals that there was no degradation of NUPs after infection with HSV-1. 
However further experiments such as using immunofluorescence are needed to 
make any firm conclusions.  
6.8  ICP27  SADET  residues  are  not  involved  in 
interaction with NUPs 
Similar  to  ICP27,  hnRNP  K  is  a  multifunctional  cellular  protein  that  shuttles 
between the nucleus and the cytoplasm. It is a regulatory protein that acts on gene 
expression at transcriptional and post-transcriptional as well as translational levels 
(Bomsztyk, Denisenko, and Ostrowski, 2004).  Also like ICP27, hnRNP K interacts 
with  several  cellular  and  viral  proteins.  It  is  capable  of  self-interaction  (Wadd, 
Bryant  et  al.  1999),  and  can  be  a  component  of  multi-protein  complexes.  This 
protein contains a classical  nuclear localization signals and a KNS domain that 
contains a SADET sequence that is perfectly conserved between hnRNP K KNS 
and  ICP27  suggesting  the  possibility  of  access  to  common  cellular  transport 
pathways  and  direct  interaction  with  the  nucleoprotein  complexes  (Figure  1.7)                                                                                                                     Chapter 6, Discussion               
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(Michael, Eder et al. 1997). hnRNP K can bind RNA and single or double stranded 
DNA via a GRGG box and three repeats of a motif termed the K homology domain 
(Siomi,  Matunis  et  al.  1993;  Bomsztyk,  Denisenko  et  al.  2004).  The  KNS 
nucleocytoplasmic shuttling signal has been suggested to mediate export of RNA 
via  a  CRM1  independent  pathway  (Henderson  and  Eleftheriou  2000).  Previous 
work of our laboratory on ICP27 SADET mutants showed that SADET mutated 
ICP27  was  no  longer  able  to  interact  with  cellular  nucleocytoplasmic  transport 
proteins REF and hnRNP K and suggested shuttling through pathways other than 
those involving REF and hnRNP K, possibly through CRM1 export or via direct 
interaction  with  nucleoporins  (Leiper  2004).  I  have  investigated  involvement  of 
ICP27  SADET  sequences  with  NUP  interactions.  Both  RNase  I  treated  and 
untreated  immunoprecipitation  assays  showed  precipitation  of  ICP27,  but  there 
was no distinct pattern in co-precipitation of NUP 62 and mutated ICP27s. Western 
blot  of  the  above  assays  with  anti-hnRNP  K  antibody  showed  precipitation  of 
hnRNP  K  by  both  wild  type  and  SADET  mutant  ICP27.  Results  with  the  fully 
changed SADET sequence, AGAGA, showed immunoprecipitation of ICP27 and 
NUP 62 indicating independency of interaction between ICP27 and NUPs from the 
SADET sequence. Claire Leiper showed in her thesis that amino acid substitution 
in  the  SADET  sequence  had  a  major  impact  on  the  localisation  of  ICP27 from 
mainly nuclear to both nuclear and cytoplasmic (Leiper 2004). In future, a good 
experiment  would  be  to  use  these  SADET  mutants  in  immunofluorescence 
experiments  with  cells  transfected  with  ICP27  expression  constructs  or  cells 
infected  with  ICP27  mutant  viruses  to  visualise  co-localisation  with  NUPs. 
Interaction of ICP27 SADET mutants with hnRNP K in immunoprecipitation assays 
in  this  project  is  inconsistent  with  Leiper’s  results  that  showed  mutagenesis  in 
SADET residues leads to loss of interaction with hnRNP K in GST pull down assay 
of transfected BHK cells (Leiper 2004). I suggest this inconsistency could be due to 
using either a different experimental procedure or to the type of cell used. In this 
study I have used an immunoprecipitation assay that is more close to the natural 
system  in  living  cells  while  previously  a  GST  pull  down  assay  was  used.  My 
experiments were in HeLa cells that may have many different properties compared 
to the BHK cells used previously. My results are more consistent with the report 
that mapped interaction sites of ICP27 with hnRNP K. amino acids242 to 397 were 
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the  interaction.  In  this  study  hnRNPK  co-immunoprecipitated  with  anti  ICP27 
antibody and this interaction was confirmed by a yeast-two hybrid system (Y2-H) 
(Wadd,  Bryant  et  al.  1999).  Interaction  of  the  ICP27  homologue  ORF57  with 
hnRNP  K  has  also  been  shown  in  our  laboratory  (Malik  and  Clements  2004). 
However, the resemblance between ICP27 and hnRNP K suggests that they utilise 
common cellular pathways, and ICP27 could prevent hnRNP
 K from entering into 
such pathways, resulting in alterations in transport of cellular
 RNAs. It is possible 
that the many gene expression-related functions of ICP27 may rely on interaction
 
with hnRNP K and this might be a key protein in  HSV-1 infection for example, 
acting  to targeting  ICP27 to transcriptionally  active nuclear domains
  or  allowing 
ICP27 to interact with one of hnRNP K's partner proteins.  
6.9  HSV-1  infection  does  not  regulate  expression  of 
NUPs 
Infection with HSV-1 has a significant effect on nuclear function by inhibiting host 
RNA  splicing.  This
  results  in  host  pre-mRNAs  being  held  in  stalled  splicing
 
complexes and thus being unable to gain access to the NPC machinery and to exit 
the nucleus (Hardwicke and Sandri-Goldin 1994). A feature of some RNA viruses, 
which replicate
 in the cytoplasm, including polioviruses, vesicular stomatitis
 virus 
(VSV) and influenza virus, is that they interfere with nucleocytoplasmic trafficking 
by  different  ways  including  degradation  of  NUPs  (Fontoura,  Faria  et  al.  2005; 
Satterly, Tsai et al. 2007).
 This would benefit RNA viruses because they replicate 
in the cytoplasmic. Inhibition  of cellular mRNA export
  would therefore  decrease 
competition for the translation machinery and promote translation of viral mRNAs. 
Also it would benefit viral replication because prevention of import might contribute 
to the accumulation
 of nuclear factors, that might be required for replication, in the 
cytoplasm (Fontoura, Faria et al. 2005; Satterly, Tsai et al. 2007). Interestingly, the 
RNA virus story indicates that nuclear pore complex components such as NUPs 
are the main target for inhibition
 of transport machinery (Gustin and Sarnow 2001; 
Gustin  2003).  A  possible  role  of  HSV-1  ICP27  protein  in  disruption  of  nucleo-
cytplasmic transport led me to determine whether ICP27 had any affect on NUP 
expression.  Infections  with  wild  type  and  mutant  ICP27  HSV-1  and  transient 
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change in expression levels of FG-repeat nucleoporins. These results back up a 
recent study showing HSV-1 infection does not interfere with nucleocytoplasmic 
trafficking  through  the  TAP  and  CRM1  pathways  (Chen,  Li  et  al.  2005).  As  I 
mentioned  above  RNA  viruses  are  capable  of  interrupting  NPCs.  For  example, 
VSV M protein binds to the mRNA export factor Rae1 which contributes to NUP 
98-mediated inhibition of mRNA export (Faria, Chakraborty et al. 2005). My data 
from the interaction assays showed ICP27 failed to interact with Rae1. In contrast, 
upon poliovirus infection degradation of certain nucleoporins such as NUP 153 and 
NUP 62 occurs. This  results in disruption of the nuclear pore complex structure 
and  nucleocytoplasmic  shuttling  (Gustin  and  Sarnow  2001).  Recently 
investigations  on  influenza  virus  infection  demonstrated  that  the  multifunctional 
protein  NS1  that  shuttles  between  the  nucleus  and  the  cytoplasm  inhibits  host 
mRNA nuclear export by interaction with nuclear export machinery. In fact, it has 
been shown that NS1 interacts with various mRNA export factors as well as NUP 
98. The level of NUP 98 is depleted by NS1, indicating that NUP 98 is actively 
degraded  during  influenza  virus  infection.  In  addition,  influenza  virus  infection 
actually interferes with the physical process of mRNA nuclear export (Satterly, Tsai 
et al. 2007). Contrasting the situation with RNA viruses, HSV-1
 infection does not 
appear to have an impact on cellular nucleoporins to disrupt nucleocytoplasmic
 
trafficking. Further investigation to give  a clearer idea of HSV-1 ICP27 function 
would involve knocking out specific nucleoporins following infection with wild type 
and ICP27-mutant HSV-1. 
6.10  General discussion 
Molecular understanding of nuclear trafficking has major implications for medical 
science  in  the  future.  It  is  clear  that  nuclear  proteins  are  synthesized  in  the 
cytoplasm and function in the
 nucleus, and RNAs are transcribed in the nucleus 
but  translated  in  the
  cytoplasm.  Therefore,  cellular  or  viral  management  of 
macromolecular shuttling across the nuclear
 membrane is an important means for 
changing the levels and activities of
 such molecules as transport factors (Conti and 
Izaurralde 2001).  
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6.10.1   ICP27  may  use  more  than  one  pathway  to  export  viral 
mRNAs 
Association  of  ICP27  with  redistributed  snRNPs  on  intron-containing  transcripts 
suggested  an  involvement  of  this  multifunctional  protein  in  regulation  of 
nucleocytoplasmic  RNA  shuttling  (Phelan,  Dunlop  et  al.  1996).  Many  studies 
showed ICP27 shuttles between the nucleus and cytoplasm and has a direct role 
in  nuclear  export  of  viral  RNAs.  This  is  via  its  binding  with  intronless  viral  and 
cellular mRNAs (Phelan and Clements 1997; Soliman, Sandri-Goldin et al. 1997; 
Sandri-Goldin  1998;  Koffa,  Clements  et  al.  2001).  It  has  been  shown  that  two 
motifs of ICP27, an RGG box and a leucine-rich nuclear export signal (NES) are 
putatively  involved  with  RNA  binding  and  export  (Sandri-Goldin  1998;  Lengyel, 
Guy  et  al.  2002).  Experimental  studies  using  leptomycin  B  (LMB)  and  ICP27 
mutants  demonstrated  these  regions  are  required  but  not  essential  for 
nucleocytoplasmic transport of RNAs. There are different pathways for export of 
RNAs (Phelan and Clements 1997; Soliman and Silverstein 2000; Koffa, Clements 
et al. 2001; Chen, Sciabica et al. 2002; Lengyel, Guy et al. 2002; Chen, Li et al. 
2005; Thiry, Muylkens et al. 2005). The main cellular mRNA export pathway is 
nuclear  export  receptor  (TAP)-mediated  that  associates  with  an  RNA-binding 
protein REF, a component of the exon junction complex. It has been shown that 
ICP27 binds to viral mRNAs and interacts directly with REF as an adaptor protein 
and indirectly recruits TAP to viral mRNAs to stimulate their nuclear export through 
this  cellular  pathway  (Koffa,  Clements  et  al.  2001;  Chen,  Sciabica  et  al.  2002; 
Sandri-Goldin 2004).  
However, certain aspects of this model are unclear. A moderate effect of the RGG 
box and REF binding site ICP27 mutants on viral gene expression, transport by the 
CRM 1 dependent pathway and export of some transcripts in absence of ICP27 
whose overall expression is ICP27-dependent show the TAP pathway is not the 
only way for export of viral RNAs (Soliman and Silverstein 2000; Lengyel, Guy et 
al. 2002; Pearson, Knipe et al. 2004). Further evidence for multiple ICP27 export 
pathways comes from our laboratory which observed ICP27 protein export in the 
absence  of  viral  RNA  in  the  Xenopus  oocyte  system  and  this  export  required 
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export of certain L RNAs but the protein itself can shuttle through another pathway 
(Koffa, Clements et al. 2001). On the other hand, other evidence for the presence, 
the function and the mechanism of the nature of any alternative pathway is not 
clear.  The  homology  of  ICP27  to  the  KNS  domain  of  hnRNP  K  (Figure  1.7) 
that has transport capability, and to the viral tegument protein VP13/14 containing 
a NES-like element that shuttles between nucleus and cytoplasm are suggested to 
show  their  involvement  in  transport  of  RNAs,  possibly  by  such  an  alternative 
pathway (Michael, Eder et al. 1997; Donnelly and Elliott 2001). Trafficking of most 
proteins and RNAs is through NES and NLS of carrier proteins (Gorlich and Mattaj 
1996). The karyopherin family of transport factors (also termed importins, exportins 
and  transportins)  uses  the  small  GTPase,  Ran  to  provide  energy  for 
association/disassociation  of  the  cargo  to  transport  them  through  the  NPC. 
However,  energy  generation  is  not  require  for  translocation  (Weis  2003). 
Movement  across  the  NPC  depends  on  direct  interaction  with  NUP  FG-repeat 
domains  (Bayliss, Littlewood  et  al. 2000).  The NPC is extremely  large  with the 
capacity to accommodate many translocating molecules. Each NPC has at least 
8−16 copies of each NUP and 128 FG domains together providing thousands of 
individual FG repeats (Rout, Aitchison et al. 2000; Cronshaw, Krutchinsky et al. 
2002). FG-NUPs are mostly large proteins, which have low overall hydrophobicity 
with  their  FG-repeat  domains  being  natively  unfolded  (Denning,  Uversky  et  al. 
2002;  Denning,  Patel  et  al.  2003).  Natively  unfolded  proteins  commonly  can 
provide multiple  binding domains and so can interact simultaneously with many 
different partner proteins (Lim, Aebi et al. 2006). 
6.10.2  Modes  of  transport  through  the  NPC:  possible  roles  of 
ICP27 
Although  much  progress  has  been  made  in  understanding  the  structure  and 
composition of the NPC in nucleocytoplasmic transport, details on the mechanisms 
of  how  individual  NUPs  translocate  cargo  are  missing  (Lim,  Aebi  et  al.  2006). 
Numerous  attempts  have  been  made  to  model  the  translocation  mechanism. 
Overall four theories have been proposed for translocation of cargoes through the 
NPC. First, the Brownian affinity gate model. This model assumes that NUPs on 
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themselves.  However,  if  these  cargos  interact  with  a  transporter  system  that 
generates energy e.g GTP, the energy generated is such that the cargo/transporter 
can overcome the NUP barrier by interacting with NUPs and exiting through the 
internal pore of the NPC by Brownian motion (Rout, Aitchison et al. 2003). The 
next model is the affinity gradient model, which suggests FG-repeat NUPs exhibit 
increasing affinities with the cargo complexes (Ben-Efraim and Gerace 2001). The 
third model is the ‘oily spaghetti’ model that hypothesises that the NPC is filled with 
FG-NUPs that normally block passage of molecules. However, if transporter/cargo 
complexes  gain  access  to  the  NPC  they  can  progress  through  by  pushing  the 
NUPs out of the way, against the sides of the pore (Macara 2001). The last model 
is known as the selective phase model. This proposes that the hydrophobic FG-
repeat NUPs  form a mesh in the pore, which transporter- cargo molecules can get 
through  (Ribbeck  and  Gorlich  2002).  Recent  studies  on  yeast  transport 
mechanisms  through  the  NPC  have  increased  the  complexity  of  the  transport 
story. It has been shown that the asymmetric FG-repeat NUPs are dispensable for 
bulk transport in the NPC (Zeitler and Weis 2004). When some asymmetric yeast 
FG domain NUPs were removed the permeability of NPCs was not reduce. Taken 
together  this  suggested  the  existence  of  multiple  translocation  mechanisms 
(Strawn,  Shen  et  al.  2004).  Furthermore,  asymmetrically  positioned  NUP  FG 
domains have been found to be non essential. However, specific combinations of 
symmetrically  localised  NUPs  FG  domains  are  essential  (Strawn,  Shen  et  al. 
2004). 
It will be necessary to carry out several more experiments before interaction of 
ICP27 with NUP 62, NUP 153 and NUP 214 in infected cells is proved definitively. 
However, I wish to propose a new mechanism by which ICP27 may be involved in 
RNA or protein trafficking. ICP27 may interacts with various NUPs, both mobile 
and fixed, at different sites in the NPC and so can pass protein or mRNA bound to 
ICP27, through the NPC.    
Our knowledge about the mechanism of ICP27 shuttling between the nucleus and 
the cytoplasm is poor. ICP27 may exit either the nucleus or the cytoplasm by more 
than  one  pathway  and  use  different  export  components  throughout  the  viral 
replication cycle. ICP27 can interact with the nonkaryopherin export receptor TAP 
that  is  believed  to  traffic  the  majority  of  mRNA  molecules  or  with  cellular                                                                                                                     Chapter 6, Discussion               
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nucleocytoplasmic
  transport  receptors  belonging  to  the  karyopherin  family  of 
soluble  transport  factors  such  as  CRM1.  Alternatively,  as  I  have  shown  here, 
ICP27 may interact directly with some nucleoporins (Figure 6.1). In this scenario, 
ICP27-FG-repeat  NUP  interaction  acts  as  a  transporter  machine  (Figure  6.3). 
Interestingly,  all  the  nucleoporins  tested  in  this  study  showed  at  least  a 
requirement of the nuclear export signal (NES) residues of ICP27 for interaction 
between NUPs and ICP27. Involvement of this region in export has been shown 
and also it is not the site for either TAP or CRM1 interaction to contribute in export 
function.  It  seems  this  site  mediates  a  novel  direct  interaction  of  ICP27  with 
nucleoporins  but  whether  this  site  is  required  for  RNA  export  remains  to  be 
determined. New lines of studies on cargo-free shuttling have suggested NUP 153 
may  play  a  role  in  receptor-independent  nuclear  transport,  as  shown  for  the 
nuclear import of the transcription factor PU.1, the signal transducer and activator 
of transcription, Stat and the transport factor, Smad2 (Gould, Martinez et al. 2000; 
Xu,  Kang  et  al.  2002;  Zhong,  Takeda  et  al.  2005).  In  addition  to  the  above 
suggestion it has been revealed that the phosphorylation of the proteins play a role 
for  cargo-dependent  and  independent  transport,  and  unphosphorylated  cellular 
Stat1 proteins directly interact with the FG repeat region of NUP153 and NUP 214 
and  provide  nucleocytoplasmic  translocation  of  Stats  as  a  carrier-independent 
process. However, the phosphorylated Stat protein is then actively transported in 
the  nucleus  via  importin  α/β  (Marg,  Shan  et  al.  2004).  The  role  of  protein 
modification in ICP27 export was investigated and showed the serine at position 
114, which lies within the major NLS modulates the efficiency of nuclear import is 
the  only  amino  acid  in  the  ICP27  protein  that  is  phosphorylated  during  HSV-1 
infection (Zhi and Sandri-Goldin 1999). It has been demonstrated that ICP27 is 
phosphorylated  by CK2 and phosphorylation of ICP27  by  CK2 is necessary for 
ICP27’s  cytoplasmic  accumulation  and  it  might  regulate  nucleocytoplasmic 
trafficking of ICP27 and/or viral RNA.  Stimulation of CK2 activity by HSV-1 occurs 
at early times post infection and correlates with partial redistribution of the CK2 
holoenzyme from the nucleus to the cytoplasm. Therefore, it is suggested that it 
might facilitate the HSV-1 lytic cycle by, for example, regulating trafficking of ICP27 
protein  and/or  viral  RNAs  (Wadd,  Bryant  et  al.  1999;  Koffa,  Kean  et  al.  2003).  
Hence,  changes  in  the  sub-cellular  localisation  of  CK2  subunits  could  control 
ICP27’s  activities  and  distribution  as  well  as  regulate  its  translocation  and                                                                                                                     Chapter 6, Discussion               
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trafficking. In the same way nuclear import of Simian virus 40 large T antigen is 
enhanced by CK2 phosphorylation in HeLa cell (Xiao and Jans 1998). 
6.10.3  Conclusion 
To conclude the mapping results, NUPs 62, 153 and 214/CAN showed association 
with the ICP27 NES region (Figure 6.2 summarises the ICP27 mapping data). In 
the case of NUP 62, the N-terminus dLeu ICP27 mutant and the C-terminus M15 
and M16 ICP27 mutants showed association. NUP 214 also interacted with the 
same  regions  of  ICP27.  However,  for  NUP  153  only  partial  binding  of  the  C-
terminal  M16 mutant  and the  N-terminus  mutant, d1-2  was observed. Thus the 
NES might be the general binding site of ICP27 for NUP interaction and different 
forms of FG-repeat including. Although I found some evidence for involvement of 
the C-terminus of ICP27 in NUP binding, the interaction varied between different 
experiments and there was no consistency in data with the M15 and 16 mutants. I 
would suggest this could be due to protein configuration changes under different 
experimental conditions. Consistent with this idea it has been shown that the main 
NUP binding domain of TAP (TAP-UBA) has half the affinity for the GLFG-repeat 
NUP 98 in comparison with FXFG-repeat NUPs (Grant, Neuhaus et al. 2003). In 
addition, another NUP binding domain of TAP, NTF2 cannot interact with GLFG 
motifs (Clarkson, Corbett et al. 1997). The C-terminal region of ICP27 is involved in 
multiple protein-protein interactions and a ICP27 self association in vivo has been 
demonstrated. It has been suggested the substitution mutations M15 and M16 may 
affect ICP27 multimerisation (Wadd, Bryant et al. 1999; Zhi, Sciabica et al. 1999; 
Koffa,  Kean  et  al.  2003).  ICP27  or  NUPs  might  be  modified  posttranslationally 
during  incubation  in  the  extracts  I  used  in  pull  down  assays  and  these 
modifications could alter binding to NUPs. The N-terminus portion of NUP 62 is 
phosphorylated  and  O-glycosylated  and  shows  that  kinases  and  glycosyl 
transefrases  could  be  potentially  important  to  modulate  these  proteins  (Miller, 
Caracciolo et al. 1999). 
 ICP27 shuttles and exports viral RNAs through the NPC (Smith, Malik et al. 2005). 
Direct interaction of ICP27 with nucleoporins might give new insights  into export of 
viral mRNA from nucleus to the cytoplasm. Based on this model ICP27 can bind to 
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pore and export them to the cytoplasm. ICP27 can bind to NUP 153 that has RNA 
binding ability and is located in the nuclear face of NPC. ICP27 also binds NUP 62 
located in the central gated channel and could to pass it to the cytoplasmic side. 
My study showed interaction of ICP27 and NUPs are not RNA mediated so for 
export,  viral  mRNAs  could  bind  directly  to  NUPs  or  indirectly  via  ICP27.  Direct 
interaction of mRNA with some nucleoporins such as NUP 153, NUP 62 and Rae1 
has been shown. For mRNA export, NUP 153 can function by recognizing either 
single  stranded  RNA  through  its  RNA  binding  domain  or  by  recognizing  TAP, 
which interacts with its C-terminus domain (Ball and Ullman 2005). Therefore, I 
suppose that TAP could be replaced with ICP27 and provide export of mRNA. My 
data is not complete enough to make strong conclusions on the export function of 
these  proteins  and  the  RNAs  and  much  more  work  requires  to  be  done  to 
consolidate the work and to determine details. 
The  molecular  mechanism  of  transport  across  NPCs  shows  directionality,  gate 
selectivity  and  energy  consumption  as  mentioned  earlier  in  this  section  and 
involves  FG-repeat  NUPs.  ICP27  alone  or  in  complex  with  viral  mRNA  might 
interact  directly  with  NUPs  and  provide  a  transporter  complex  to  translocate 
through the NPC and transfer ICP27 either to the nucleus or the cytoplasm. The 
NUPs that are located in the cytoplasmic face of the NPC could associate with 
ICP27 and provide it to other NUPs in the gated central channel, such as NUP 62, 
and then to nuclear NUPs to dissociate in the nucleus. On the other hand, nuclear 
face  NUPs  could  bind  to  ICP27  in  the  nucleus  and  shuttle  ICP27  alone  or  in 
complex with RNA, through the central basket and pass it on to cytoplasmic NUPs 
to  dissociate  in  the  cytoplasm.  This  is  consistent  with  the  current  models  for 
mechanisms of translocation. However, it has been demonstrated that individual 
nucleoporins  can  have  a  major  function  in  specific  nucleocytoplasmic  transport 
pathways. This idea comes from the role of NUP 214 in CRM1-mediated nuclear 
protein export in vivo (Hutten and Kehlenbach 2006). In a study to examine the 
contribution of cytoplasmic NUPs in the transport machinery, depletion of NUP 214 
strongly reduced nuclear protein export in comparison with depletion of NUP 358 
that  had  only  a  modest  effect  on  the  same  transport  pathway  (Hutten  and 
Kehlenbach 2006). The association of NUP 62 with other FG-repeat nucleoporins, 
NUP 358, NUP 214 and NUP 153 has been shown (Stochaj, Banski et al. 2006).                                                                                                                     Chapter 6, Discussion               
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However, in this study it was demonstrated that in nuclear extracts there was no 
direct interaction of NUP 62 and NUP 153 and they suggested NUP 153 requires 
an adaptor molecule to link to the NUP62 (Stochaj, Banski et al. 2006). ICP27 
could be a good candidate adaptor protein in the case of its function in transport of 
RNA or protein. 
Fahrenkrog and colleagues proposed sometimes cargoes can bind to two transport 
receptors and may utilise both receptors simultaneously to translocate through the 
NPC (Fahrenkrog, Koser et al. 2004). ICP27 can interact directly with TAP and 
(possibly) NUPs and there is an indirect contribution of CRM1 in transport activity 
of ICP27 (Lengyel, Strain et al. 2006). So I suggest that cargo might interact with 
either  TAP  and  ICP27  or  CRM1  and  ICP27  simultaneously  for  translocation 
through NPC to shuttle between the nucleus and the cytoplasm (Figures 6.5 and 
6.6). In fact, NUP directionality in transport, the ability of the FG-repeat domains to 
allow inter-NUP interaction, their capacity for multiple simultaneous and transient 
interactions,  and  their  mobility  make  NUPs  the  best  option  for  interaction  with 
ICP27 to shuttle it as a cargo-free or cargo-dependent protein.  
In conclusion, it is hypothesised that the multifunctional protein ICP27 regulates 
transport  of  protein  and  RNAs  during  HSV-1  life  cycle  via  interaction  with 
nucleoporins in addition to other export pathways previously demonstrated. There 
are many aspects of the interaction and function of NUPs and ICP27 interaction 
that could not be investigated fully in the assays performed during the course of 
this  PhD.  However  it  is  clear  that  ICP27  utilises  different  export  pathways  to 
regulate transport of protein and RNAs during herpesvirus infection. 
6.10.4  Future work 
In this thesis I have provided evidence that the multifunctional regulatory HSV-1 
ICP27  protein  may  interact  with  some  nucleoporins  during  the  life  cycle  of  the 
virus. The findings reported in this study create a new road into elucidating the role 
of  the  NPC  and  NUPs  as  well  as  how  individual  nucleoporins  contribute  in 
transport of HSV-1 ICP27 protein and RNAs. Compared to our knowledge about 
the mechanism and the role of ICP27 in transport of viral RNA, our understanding 
about the mechanism of import and export of ICP27 is limited. A new insight into                                                                                                                     Chapter 6, Discussion               
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cargo-free export of ICP27 could be obtained by removing viral RNAs from cells 
and using single-molecule fluorescence (SMF) techniques. SMF is a complex of 
four  common  approaches  including  wide-field  epifluorescence  microscopy, 
fluorescence  correlation  microscopy,  scanning  confocal  microscopy  and  total 
internal  reflection  fluorescence  microscopy  that  could  allow  visualisation  of 
interaction of single molecules with nucleoporins in the NPC (Yang and Musser 
2006).  For  cargo-dependent  export  and  further  investigation  on  RNA  export,  it 
could help to determine whether a complex of ICP27 and RNA shuttles by direct 
interaction  with  nucleoporins  or  using  the  TAP  export  pathway  as  indicated  in 
previous studies. Future work could investigate the idea that ICP27 competes with 
other identified cellular pathways such as TAP and CRM1 to supply the transport 
machinery.  Understanding  the  mechanism  by  which  ICP27  mediates  directional 
transport of RNA substrates across the NPC is an important goal for the future. In 
fact, to characterise molecular interactions underlying nucleocytoplasmic transport, 
individual nuclear export pathways need to be selectively interfered with in living 
cells.  It  has  been  clearly  reported  that  some  nucleoporins  interact  directly  with 
RNAs.  This  specificity  is  shown  for  NUP  153  that  interacts  directly  with  single 
stranded RNAs indiscriminately. It is possible that ICP27 recruits viral mRNA to 
NUP 153 in the nuclear side of the NPC to interact with it, translocate and export to 
the cytoplasm directly or by handing to other NUPs. Future work could be based 
on gel shift assays to find interactions of NUP 153 with HSV-1 RNAs that also bind 
ICP27.  Also  approaches  such  as  SELEX  (systematic  evolution  of  ligands  by 
exponential  enrichment)
  will  be  a  good  method  to  gain  possible  NUP  153 
recognition motifs of RNAs for their ability to bind NUP 153.  
Further investigation of ICP27 N-terminus and C-terminus mutants is another way 
that could improve this study and develop functional studies on the role of ICP27-
nucleoporin interactions. Using the mutants in mapping studies or together with 
siRNA knock down studies of nucleoporins and transport receptors TAP or CRM1 
would give a better view of the structural interactions and their function. Further 
mapping of the NUPs that I studied during my project to show exactly which FG 
domains are involved in interaction could be interesting.  
Viruses  have  contributed  to  the  discovery  of  key  nuclear  transport  pathways. 
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transport  of  ICP27,  we  can  perhaps  design  drugs  to  target  the  viral  mRNA 
transport  machinery.  Results  may  provide  insights  into  multiple  and  novel  key 
regulatory steps of nucleocytoplasmic trafficking that may also serve as potential 
targets for viral and cancer therapies. 
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Figure 1.1: HSV virion, a. The tegument surrounds the double stranded DNA in 
an  icosahedral  capsid.  The  viral  envelope  containing  glycoprotein  spikes 
surrounds it (Clements and Brown, 1997). b. Schematic representation of the HSV 
virion. Reproduced from Marko Reschke et al., 1997.  
(a)
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Figure 1.2.  Schematic diagram of the HSV-1 genome: 
The  organization  of  the  HSV-1  genome,  showing  the  unique  long  and  short 
regions (UL and Us, respectively), which are covalently linked and flanked by the 
terminal  and  internal  repeats  (TR  and  IR,  respectively).    The  ‘a’  sequence  is 
present  at  each  end  of  the  genome  and  in  an  inverted  orientation  at  the  L-S 
junction.    The  L  and  S  regions  can  invert  relative  to  each  other  to  form  four 
isomers (Hayward et al., 1975). The orientation of the four isomers is shown by the 
arrows.                                         
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Figure 1.3: Diagram of the replication cycle of HSV.  
In the upper left of the figure, in the first step of replication, the HSV virion attaches 
to the cell membrane. Next there is fusion of the virus envelope with the plasma 
membrane and the capsid and tegument proteins are release into the cytoplasm. 
vhs protein in the tegument causes cellular mRNAs degradation. In the second 
step, the viral DNA enters the nucleus by shuttling of the capsid through the NPC. 
In  next  step,  replication  and  transcription  of  viral  DNA  take  place.  Virus  gene 
expression follows a cascade pathway with the immediate early (IE) or α, the early 
(E) or β and the late (L) or γ genes expressed sequentially making regulatory and 
structural proteins. Virus assembly is next step in the HSV life cycle. The virion is 
enveloped by budding through cellular membranes, and finally, from the plasma 
membrane of the cell allowing the virion to exit from the cell (Whitely, 2001). 
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Fig.1.4:  Diagram  of  a  model  of  HSV  DNA  replication,  with  the  following 
steps:  
1. Circularisation of DNA occurs upon entry into the nucleus. 2. UL9 begins to 
unwind the DNA by binding to either oril or oris and then recruits ICP8 to the 
unwound single-stranded DNA. 3. Five viral DNA replication proteins are recruited 
to the replication fork by UL9 and ICP8. 4. A complex of the helicase–primase 
proteins and the viral polymerase at each replication fork initiates rounds of theta-
form  replication.  5.  An  unknown  mechanism  switches  replication  of  DNA  from 
theta to rolling-circle mode. UL9 is not necessary for this step because it is not 
origin dependent. 6. Replication of DNA through the rolling-circle mode produces 
concatamers of viral DNA, which are cleaved into monomeric molecules during 
packaging. Diagram courtesy of E. McNamee from (Whitely, 2001). 
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Fig.1.5: Schematic representation of the regulation of HSV gene expression. 
Open  and  filled  arrows  showing  events  in  the  reproductive  cycle  of  HSV  that 
switch gene expression “on” and “off,” respectively. 1. α-TIF switches on IE or α 
gene transcription. 2. Autoregulation of α gene expression. 3. Switching on of E or 
β gene transcription. 4. Switching on of L or γ gene transcription by α and β gene 
products  through  transactivation  of  γ  genes.  The  heterogeneity  is  shown  as  a 
continuum in which inhibitors of viral DNA synthesis are shown to have minimal 
effect on γa gene expression but totally preclude the expression of γz genes. 5. γ 
genes late in infection product switches off of α and β gene expression (Whitely, 
2001).                                                                                                                     Chapter 1, Figures              
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Figure  1.6:  Levels  of  ICP27  action.  ICP27  acts  at  transcriptional  and 
posttranscriptional  levels  and  positively  regulates  mRNA  processing,  include: 
levels  of  action  capping,  polyadenylation,  transport,  RNA  stability,  negatively 
regulates splicing action and recently, translation (Leiper, 2004).  
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        Figure 1.7: Cartoon of ICP27 highlighting its functional domains. 
 
 
 
 
 
 
 
 
Figure 1.8: Sequence alignment of hnRNP K and ICP27: showing homology 
between the minimally defined KNS region of hnRNP K and a region in ICP27.   
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Figure 1.9: Import and export cycles mediated by Importins and Exportins. Importins 
bind to cargo molecules with NLS in the cytoplasm and mediate interactions with the NPC 
to translocate into the nucleus, and then RanGTP binds to importin for cargo release and 
recycling. The export cycle is similar but with the crucial difference that RanGTP induces 
cargo binding to an export receptor in the nucleus (Hetzer, Walther, and Mattaj, 2005). 
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Figure 1.10: Various RNA export pathways: The diagram shows different types 
of RNAs utilising various export pathways for receptor-export adaptor molecules 
such as exportin, PHAX-CRM-1, REF-TAP, Rev-CRM-1 and CTE-TAP for export 
to the cytoplasm; MPMV: Mason Pfizer Monkey virus (Conti and Izaurralde, 2001; 
Cullen, 2000; Stutz and Rosbash, 1998). 
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Figure1.11: HSV-1 utilises cellular pathways to export viral spliced mRNAs.  
The cellular TAP/NXF1 pathway is used to export unspliced mRNA encoded by 
simple  retroviruses  and  intronless  mRNAs  encoded  by  HSV-1.  At  the  left,  in 
Mason-Pfizer  monkey  virus  (MPMV),  the  CTE  interacts  directly  with 
TAP/NXF1/p15, and exports mRNAs. At the right, in HSV-1-infected cells, ICP27 
interacts with Aly/REF and recruits it to sites of HSV-1 transcription. ICP27 binds 
viral  mRNAs,  and  the  ICP27-Aly/REF-RNA  complex  is  directed  to  TAP/NXF1 
(Sandri-Goldin, 2004).                                                                                                                      Chapter 1, Figures              
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Figure  1.12:   Imaging  the  nuclear  pore  complex  (NPC)  by  various 
microscopy techniques. Image of a thin-section of embedded nuclear envelope 
(NE)  captured  by  transmission  electron  microscopy  (TEM).  b  Image  of  the  NE 
embedded in thick  amorphous  ice taken  by  energy-filtered  electron microscopy 
(EFTEM). c. the cytoplasmic and d the nuclear face of the NE. e, f Scanning force 
microscopy (SFM) images of the cytoplasmic (e) and the nuclear face (f) of the 
NE. Scale bars in panels a–f, 100 nm (Lim, Aebi, and Stoffler, 2006). 
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Figure 1.13:  Diagramme of a vertebrate NPC showing possible architecture. 
The cytoplasmic, central and nuclear rings are shown in green. The inner nuclear 
membrane (INM) and outer nuclear membrane (ONM) (yellow) come together at 
the sites of NPC insertion. Cytoplasmic and nuclear filaments are attached to the 
ring structures. The nuclear filaments form a basket structure topped by a terminal 
ring (grey). Nucleoporins are located throughout the NPC as shown. The colour 
code  represents  the  three  dynamic  classes  of  nucleoporins:  Structural  scaffold 
NUPs are shown in blue, mobile NUPs in purple and the highly dynamic NUPS in 
orange. (Hetzer, Walther, and Mattaj, 2005).                                                                                                                     Chapter 1, Figures              
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Figure 1.14: Distribution of FG repeats on mammalian nucleoporins. The C-
terminal region (amino acids 1000–3224) of human NUP 358, and full-length NUP 
45 (rat), NUP 54 (human), NUP 58 (rat), NUP 62 (human), NUP 98 (human), NUP 
153  (human)  and  NUP  214(human)  are  shown.  The  FG-repeat  sequences  are 
indicated by coloured bar. FxFG-repeats, red bars, GLFG repeats are green bars. 
(Bednenko, Cingolani, and Gerace, 2003).                                                                                                                     Chapter 1, Figures              
  152 
                        
 
 
 
Figure  1.15:  Domain  size  and  organisation  and  spatial  distribution  in  the 
NPC of FG-repeat nucleoporins. (a) A comparison of the size and structure of 
the FG-repeat nucleoporins NUP 153, NUP 214/CAN and NUP 62. The FG-repeat 
portions of the NUPs are generally unfolded in their native state. The C-terminal 
portions of NUP 153 and NUP 214/CAN and the N-terminal part of NUP 62 might 
be flexible for interaction with cargos. (b) Immunogold EM indicated high densities 
of FG repeat NUPs in the cytoplasmic and nuclear periphery of the central basket 
(deep red colour) but a decreased density towards the centre of the central pore 
and the extremity of the NPC (pale red to white shading) (Fahrenkrog, Koser, and 
Aebi, 2004).                                                                                                                      Chapter 1, Figures              
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Figure 1.16: NUP 153 organization. A. The architecture of NUP 153 shows three 
main domains. 1. The N-terminal region that displays three functional components: 
the  nuclear  envelope  targeting  cassette  (NETC;  2–144),  the  nuclear  pore 
associating region (NPAR; 39–339), and an RNA binding domain (RBD; 250–400). 
2.  The  central  zinc  finger  domain  (650–880)  with  four  zinc  fingers.  3.  The  C-
terminal region (881–1475) that contains FG-rich motifs. B. A range of proteins 
that may interact with NUP 153. Their interacting regions are indicated  (Ball and 
Ullman, 2005). 
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Figure 1.17: Location and mobility of NUPs and related factors involved in 
mRNA export. There is a stable and mobile population of NUP 153 each located 
in different sites of the NPC.  NUP 98 is a highly mobile NUP that cooperates with 
components of the NPC on both the nuclear and cytoplasmic sides. NUP 98 binds 
to RAE1 in mRNA export. Some stable NUPs such as those of the NUP 107-160 
complex can be found in association with both NUP 153 and NUP 98. Association 
of  NUP  153  with  the  nuclear  basket  component  Tpr  is  necessary  for  its 
localisation. NUP 214/CAN is localised to the filaments on the cytoplasmic face of 
the NPC. This NUP is thought to  be  a docking  site for  transport of RNAs  and 
proteins such as the dynamically-located DEAD box helicase, Dbp5 (Dimaano and 
Ullman, 2004). 
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Figure  1.18:  Models  for  NPC  translocation:  (A)  On  the  left,  the  karyopherin 
(Kap)-dependent transport pathways is shown and described in Figure 1.9. On the 
right,  different  translocation  models  are  shown.  (B)  The  FG  NUPs  form  a 
filamentous network that excludes most large molecules. FG-repeat interactions 
may allow movement through the network and the NPC. (C) The FG-repeat NUPs 
may  interact  weakly  and  cause  the  central  chanel  to  be  hydrophobic.  The  FG 
binding  sites  on  the  cargo  receptors  facilitate  selective  passage  through  the 
hydrophobic  environment.  (D)  The  FG-repeat  NUPs  may  provide  a  series  of 
sequential  binding  sites  of  increasing  affinity  for  receptor-cargo  complex 
(Suntharalingam and Wente, 2003).                                                                                                                      Chapter 1, Figures              
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Figure  1.19:  Schematic  diagram  shows  proposed  mechanisms  of  NPC 
translocation  of  transport  receptors  and  cargoes.  (a)  A  model  showing 
translocation of a cargo receptor with two nucleoporin-binding sites. For import in 
the cytoplasmic periphery of the NPC the receptor can use the first FG-repeat-
binding  site  (orange  for  NUP  interaction.  For  translocation  through  the  central 
basket it may use both of its FG-binding sites (orange and pink).  Its second site 
(pink) may be implicated in accessing the nuclear side of the NPC. (b) A transport 
receptor  (purple)  that  may  interact  with  two  transport  factors  (blue  and  green) 
could use both receptors simultaneously one or other to translocate through the 
central basket. c, cytoplasm; n, nucleus (Fahrenkrog, Koser, and Aebi, 2004).                                                                                                                     Chapter 1, Figures              
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Table1.1: Human Herpesviruses
Tumors, Kaposi’s sarcoma, some B cell 
tumors
170/
210
γ(Rhad Human 
herpesvirus-8
Kaposi’s 
sarcoma-
associated virus
HHV-8
Some case of Roseola 145 β Human 
herpesvirus-7
HHV-7
Roseola in infants, infection in allograft 
recipients and AIDS patients,possible 
role in multiple sclerosis
162-
168
β Human 
herpesvirus
6B
HHV-6B
Some infection in allograft recipient and 
AIDS patients 
(Pneumonia, Marrow failure, 
encephalitis)
159-
170
β Human 
herpesvirus
6A
HHV-6A
IM, Congenital infections, Infection in 
allograft recipients, possible role in 
atherosclerosis and restenosis
248 β Cytomegalovirus HHV-5
Infectious mononucleosis(IM), Tumors 184 γ(LCV) Epstein-Bar virus HHV-4
Chickenpox, Shingles 125 α Varicella zoster 
virus
HHV-3
Genital, Anal lesions (severe fatal 
neonatal!)
152 α Herpes simplex 
virus
Type 2
HHV-2
Oral, Ocular lesions(fever 
blisters),Encephalitis
152 α Herpes simplex 
virus
Type 1
HHV-1
Disease Genoe
Size
(KB)
Sub 
Fam
Common name Designatin
Tumors, Kaposi’s sarcoma, some B cell 
tumors
170/
210
γ(Rhad Human 
herpesvirus-8
Kaposi’s 
sarcoma-
associated virus
HHV-8
Some case of Roseola 145 β Human 
herpesvirus-7
HHV-7
Roseola in infants, infection in allograft 
recipients and AIDS patients,possible 
role in multiple sclerosis
162-
168
β Human 
herpesvirus
6B
HHV-6B
Some infection in allograft recipient and 
AIDS patients 
(Pneumonia, Marrow failure, 
encephalitis)
159-
170
β Human 
herpesvirus
6A
HHV-6A
IM, Congenital infections, Infection in 
allograft recipients, possible role in 
atherosclerosis and restenosis
248 β Cytomegalovirus HHV-5
Infectious mononucleosis(IM), Tumors 184 γ(LCV) Epstein-Bar virus HHV-4
Chickenpox, Shingles 125 α Varicella zoster 
virus
HHV-3
Genital, Anal lesions (severe fatal 
neonatal!)
152 α Herpes simplex 
virus
Type 2
HHV-2
Oral, Ocular lesions(fever 
blisters),Encephalitis
152 α Herpes simplex 
virus
Type 1
HHV-1
Disease Genoe
Size
(KB)
Sub 
Fam
Common name Designatin
Nine human Herpesviruses, classification, G+C% content genomic size and disease associated with them.
( LCV: Lymphocryptovirus, Rhad: Rhadinovirus) (Field Virology,Fig72-3,2001).                                                                                                                    Chapter 1, Figures              
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           Table 1. 2: Nucleolar localisation signals (NuLs)
Protein Function NuLs Reference
MDV MEQ Transcriptional 
transactivator
RRRKRNDAARRRRRKQ Liu et al.,
1997
HIV-1 Rev Nucleocytoplasmi
c targetting of 
intron containing 
viral transcripts
RRNRRRRWRERQRQ Cochrane et 
al., 1990
HIV-1 Tat Transcriptional 
transactivator
GRKKRRQRRRAHQN Dang and 
Lee, 1989
HTLV-1 Rex Nucleocytoplasmi
c targetting of 
intron containing 
viral transcripts
PKTRRRPRRSQRKRPPTP Nosaka et al.,
1989
PRRV N 
protein
Nucleocapsid
protein
RGKGPGKKNKKKNPEK Rowland et 
al., 1999
Hsp 70 Stress response 
protein
FKRKHKKDISQNKRAVR
R
Dang and 
Lee, 1989
Topoisomeras
e 1
Unwinding 
supercoiled DNA
RESIDUES 157-199 K 
RICH
Mo et al.,
2000
FXR2P Associates with 
FMRP, ribosomes
and RNA
RPQRRNRSRRRRFR Tamanini et 
al., 2000 
Protein Function NuLs Reference
MDV MEQ Transcriptional 
transactivator
RRRKRNDAARRRRRKQ Liu et al.,
1997
HIV-1 Rev Nucleocytoplasmi
c targetting of 
intron containing 
viral transcripts
RRNRRRRWRERQRQ Cochrane et 
al., 1990
HIV-1 Tat Transcriptional 
transactivator
GRKKRRQRRRAHQN Dang and 
Lee, 1989
HTLV-1 Rex Nucleocytoplasmi
c targetting of 
intron containing 
viral transcripts
PKTRRRPRRSQRKRPPTP Nosaka et al.,
1989
PRRV N 
protein
Nucleocapsid
protein
RGKGPGKKNKKKNPEK Rowland et 
al., 1999
Hsp 70 Stress response 
protein
FKRKHKKDISQNKRAVR
R
Dang and 
Lee, 1989
Topoisomeras
e 1
Unwinding 
supercoiled DNA
RESIDUES 157-199 K 
RICH
Mo et al.,
2000
FXR2P Associates with 
FMRP, ribosomes
and RNA
RPQRRNRSRRRRFR Tamanini et 
al., 2000 
Protein Protein Function Function NuLs NuLs Reference Reference
MDV MEQ MDV MEQ Transcriptional 
transactivator
Transcriptional 
transactivator
RRRKRNDAARRRRRKQ RRRKRNDAARRRRRKQ Liu et al.,
1997
Liu et al.,
1997
HIV-1 Rev HIV-1 Rev Nucleocytoplasmi
c targetting of 
intron containing 
viral transcripts
Nucleocytoplasmi
c targetting of 
intron containing 
viral transcripts
RRNRRRRWRERQRQ RRNRRRRWRERQRQ Cochrane et 
al., 1990
Cochrane et 
al., 1990
HIV-1 Tat HIV-1 Tat Transcriptional 
transactivator
Transcriptional 
transactivator
GRKKRRQRRRAHQN GRKKRRQRRRAHQN Dang and 
Lee, 1989
Dang and 
Lee, 1989
HTLV-1 Rex HTLV-1 Rex Nucleocytoplasmi
c targetting of 
intron containing 
viral transcripts
Nucleocytoplasmi
c targetting of 
intron containing 
viral transcripts
PKTRRRPRRSQRKRPPTP PKTRRRPRRSQRKRPPTP Nosaka et al.,
1989
Nosaka et al.,
1989
PRRV N 
protein
PRRV N 
protein
Nucleocapsid
protein
Nucleocapsid
protein
RGKGPGKKNKKKNPEK RGKGPGKKNKKKNPEK Rowland et 
al., 1999
Rowland et 
al., 1999
Hsp 70 Hsp 70 Stress response 
protein
Stress response 
protein
FKRKHKKDISQNKRAVR
R
FKRKHKKDISQNKRAVR
R
Dang and 
Lee, 1989
Dang and 
Lee, 1989
Topoisomeras
e 1
Topoisomeras
e 1
Unwinding 
supercoiled DNA
Unwinding 
supercoiled DNA
RESIDUES 157-199 K 
RICH
RESIDUES 157-199 K 
RICH
Mo et al.,
2000
Mo et al.,
2000
FXR2P FXR2P Associates with 
FMRP, ribosomes
and RNA
Associates with 
FMRP, ribosomes
and RNA
RPQRRNRSRRRRFR RPQRRNRSRRRRFR Tamanini et 
al., 2000 
Tamanini et 
al., 2000 
This Table lists several examples of NuLs.  Abbreviations: MDV: Mareks disease virus; 
MEQ: MDV Eco Q; HIV-1: Human immunodeficiency virus type 1; HTLV-1: Human T cell 
lymphotropic virus type 1; PRRV: Porcine reproductive and respiratory syndrome virus; Hsp: 
heat shock protein; FMRP: Fragile X mental retardation protein; FXR2P: FMRP related 
protein 2.                                                                                                                     Chapter 1, Figures              
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Herpes virus Subfamily ICP27 homologue Reference
a-Herpes virus Varicella-Zoster 
virus (VZV)
Equine herpes virus 
type 1 (EHV-1) 
ORF4
UL3
Inchauspe, Nagpal
et al 1989
Zhao, Holden et al 
1992
b-Herpes virus Human 
cytomegalovirus 
(CMV)
UL69 Chee, Bankier et al 
1990
g-Herpes virus Eptein-Bar virus 
(EBV)
Herpes virus samiri
(HVS)
Human herpes 
virus 8 (HHV8)/ 
Kaposi’s sarcoma 
associated 
virus(KSHV)
SM
ORF57
ORF57
Cook, Shanahan et 
al 1994
Nicholas, Gompels
et al 1988
Bello, Davison et al 
1999
Herpes virus Subfamily ICP27 homologue Reference
a-Herpes virus Varicella-Zoster 
virus (VZV)
Equine herpes virus 
type 1 (EHV-1) 
ORF4
UL3
Inchauspe, Nagpal
et al 1989
Zhao, Holden et al 
1992
b-Herpes virus Human 
cytomegalovirus 
(CMV)
UL69 Chee, Bankier et al 
1990
g-Herpes virus Eptein-Bar virus 
(EBV)
Herpes virus samiri
(HVS)
Human herpes 
virus 8 (HHV8)/ 
Kaposi’s sarcoma 
associated 
virus(KSHV)
SM
ORF57
ORF57
Cook, Shanahan et 
al 1994
Nicholas, Gompels
et al 1988
Bello, Davison et al 
1999
Herpes virus Herpes virus Subfamily Subfamily ICP27 homologue ICP27 homologue Reference Reference
a-Herpes virus a-Herpes virus Varicella-Zoster 
virus (VZV)
Equine herpes virus 
type 1 (EHV-1) 
Varicella-Zoster 
virus (VZV)
Equine herpes virus 
type 1 (EHV-1) 
ORF4
UL3
ORF4
UL3
Inchauspe, Nagpal
et al 1989
Zhao, Holden et al 
1992
Inchauspe, Nagpal
et al 1989
Zhao, Holden et al 
1992
b-Herpes virus b-Herpes virus Human 
cytomegalovirus 
(CMV)
Human 
cytomegalovirus 
(CMV)
UL69 UL69 Chee, Bankier et al 
1990
Chee, Bankier et al 
1990
g-Herpes virus g-Herpes virus Eptein-Bar virus 
(EBV)
Herpes virus samiri
(HVS)
Human herpes 
virus 8 (HHV8)/ 
Kaposi’s sarcoma 
associated 
virus(KSHV)
Eptein-Bar virus 
(EBV)
Herpes virus samiri
(HVS)
Human herpes 
virus 8 (HHV8)/ 
Kaposi’s sarcoma 
associated 
virus(KSHV)
SM
ORF57
ORF57
SM
ORF57
ORF57
Cook, Shanahan et 
al 1994
Nicholas, Gompels
et al 1988
Bello, Davison et al 
1999
Cook, Shanahan et 
al 1994
Nicholas, Gompels
et al 1988
Bello, Davison et al 
1999
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Protein Activity Method Reference
hnRNP K Transcription 
activator, regulate 
translation
Yeast-two hybrid 
screen in vivo 
binding studies
Wadd, Bryant et al 
1999
Casein kinase 2 Serine/threonin
protein kinase
Yeast-two hybrid 
screen in vivo 
binding studies
Wadd, Bryant et al 
1999
Common sm
protein
Protein component 
of snRNP
in vivo binding 
studies with anti  
sm serum
Sondri-Goldin and 
Hibbard 1996
SAP 145 Protein component 
of  U2 snRNP
Yeast-two hybrid 
screen in vivo 
binding studies
Bryant, Wadd et al 
2001
TAP Cellular export 
receptor
Yeast-two hybrid 
screen in vivo 
binding studies
Chen, Sciabica et al 
2002
REF Cellular RNA 
export factor
Yeast-two hybrid 
screen in vivo 
binding studies
Koffa, Clements et 
al 2001
RNA pol II 
holoenzym
Catalyses synthesis 
of RNA
in vivo binding 
studies
Zhou and Knipe
2002
P32 Cellular (mainly 
mitochonderial) 
multifunctional 
protein
Yeast-two hybrid 
screen in vivo 
binding studies
Bryant, Matheows
et al 2000
SRp20 Member of the SR 
protein family 
splicing factors
Yeast-two hybrid 
screen in vivo 
binding studies
Scibica, Dai et al 
2003
SRPK1 SR protein kinase1, 
highly specific for 
serin/arginine
dipeptides
in vivo binding 
studies
Scibica, Dai et al 
2003
Protein Activity Method Reference
hnRNP K Transcription 
activator, regulate 
translation
Yeast-two hybrid 
screen in vivo 
binding studies
Wadd, Bryant et al 
1999
Casein kinase 2 Serine/threonin
protein kinase
Yeast-two hybrid 
screen in vivo 
binding studies
Wadd, Bryant et al 
1999
Common sm
protein
Protein component 
of snRNP
in vivo binding 
studies with anti  
sm serum
Sondri-Goldin and 
Hibbard 1996
SAP 145 Protein component 
of  U2 snRNP
Yeast-two hybrid 
screen in vivo 
binding studies
Bryant, Wadd et al 
2001
TAP Cellular export 
receptor
Yeast-two hybrid 
screen in vivo 
binding studies
Chen, Sciabica et al 
2002
REF Cellular RNA 
export factor
Yeast-two hybrid 
screen in vivo 
binding studies
Koffa, Clements et 
al 2001
RNA pol II 
holoenzym
Catalyses synthesis 
of RNA
in vivo binding 
studies
Zhou and Knipe
2002
P32 Cellular (mainly 
mitochonderial) 
multifunctional 
protein
Yeast-two hybrid 
screen in vivo 
binding studies
Bryant, Matheows
et al 2000
SRp20 Member of the SR 
protein family 
splicing factors
Yeast-two hybrid 
screen in vivo 
binding studies
Scibica, Dai et al 
2003
SRPK1 SR protein kinase1, 
highly specific for 
serin/arginine
dipeptides
in vivo binding 
studies
Scibica, Dai et al 
2003
Protein Protein Activity Activity Method Method Reference Reference
hnRNP K hnRNP K Transcription 
activator, regulate 
translation
Transcription 
activator, regulate 
translation
Yeast-two hybrid 
screen in vivo 
binding studies
Yeast-two hybrid 
screen in vivo 
binding studies
Wadd, Bryant et al 
1999
Wadd, Bryant et al 
1999
Casein kinase 2 Casein kinase 2 Serine/threonin
protein kinase
Serine/threonin
protein kinase
Yeast-two hybrid 
screen in vivo 
binding studies
Yeast-two hybrid 
screen in vivo 
binding studies
Wadd, Bryant et al 
1999
Wadd, Bryant et al 
1999
Common sm
protein
Common sm
protein
Protein component 
of snRNP
Protein component 
of snRNP
in vivo binding 
studies with anti  
sm serum
in vivo binding 
studies with anti  
sm serum
Sondri-Goldin and 
Hibbard 1996
Sondri-Goldin and 
Hibbard 1996
SAP 145 SAP 145 Protein component 
of  U2 snRNP
Protein component 
of  U2 snRNP
Yeast-two hybrid 
screen in vivo 
binding studies
Yeast-two hybrid 
screen in vivo 
binding studies
Bryant, Wadd et al 
2001
Bryant, Wadd et al 
2001
TAP TAP Cellular export 
receptor
Cellular export 
receptor
Yeast-two hybrid 
screen in vivo 
binding studies
Yeast-two hybrid 
screen in vivo 
binding studies
Chen, Sciabica et al 
2002
Chen, Sciabica et al 
2002
REF REF Cellular RNA 
export factor
Cellular RNA 
export factor
Yeast-two hybrid 
screen in vivo 
binding studies
Yeast-two hybrid 
screen in vivo 
binding studies
Koffa, Clements et 
al 2001
Koffa, Clements et 
al 2001
RNA pol II 
holoenzym
RNA pol II 
holoenzym
Catalyses synthesis 
of RNA
Catalyses synthesis 
of RNA
in vivo binding 
studies
in vivo binding 
studies
Zhou and Knipe
2002
Zhou and Knipe
2002
P32 P32 Cellular (mainly 
mitochonderial) 
multifunctional 
protein
Cellular (mainly 
mitochonderial) 
multifunctional 
protein
Yeast-two hybrid 
screen in vivo 
binding studies
Yeast-two hybrid 
screen in vivo 
binding studies
Bryant, Matheows
et al 2000
Bryant, Matheows
et al 2000
SRp20 SRp20 Member of the SR 
protein family 
splicing factors
Member of the SR 
protein family 
splicing factors
Yeast-two hybrid 
screen in vivo 
binding studies
Yeast-two hybrid 
screen in vivo 
binding studies
Scibica, Dai et al 
2003
Scibica, Dai et al 
2003
SRPK1 SRPK1 SR protein kinase1, 
highly specific for 
serin/arginine
dipeptides
SR protein kinase1, 
highly specific for 
serin/arginine
dipeptides
in vivo binding 
studies
in vivo binding 
studies
Scibica, Dai et al 
2003
Scibica, Dai et al 
2003
Table 1.4. HSV-1 ICP27 partner proteins
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Vertebrate S. cerevisiae C. elegans D. melanogaster
Nup358 npp-9 Nup358
Nup214 yNup159 npp-14 Dnup214
gp210 --- npp-12 Gp210
Nup205 yNup192 npp-3 CG11953
Tpr Mip1/Mip2 R07G3.3 ---
Nup188 yNup188 --- ---
Nup160 yNup120 npp-6 CG4738
Nup155 yNup170/yNup157 npp-8 CG4579
Nup153 yNup1/2, yNup60 npp-7 NUP153
Nup133 yNup133 npp-15 CG6958
POM121 --- --- ---
Nup107 yNup84 npp-5 CG6743
Nup98 yNup145-N npp-10 Nup98
Nup96 ynup145-C npp-10 Nup96
Nup98 yNic96 npp-13 CG11092
Nup88 yNup82 --- Mbo
Nup85/75 --- npp-2 ---
p62/Nup62 yNsp1 npp-11 Nup62
Nup58 yNup49 --- Nup58
Nup54 yNup57 npp-1 Nup54
Nup50 --- npp-16 ---
Nup45 --- npp-4 ---
Nup43 --- C09G9.2 CG11875
Nup37 --- --- ---
Nup35 --- npp-19 CG6773
Sec13 ySec13 npp-20 CG8722
Seh1 ySeh1 npp-18 ---
RAE1 --- npp-17 ---
Gle1 yGle1 --- ---
Gle2 yGle2(Rae1) --- ---
hCG1 yNup42(Rip)ddNdc1 --- ---
--- POM152, Nup60,POM34 --- ---
--- Ndc1, yNup85,yNup53, yNup59 --- ---
--- yNup59, cdc31 --- ---
Vertebrate S. cerevisiae C. elegans D. melanogaster
Nup358 npp-9 Nup358
Nup214 yNup159 npp-14 Dnup214
gp210 --- npp-12 Gp210
Nup205 yNup192 npp-3 CG11953
Tpr Mip1/Mip2 R07G3.3 ---
Nup188 yNup188 --- ---
Nup160 yNup120 npp-6 CG4738
Nup155 yNup170/yNup157 npp-8 CG4579
Nup153 yNup1/2, yNup60 npp-7 NUP153
Nup133 yNup133 npp-15 CG6958
POM121 --- --- ---
Nup107 yNup84 npp-5 CG6743
Nup98 yNup145-N npp-10 Nup98
Nup96 ynup145-C npp-10 Nup96
Nup98 yNic96 npp-13 CG11092
Nup88 yNup82 --- Mbo
Nup85/75 --- npp-2 ---
p62/Nup62 yNsp1 npp-11 Nup62
Nup58 yNup49 --- Nup58
Nup54 yNup57 npp-1 Nup54
Nup50 --- npp-16 ---
Nup45 --- npp-4 ---
Nup43 --- C09G9.2 CG11875
Nup37 --- --- ---
Nup35 --- npp-19 CG6773
Sec13 ySec13 npp-20 CG8722
Seh1 ySeh1 npp-18 ---
RAE1 --- npp-17 ---
Gle1 yGle1 --- ---
Gle2 yGle2(Rae1) --- ---
hCG1 yNup42(Rip)ddNdc1 --- ---
--- POM152, Nup60,POM34 --- ---
--- Ndc1, yNup85,yNup53, yNup59 --- ---
--- yNup59, cdc31 --- ---
Vertebrate Vertebrate S. cerevisiae S. cerevisiae C. elegans C. elegans D. melanogaster D. melanogaster
Nup358 Nup358 npp-9 npp-9 Nup358 Nup358
Nup214 Nup214 yNup159 yNup159 npp-14 npp-14 Dnup214 Dnup214
gp210 gp210 --- --- npp-12 npp-12 Gp210 Gp210
Nup205 Nup205 yNup192 yNup192 npp-3 npp-3 CG11953 CG11953
Tpr Tpr Mip1/Mip2 Mip1/Mip2 R07G3.3 R07G3.3 --- ---
Nup188 Nup188 yNup188 yNup188 --- --- --- ---
Nup160 Nup160 yNup120 yNup120 npp-6 npp-6 CG4738 CG4738
Nup155 Nup155 yNup170/yNup157 yNup170/yNup157 npp-8 npp-8 CG4579 CG4579
Nup153 Nup153 yNup1/2, yNup60 yNup1/2, yNup60 npp-7 npp-7 NUP153 NUP153
Nup133 Nup133 yNup133 yNup133 npp-15 npp-15 CG6958 CG6958
POM121 POM121 --- --- --- --- --- ---
Nup107 Nup107 yNup84 yNup84 npp-5 npp-5 CG6743 CG6743
Nup98 Nup98 yNup145-N yNup145-N npp-10 npp-10 Nup98 Nup98
Nup96 Nup96 ynup145-C ynup145-C npp-10 npp-10 Nup96 Nup96
Nup98 Nup98 yNic96 yNic96 npp-13 npp-13 CG11092 CG11092
Nup88 Nup88 yNup82 yNup82 --- --- Mbo Mbo
Nup85/75 Nup85/75 --- --- npp-2 npp-2 --- ---
p62/Nup62 p62/Nup62 yNsp1 yNsp1 npp-11 npp-11 Nup62 Nup62
Nup58 Nup58 yNup49 yNup49 --- --- Nup58 Nup58
Nup54 Nup54 yNup57 yNup57 npp-1 npp-1 Nup54 Nup54
Nup50 Nup50 --- --- npp-16 npp-16 --- ---
Nup45 Nup45 --- --- npp-4 npp-4 --- ---
Nup43 Nup43 --- --- C09G9.2 C09G9.2 CG11875 CG11875
Nup37 Nup37 --- --- --- --- --- ---
Nup35 Nup35 --- --- npp-19 npp-19 CG6773 CG6773
Sec13 Sec13 ySec13 ySec13 npp-20 npp-20 CG8722 CG8722
Seh1 Seh1 ySeh1 ySeh1 npp-18 npp-18 --- ---
RAE1 RAE1 --- --- npp-17 npp-17 --- ---
Gle1 Gle1 yGle1 yGle1 --- --- --- ---
Gle2 Gle2 yGle2(Rae1) yGle2(Rae1) --- --- --- ---
hCG1 hCG1 yNup42(Rip)ddNdc1 yNup42(Rip)ddNdc1 --- --- --- ---
--- --- POM152, Nup60,POM34 POM152, Nup60,POM34 --- --- --- ---
--- --- Ndc1, yNup85,yNup53, yNup59 Ndc1, yNup85,yNup53, yNup59 --- --- --- ---
--- --- yNup59, cdc31 yNup59, cdc31 --- --- --- ---
Table 1.5: List of nucleoporins in different species: vertebrate, yeast, worm and fly
The vertebrate nucleoporins are listed according to their molecular weight. 
The S. cerevisiae, C. elegans, and D. melanogaster homologues are listed.                                                                                                                     Chapter 1, Figures              
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Table 1.6: mRNA export factors 
Name Alternative name Role and/or function 
CRM1 Exportin Nuclear export receptor for proteins and some mRNAs 
GTPase
Ran
Cofactor for CRM1 
NES Nuclear export 
sequence
Short leucine-rich sequence in nuclear export proteins that 
interacts with CRM1 
LMB Leptomycin B Drug that inhibits binding of NES to CRM1 by covalent 
modification at a conserved cysteine residue 
CTE Constitutive transport 
element
Highly structured RNA sequence in unspliced retrovirus 
mRNA that binds to TAP 
TAP NXF1 The major nuclear mRNA export receptor in metazoans; 
homologue of Mex67p in yeasts 
p15 NXT1 Heterodimeric binding partner of TAP/NXF1 
EJC Multiprotein complex that is deposited upstream of exon-
exon junctions during splicing; EJC proteins have roles in 
mRNA export, localization, and surveillance 
Aly REF An mRNA export adaptor protein that is part of the EJC; 
the yeast homologue is termed Yra1 
UAP56 Splicing factor required for spliceosome assembly and for 
the recruitment of Aly/REF to the EJC; the yeast 
homologue is Sub2p 
Name Alternative name Role and/or function 
CRM1 Exportin Nuclear export receptor for proteins and some mRNAs 
GTPase
Ran
Cofactor for CRM1 
NES Nuclear export 
sequence
Short leucine-rich sequence in nuclear export proteins that 
interacts with CRM1 
LMB Leptomycin B Drug that inhibits binding of NES to CRM1 by covalent 
modification at a conserved cysteine residue 
CTE Constitutive transport 
element
Highly structured RNA sequence in unspliced retrovirus 
mRNA that binds to TAP 
TAP NXF1 The major nuclear mRNA export receptor in metazoans; 
homologue of Mex67p in yeasts 
p15 NXT1 Heterodimeric binding partner of TAP/NXF1 
EJC Multiprotein complex that is deposited upstream of exon-
exon junctions during splicing; EJC proteins have roles in 
mRNA export, localization, and surveillance 
Aly REF An mRNA export adaptor protein that is part of the EJC; 
the yeast homologue is termed Yra1 
UAP56 Splicing factor required for spliceosome assembly and for 
the recruitment of Aly/REF to the EJC; the yeast 
homologue is Sub2p 
Name Alternative name Role and/or function 
CRM1 Exportin Nuclear export receptor for proteins and some mRNAs 
GTPase
Ran
Cofactor for CRM1 
NES Nuclear export 
sequence
Short leucine-rich sequence in nuclear export proteins that 
interacts with CRM1 
LMB Leptomycin B Drug that inhibits binding of NES to CRM1 by covalent 
modification at a conserved cysteine residue 
CTE Constitutive transport 
element
Highly structured RNA sequence in unspliced retrovirus 
mRNA that binds to TAP 
TAP NXF1 The major nuclear mRNA export receptor in metazoans; 
homologue of Mex67p in yeasts 
p15 NXT1 Heterodimeric binding partner of TAP/NXF1 
EJC Multiprotein complex that is deposited upstream of exon-
exon junctions during splicing; EJC proteins have roles in 
mRNA export, localization, and surveillance 
Aly REF An mRNA export adaptor protein that is part of the EJC; 
the yeast homologue is termed Yra1 
UAP56 Splicing factor required for spliceosome assembly and for 
the recruitment of Aly/REF to the EJC; the yeast 
homologue is Sub2p 
Name Alternative name Role and/or function 
CRM1 Exportin Nuclear export receptor for proteins and some mRNAs 
GTPase
Ran
Cofactor for CRM1 
NES Nuclear export 
sequence
Short leucine-rich sequence in nuclear export proteins that 
interacts with CRM1 
LMB Leptomycin B Drug that inhibits binding of NES to CRM1 by covalent 
modification at a conserved cysteine residue 
CTE Constitutive transport 
element
Highly structured RNA sequence in unspliced retrovirus 
mRNA that binds to TAP 
TAP NXF1 The major nuclear mRNA export receptor in metazoans; 
homologue of Mex67p in yeasts 
p15 NXT1 Heterodimeric binding partner of TAP/NXF1 
EJC Multiprotein complex that is deposited upstream of exon-
exon junctions during splicing; EJC proteins have roles in 
mRNA export, localization, and surveillance 
Aly REF An mRNA export adaptor protein that is part of the EJC; 
the yeast homologue is termed Yra1 
UAP56 Splicing factor required for spliceosome assembly and for 
the recruitment of Aly/REF to the EJC; the yeast 
homologue is Sub2p 
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Table 1.7:  NUP 153 partner proteins
DNA 
RNA 
Caspase-3 
(inferred)
SENP2 
(SUMO 
protease)
Smad2
Stat1 
PU.1 
COPI  Nup160-
complex 
Tpr
Lamin B 
NXF1/TAP 
Exportin-t
Exportin-5
eIF5A 
Importin-β
RanGTPase
Importin-α2 
Kapβ3/RanBP5
Transportin-1
Crm1/Exportin-1 
Importin-
7/RanBP7
Nup50/Npap60 
NTF2
Nucleic 
acid
Cellular 
regulation
Transcripti
on factors
Membrane 
remodeling
NPC/
lamina
RNA 
transport Protein transport
DNA 
RNA 
Caspase-3 
(inferred)
SENP2 
(SUMO 
protease)
Smad2
Stat1 
PU.1 
COPI  Nup160-
complex 
Tpr
Lamin B 
NXF1/TAP 
Exportin-t
Exportin-5
eIF5A 
Importin-β
RanGTPase
Importin-α2 
Kapβ3/RanBP5
Transportin-1
Crm1/Exportin-1 
Importin-
7/RanBP7
Nup50/Npap60 
NTF2
Nucleic 
acid
Cellular 
regulation
Transcripti
on factors
Membrane 
remodeling
NPC/
lamina
RNA 
transport Protein transport
Table showing NUP 153 interaction with nucleic acids and proteins. These interactions are listed 
and grouped within functional categories related to transport, nuclear envelope assembly and 
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Figure 2.1: ICP27 deletion, truncation and substitution mutants. A schematic 
representation  of  the  512-amino-acid  protein,  ICP27  showing  positions  of  the 
various mutations used in this study.   
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Figure  2.2:  Co-immunoprecipitation  assay:  The  appropriate  antibody  is 
incubated  with  cell  extracts  (i).  Antibody  binds  to  its  antigen,  and  also  to  any 
protein antigen bound to it. Protein A-Sepharose is added to form a complex of 
antibody,  antigen  and  interacted  proteins  (iii).  This  complex  is  precipitated  by 
centrifugation  (iv).  Complexes  are  washed  and  boiled  to  break  protein:protein 
interactions  and  proteins  are  separated  by  SDS-PAGE  gel  electrophoresis  (v) 
(Bryant et al., 2000).     
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Figure  2.3:  GST  pull  down  assay:  E.coli  transfected  with  GST-ICP27  (I)  are 
induced with IPTG (ii) to allow protein expression and lysates prepared (iii). GST-
ICP27 is purified by addition of glutathione attached to Sepharose beads (iv). The 
pull  down  assay  is  performed  by  adding  infected  cell  extracts  to  purified  GST-
ICP27 (v). Complexes are washed and boiled to break protein:protein interactions 
and proteins are separated by SDS-PAGE (Bryant et al., 2000)      
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Virus Mutation Amino 
acid(s) 
affected
Nuclear 
localization
Growth in 
BHK-21 
cells
Reference
Type Funtional
domain(s)
D D D D27 All 1-512 ND Defective (Rice & Knipe, 1990)
dLeu NES 6-19 N>C Deficient (Lengyel et al., 2002)
d1-2 Acidic 12-63 N, Shuttling 
reduced
Deficient (Rice et al., 1993)
d2-3 ND 64-109 ND Deficient (Aubert et al., 2001)
d3-4 NLS 109-138 C>N Deficient (Mears et al., 1995)
d4-5 RGG box 139-153 N, not Nu Defective (Mears et al., 1995)
d5-6 ND 154-173 ND Competent (Mears & Rice, 1996)
d6-7
Deletion
Deletion
Deletion
Deletion
Deletion
Deletion
Deletion
Deletion ND 174-200 ND Competent (Aubert et al., 2001)
M11 Point KH1 340-341 N, Shuttling 
reduced
Defective (Rice & Lam, 1994)
M15 Point Zinc 
finger
465-466 N, No Shuttling  Defective (Rice & Lam, 1994)
M16 Point Zinc 
finger
488 N, Shuttling 
reduced
Defective (Rice & Lam, 1994)
Table 2.1 Characteristics of HSV-1 ICP27 mutants used
Abbreviations: ND, not determined; N, nuclear; Nu, nucleolar; C, cytoplasmic
Virus Virus Mutation Mutation Amino 
acid(s) 
affected
Amino 
acid(s) 
affected
Nuclear 
localization
Nuclear 
localization
Growth in 
BHK-21 
cells
Growth in 
BHK-21 
cells
Reference Reference
Type Type Funtional
domain(s)
Funtional
domain(s)
D D D D27 D D D D27 All All 1-512 1-512 ND ND Defective Defective (Rice & Knipe, 1990) (Rice & Knipe, 1990)
dLeu dLeu NES NES 6-19 6-19 N>C N>C Deficient Deficient (Lengyel et al., 2002) (Lengyel et al., 2002)
d1-2 d1-2 Acidic Acidic 12-63 12-63 N, Shuttling 
reduced
N, Shuttling 
reduced
Deficient Deficient (Rice et al., 1993) (Rice et al., 1993)
d2-3 d2-3 ND ND 64-109 64-109 ND ND Deficient Deficient (Aubert et al., 2001) (Aubert et al., 2001)
d3-4 d3-4 NLS NLS 109-138 109-138 C>N C>N Deficient Deficient (Mears et al., 1995) (Mears et al., 1995)
d4-5 d4-5 RGG box RGG box 139-153 139-153 N, not Nu N, not Nu Defective Defective (Mears et al., 1995) (Mears et al., 1995)
d5-6 d5-6 ND ND 154-173 154-173 ND ND Competent Competent (Mears & Rice, 1996) (Mears & Rice, 1996)
d6-7 d6-7
Deletion
Deletion
Deletion
Deletion
Deletion
Deletion
Deletion
Deletion
Deletion Deletion
Deletion Deletion
Deletion Deletion
Deletion Deletion
Deletion Deletion
Deletion Deletion
Deletion Deletion
Deletion Deletion ND ND 174-200 174-200 ND ND Competent Competent (Aubert et al., 2001) (Aubert et al., 2001)
M11 M11 Point Point KH1 KH1 340-341 340-341 N, Shuttling 
reduced
N, Shuttling 
reduced
Defective Defective (Rice & Lam, 1994) (Rice & Lam, 1994)
M15 M15 Point Point Zinc 
finger
Zinc 
finger
465-466 465-466 N, No Shuttling  N, No Shuttling  Defective Defective (Rice & Lam, 1994) (Rice & Lam, 1994)
M16 M16 Point Point Zinc 
finger
Zinc 
finger
488 488 N, Shuttling 
reduced
N, Shuttling 
reduced
Defective Defective (Rice & Lam, 1994) (Rice & Lam, 1994)
Table 2.1 Characteristics of HSV-1 ICP27 mutants used
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Santa Cruz Biotechnology Cat No. sc-25768 1:1000 NA Rabbit /IgG TAP/NXF1 (H-120)
Santa Cruz Biotechnology Cat No. sc-28377 1:100 NA Mouse /IgG1 TAP/NXF1 (G-12)
Covance Cat No. MMS-120R 1:2000 1:2000 Mouse /IgG1 NUPs 414
Santa Cruz Biotechnology Cat No. sc-26055 1:100 NA Goat /IgG NUP 214 (N-15)
Covance Cat No. MMS-102P 1:250 1:250 Mouse /IgG1 NUP 153 
Santa Cruz Biotechnology Cat No. sc-30112 1:100 1:50 Rabbit/IgG NUP 98 (H-300)
Santa Cruz Biotechnology Cat No. sc-14153 1:100 NA Goat /IgG NUP 98 (L-20)
Santa Cruz Biotechnology Cat No. sc-14155 1:100 NA Goat /IgG NUP 98 (C-16)
Santa Cruz Biotechnology Cat No. sc-25523 1:100 1:50 Goat /IgG NUP 62 (H-122)
Santa Cruz Biotechnology Cat No. sc-6078 1:250 NA Goat /IgG NUP 62 (D-20)
Santa Cruz Biotechnology Cat No. sc-1916 1:500 NA Goat /IgG NUP 62 (N-19)
Santa Cruz Biotechnology Cat No. sc-2027   NA NA Rabbit/ IgG Normal rabbit serum
Santa Cruz Biotechnology Cat No. sc-2025 NA NA Mouse/ IgG Normal mouse serum
Santa Cruz Biotechnology Cat No. sc-2028 NA NA Goat Normal goat serum
Goodwin Institute for Cancer Research, Florida (Lengyel et al., 2002) 1:2 000 1:400 Mouse/IgG1 HSV-1 ICP27(1119)
Goodwin Institute for Cancer Research, Florida (Ackermann et al,1984) 1:2 000 1:400 Mouse/IgG1 HSV-1 ICP27 (1113)
Santa Cruz Biotechnology Cat No. sc-16554 1:200 NA Goat / IgG hnRNP K (P-20)
Amersham Bioscience Cat No. 27-4577-01 1:10 000 NA Goat GST
Santa Cruz Biotechnology Cat No. sc-8334 1:2500 NA Rabbit/ IgG GFP
Ambion Cat No. 4300 1:10 000 NA Mouse / IgG2b GAPDH
IF dil Source References WB dil Host/Isotype Immunogen
Santa Cruz Biotechnology Cat No. sc-25768 1:1000 NA Rabbit /IgG TAP/NXF1 (H-120)
Santa Cruz Biotechnology Cat No. sc-28377 1:100 NA Mouse /IgG1 TAP/NXF1 (G-12)
Covance Cat No. MMS-120R 1:2000 1:2000 Mouse /IgG1 NUPs 414
Santa Cruz Biotechnology Cat No. sc-26055 1:100 NA Goat /IgG NUP 214 (N-15)
Covance Cat No. MMS-102P 1:250 1:250 Mouse /IgG1 NUP 153 
Santa Cruz Biotechnology Cat No. sc-30112 1:100 1:50 Rabbit/IgG NUP 98 (H-300)
Santa Cruz Biotechnology Cat No. sc-14153 1:100 NA Goat /IgG NUP 98 (L-20)
Santa Cruz Biotechnology Cat No. sc-14155 1:100 NA Goat /IgG NUP 98 (C-16)
Santa Cruz Biotechnology Cat No. sc-25523 1:100 1:50 Goat /IgG NUP 62 (H-122)
Santa Cruz Biotechnology Cat No. sc-6078 1:250 NA Goat /IgG NUP 62 (D-20)
Santa Cruz Biotechnology Cat No. sc-1916 1:500 NA Goat /IgG NUP 62 (N-19)
Santa Cruz Biotechnology Cat No. sc-2027   NA NA Rabbit/ IgG Normal rabbit serum
Santa Cruz Biotechnology Cat No. sc-2025 NA NA Mouse/ IgG Normal mouse serum
Santa Cruz Biotechnology Cat No. sc-2028 NA NA Goat Normal goat serum
Goodwin Institute for Cancer Research, Florida (Lengyel et al., 2002) 1:2 000 1:400 Mouse/IgG1 HSV-1 ICP27(1119)
Goodwin Institute for Cancer Research, Florida (Ackermann et al,1984) 1:2 000 1:400 Mouse/IgG1 HSV-1 ICP27 (1113)
Santa Cruz Biotechnology Cat No. sc-16554 1:200 NA Goat / IgG hnRNP K (P-20)
Amersham Bioscience Cat No. 27-4577-01 1:10 000 NA Goat GST
Santa Cruz Biotechnology Cat No. sc-8334 1:2500 NA Rabbit/ IgG GFP
Ambion Cat No. 4300 1:10 000 NA Mouse / IgG2b GAPDH
IF dil Source References WB dil Host/Isotype Immunogen
Table 2.2: Primary antibodies used in this study (NA, not applicable; WB, western blot; IF, immunoflorecense; dil, dilution)
Sigma Cat No. A0542 1:1 000 HRP Rabbit
Sigma Cat No. A9044 1:1 000 HRP Mouse
Sigma Cat No. A9452 1:1 000 HRP Goat
Source References WB dilution Conjugated Antiserum against
Sigma Cat No. A0542 1:1 000 HRP Rabbit
Sigma Cat No. A9044 1:1 000 HRP Mouse
Sigma Cat No. A9452 1:1 000 HRP Goat
Source References WB dilution Conjugated Antiserum against
Table 2.3: Secondary antibodies used in this study
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Figure 3.1: GST-ICP27 protein expression in BL21 cells 
 
 
Coomassie  blue  stained  and  western  blot  SDS-PAGE  showing  GST-ICP27 
full  length  fusion  protein  bound  onto  and  eluted  from  glutathione  4B 
sepharose beads. GST-ICP27 was expressed in E.coli strain BL21 at 37°C and 
bound to GST-beads. Expressed protein was mixed with SDS loading buffer and 
boiled and separated by 10% SDS-PAGE gel and Bionalyzer.  
Panel I: Gels were stained with Coomassie blue showing bound proteins (lane 1) 
and unbound proteins (lane 2) and purified fractions were analysed using a Protein 
200  Plus  LabChip  kit  (Agilent  technologies)  (lane  3),  in  order  to  monitor 
expression, protein concentration and purity.  
Panel II: Similar SDS PAGE gels to that shown in Panel II were western blotted 
using anti GST antibody (lane 1) and anti ICP27 (1113) antibody (lane 2) to show 
expression and purity of the GST-ICP27.  
Full  length  GST-ICP27  is  marked.  The  smaller  bands  represent  degradation 
products/truncations of GST-ICP27. 
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Figure 3.2: In vitro expressed His-ICP27 protein 
 
 
Panel I: Western blot of 10% SDS-PAGE gel with anti His Ab showing the purified 
His tagged protein from the bacterial lysates bound to Ni-NTA Agarose beads to 
elute 6xHis-tagged proteins. Lanes 1 and 2, first and second fractions of eluted 
His-ICP27. Full length ICP27 is marked and lower bands are its truncations.   
 
Panel II: Western blot of 10% SDS-PAGE gel with anti ICP27 Ab (1113) showing 
the purified His tagged protein from the bacterial lysates bound to Ni-NTA Agarose 
beads to elute 6xHis-tagged proteins. Lanes 1 and 2, first and second fractions of 
eluted His-ICP27. Full length ICP27 marked and lower bands are its truncations.  
 
Panel III: Coomassie blue stained 10% SDS-PAGE gel showing the purified His 
tagged protein from the bacterial lysates bound to Ni-NTA Agarose beads to elute 
6xHis-tagged proteins. Lanes 1, 2, 3 and 4, four fractions of His-ICP27. Full length 
ICP27 marked and lower bands are its truncations.   
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Figure 3.3: Optimising expression of GST-NUP 62  
 
 
Coomassie blue stained 10% SDS-PAGE gel showing purified proteins from 
the  bacterial  lysates  bound  to  Glutathione  4B  sepharose.  Full  length  GST-
NUP 62 is marked. 
Panel  I,  purified  GST  fusion  protein  from  bacterial  cultures  transformed  with  a 
GST-NUP 62 expression plasmid and pUC (negative control) were induced with 
IPTG at 29°C (lane 1 GST-NUP 62 and lane 2 negative control  pUC plasmid).  
Panel  2, purified GST fusion bound protein from bacterial cultures transformed 
with a GST-NUP 62 expression plasmid and pUC (negative control) were induced 
with IPTG at 37°C (lane 1 GST-NUP 62 and lane 2 negative control pUC plasmid). 
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Figure 3.4: Improved expression of GST-NUP 62 obtained 
with using E.coli strain BL21-Codon plus-RP competent 
cells  
 
Coomassie blue stained and western blotted 10% SDS-PAGE gel showing 
the  purified  protein  from  the  bacterial  lysates  bound  to  Glutathione  4B 
sepharose.  Panel  I,  bacterial  cultures  of  BL21  and  BL21-codon  plus-RP 
competent cells E.coli containing GST-NUP 62 expressing plasmids  were induced 
with IPTG at 29°C (lane 1 BL21-codon plus-RP and lane 2 BL21).  
Panel  II,  bacterial  cultures  of  BL21  and  BL21-codon  plus-RP  competent  cells 
E.coli containing GST-NUP 62 expressing plasmids were induced with IPTG at 
29°C and blotted  with anti-GST antibody (lane 3 BL21 and lane 2 BL21-codon 
plus-RP).  
Panel III, Purified GST-NUP 62 expressed in BL21-codon plus-RP E.coli at 29°C 
and blotted with anti-GST antibody (lane 5) and anti-NUP 62 antibody (lane 6). Full 
length GST-NUP 62 is marked. 
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Figure 3.5: Lysis of bacteria by sonication is better than 
using  bug  buster  master  mix  to  produce  GST-NUP  62 
which binds to glutathione beads 
 
Using sonication and bug buster master mix methods to assay their effect on 
the level of GST-NUP 62 full length expression. Bacteria from induced cultures 
were lysed by sonication (lanes 1 & 3) and using bug buster master mix (lanes 2 & 
4).  Lysates  were  mixed  with  glutathione  beads  and  eluted  by  boiling  in  SDS 
loading  buffer.  Purified  GST  fusion  bound  protein  and  unbound  proteins  were 
separated by 10% SDS-PAGE and visualised by western blotting with anti NUP 62 
(D-20) goat antibody. 
Lane 1. Sonicated bound full length GST-NUP 62. Lane 2. Bug buster lysed bound 
full length GST-NUP 62. Lane 3. Sonicated unbound GST-NUP 62. Lane 4. Bug 
buster lysed unbound GST-NUP 62.  
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Figure  3.6:  Optimised  expression  of  GST  fusion 
nucleoporins 
 
Expression of GST fusion NUPs optimised. Bacterial cultures of BL21-codon 
plus-RP competent E.coli containing GST fusion nucleoporin expressing plasmids  
were induced with IPTG at 29°C, protein lysates were prepared and separated on 
10% SDS-PAGE followed by western blotting.  
Panel I: Western blot of GST fusion proteins against GST antibody (lane 1 GST-
Rae 1 and lane 2 GST-NUP 62). Full length protein bands at around 60 & 90 KDa 
were detected representing GST-Rae 1 and GST-NUP 62 respectively and lower 
bands indicating truncations and degraded fusion proteins.  
Panel II: Western blot of GST fusion proteins against anti FG-repeat NUPs 414 Ab 
(lane  1  GST-NUP  214/CAN  (1690-2090)  and  lane  2  GST-NUP  98  (66-515). 
Protein bands at around 67 & 86 KDa representing GST-NUP 214/CAN (1690-
2090)  and  GST-NUP  98  (66-515)  respectively  and  lower  bands  indicating 
truncations and degraded fusion proteins  
Panel  III:  Western  blot  of  GST-NUP  214/CAN  (1690-1894)  against  anti  GST 
antibody.  Protein  bands  at  around  50  KDa  representing  GST-NUP  214/CAN 
(1690-1894) and lower bands indicating truncations and degraded fusion protein.  
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Figure 3.7: ICP27 and its homologue ORF57 interact with NUP 62 
in the GST pull down assay.  
Panel I: Coomassie stain of 10% SDS-PAGE of expression of GST-ORF57 (lane 
1), GST-ICP27 (lane 2) and GST alone (lane 3) used in this pull down assay.  
Panel II: Western blotting with anti NUP 62 (N-19) antibody. Lane 1, input 10% of 
sample of mock infected cell lysate; lane 2, GST-ICP27; lane 3, GST-ORF57; lane 
4, GST alone. 
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Figure 3.8: NUP 62 interacts with ICP27 in the pull down assay.  
Full length GST-NUP 62 expressed and purified and incubated with extracts of 
HeLa cells infected (MOI=10) with wt HSV-1 17+,  27, CMV27 (transfected with 
plasmid CMV27) and mock infected. 
 
Panel  I:  Pulled  down  proteins  fractionated  on  SDS-PAGE  and  transferred  to 
nitrocellulose  membrane  followed  by  immunoblotting  using  anti-ICP27  (1113) 
monoclonal antibody. Lane 1, showing input that is 10% of HSV-1 wt infected cell 
extract lysate; lane 2, wild type infected cell extract incubated with GST-NUP 62; 
lane  3,   27  infected  cell  extract  incubated  with  GST-NUP  62;  lane  4,  CMV27 
transfected cell extract incubated  with GST-NUP 62; lane 5, mock infected cell 
extract incubated with GST-NUP 62; lane 6, wt infected cell extract incubated with 
GST alone. 
 
Panel II: Unbound samples run on 10% SDS-PAGE and western blotted against 
GAPDH by using anti GAPDH antibody and showed roughly equal amount protein 
used in this experiment. 
 
Panel III: Unbound samples stripped and immunoblotted against GST-NUP 62 by 
using anti GST antibody showed input level of GST-NUP62 in lanes 2, 3, 4, 5 and 
GST alone in lane 6. Lane 1 indicates just input of wt infected cell extract and so 
does not show any GST fusion protein. 
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Figure 3.9: NUP 62 interacts directly with ICP27 in the pull down 
assay. GST fusion NUP 62 and His-tagged ICP27 were expressed and purified 
and infected cell extracts (MOI=10) were prepared and pull down assays carried 
out. 
 
Panel  I:  GST-NUP  62  and  GST  alone  were  incubated  with  purified  His-ICP27 
followed with fractionation on a 10% SDS-PAGE and western blotting with anti-His 
antibody.  Lane  1,  showing  input  that  is  10%  of  His-ICP27;  lane  2,  His-ICP27 
incubated with GST-NUP 62; lane 3, His-ICP27 incubated with GST alone. Image 
quantification of the band in lane 2 showed 0.1% density in comparison with input. 
 
Panel II: RNase I was used in pull down assay to remove RNAs from interaction 
complex.  GST-NUP  62  and  GST-alone  incubated  with  wt  17+  HSV-1  infected 
HeLa cell extracts in the presence (lane 2) and absence (lane 1) of RNase I. Lane 
3, GST alone incubated with wt infected cell extract. Lane 4, 10 l input wt infected 
cell extract ICP27.       
  
Panel  III:  Above  unbound  complex  formed  samples  western  blotted  with  anti 
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Figure 3.10: Testing immunoprecipitation of ICP27.  
17+  wt  HSV-1  infected  extracts  (MOI=10)  immunoprecipitated  by  using 
anti-ICP27 Ab and anti-FG NUP 414 antibody and beads alone. Samples 
analysed  by  10%  SDS-PAGE  and  western  blotted  against  anti-ICP27 
(1113) antibody. 
 
Lane 1, IP with HSV-1 17+ HeLa infected cell lysate and 1113 antibody. 
Lane 2, IP with HSV-1 17+ HeLa infected cell lysate and anti FG repeat 
414  control  antibody.  Lane  3,  supernatant  of  IP  with  HSV-1  17+  HeLa 
infected cell lysate and 1113 antibody. Lane 4, supernatant of IP with HSV-
1 17+ HeLa infected cell lysate and anti FG repeat 414 control antibody. 
Lane 5, showing input that is 10% of HSV-1 17+ HeLa infected cell lysate . 
Lane 6 shows that beads alone, incubated in the presence of HSV-1 wild 
type infected cell extracts did not precipitate any ICP27.  
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Figure 3.11: Stringency of interaction between ICP27 and nucleoporin NUP 
62 in co-immunoprecipitation assay 
 
Co-immunoprecipitation assay carried out to check stringency of interaction 
of ICP27 with nucleoporin 62: Mock and wt HSV-1 HeLa cell infected extracts 
(MOI=10) immunoprecipitated by using anti-ICP27 Ab and normal mouse serum 
(NMS) then washed with various concentration of salt buffer from 100 to 500 mM. 
Samples were analysed by 10% SDS-PAGE.  
 
Panel I, western blot with anti-ICP27 Ab shows ICP27 protein immunoprecipitated 
by anti-ICP27 Ab in the range of 100-500mM salt. Lane 1 at 100mM salt. Lane 3 at 
200nmM salt. Lane 5 at 300mM salt. Lane 8 at 400mM salt. Lane 10 at 500mM 
salt. Lanes 2, 4, 6, 9 and 11 for NMS at 100-500 mM salt. Lane 7 showing input 
that is 10% of HSV-1 wt infected cell extract lysate 
 
Panel  II,  western  blot  with  414  antibody  shows  ICP27  co-immunoprecipitated 
nucleoporin p62 at concentration of 100 to 500mM in lanes 1, 3, 5, 7 and 9 but 
NMS antibody in lanes 2, 4, 6, 8 and 10 did not co-immunoprecipitated NUP 62 at 
the level of 100-500 mM salt.  
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Figure 3.12: RNase I treatment of HeLa mock and wt HSV-
1  infected  cell  extracts  and  protein  interaction  assay 
experiments 
 
 
Panel I: RNase treatment  HeLa infected cell extracts. 100  g protein of HeLa 
cell extracts infected (MOI=10) with 17+ wt HSV-1 and mock infected, treated with 
100  U  RNase  I  for  45  minutes  at  37°C,  were  analysed   by  agarose  gel 
electrophoresis to check RNA integrity. Untreated mock infected cell extract was 
included as a control to show native RNA. Lane 1 RNase I untreated HeLa mock 
infected. Lane 2 RNase I treated HeLa mock infected cell extract. Lane 3 RNase I 
treated HeLa 17+ wt HSV-1 infected cell extract. 
Panel  II:  RNase  I  treatment  used  in  an  immunoprecipitation  assay  of 
ICP27/ICP27.  Immunoprecipitation test of HeLa infected wt HSV-1 cell extracts 
carried out with anti ICP27 Ab (1113) and normal mouse serum then treated with 
RNase I as described in Materials and Methods and western blotted with 1113 
mAb. Lane 1 ICP27 bound to the antibody and immunoprecipitated. Lane 2. ICP27 
did not bind to normal mouse serum.  
Panel  III:  RNase  I  treatment  used  in  on  immunoprecipitation  assay  of 
ICP27/NUP 62. The ICP27 precipitation membrane from the previous experiment 
was stripped and western blotted with 414 antibody. Lane 1 NUP 62 bound to 
ICP27 and co-immunoprecipitated. Lane 2 NUP 62 did not bind to normal mouse 
serum.  
 
Panel IV: RNase I treatment used in a GST pull down assay. HSV-1 wt HeLa 
infected cell extracts mixed with GST-NUP 62 in the presence and absence of 
RNase  I  treatment  and  western  blotted  with  1113  mAb.  Lane  1  GST-NUP  62 
pulled down ICP27 in the presence of RNase I. Lane 2 GST-NUP 62 pulled down 
ICP27 in absence of RNase I. Lane 3  27 in absence of RNase I. Lane 4 mock 
infected in absence of RNase I  
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Figure  3.13:  Anti  ICP27  monoclonal  antibodies  used  to 
co-immunoprecipitate  nucleoporin  62  from  extracts  of 
HeLa  cells  infected  and  uninfected  with  wt  and  mutant 
HSV-1.  
 
Co-immunoprecipitation of  nucleoporin  62 from wild type (wt) HSV-1,   27 
and mock-infected HeLa cell extracts (MOI=10). 
Panel  I:  Immunoprecipitated  complexes  fractionated  on  a  10%  SDS-PAGE  gel 
and separated and analysed by western blotting with anti ICP27 antibody. ICP27 
precipitated from wt sample lane 1, but not with lane 2,  27 and lane 3, mock 
infected. NMS control test did not precipitate ICP27 from wt infected sample (lane 
4). Lane 5, showing input that is 10% of HSV-1 wt infected cell extract lysate. 
 
Panel II: Above membrane stripped and western blotted against NUP 62  
 
Panel III: Unbound precipitated samples fractionated on a 10% SDS-PAGE gel 
and western blotted with anti 414 antibody. 
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Figure  3.14:  Anti  nucleoporin  62  antibodies  (N-19,  D-20 
and  H-122)  used  to  immunoprecipitate  NUP  62  from 
extracts of HeLa cells infected with wt HSV-1.  
Three  anti-NUP  62  antibodies  incubated  with  wt  infected  HeLa  cell  extracts 
(MOI=10) and separated on 10% SDS-PAGE and visualised by western blotting 
with anti-FG-repeat Nups 414 antibody. 
Panel I showed NUP 62 precipitated by all of these antibodies in the presence 
(lanes 5-7) and absence (lanes 1-3) of RNase I. Lane 4 showing input that is 10% 
of HSV-1 wt infected cell extract lysate. 
Panel II showing level of GAPDH in lysates. 
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Figure 3.15: Anti nucleoporin 62 antibody (N-19) used to 
co-immunoprecipitate HSV-1 ICP27 from extracts of HeLa 
cells infected and uninfected with HSV-1.  
 
 
Co-immunoprecipitation experiment in the presence of RNase I using anti-NUP 62 
(N-19) antibody and HeLa cells lysates infected (MOI=10) with wt, M15 and  27 
HSV-1 were incubated with antibody as well as wt infected extract with normal 
goat  serum  (NGS).  Samples  were  fractionated  on  a  10%  SDS-PAGE  and 
visualised with western blotting with anti-ICP27 antibody (1113) and anti-NUP 62 
(N-19) to show interacting proteins. 
 
Panel I: The complexes formed visualised with western blotting with anti-ICP27 
antibody (1113). Lane 1 showing input that is 10% of mock infected cell, lane 2 
showing input that is 10% of wt infected cell extract lysate, lane 3 wt, Lane 4  27, 
lane 5 M15, lane 6 wt control with NGS 
 
Panel II: Above membrane stripped and western blotted with anti-NUP 62 (N-19) 
and showed anti NUP 62 antibody precipitated NUP 62 from all lysates (lanes 3, 4 
and 5) except NGS sample (lane 6). 
 
Panel III: Schematic representative of the location of the M15 ICP27 mutants. 
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Figure  3.16:  Anti-NUP  62  (N-19)  antibody  co-
immunoprecipitates  ICP27  from  wt  HSV-1  17+  infected 
extracts of BHK cells.  
 
Co-immunoprecipitation  experiment  using  anti-NUP  62  (N-19)  and  BHK  cell 
infected  with  HSV-1  wt  and   27  mutant  (MOI=10)  and  transfected  pCMV-27 
(ICP27)  lysates.  Samples  were  incubated  with  antibody  as  well  as  HSV-1  wt 
infected cell extract with normal goat serum (NGS). Samples were fractionated on 
a 10% SDS-PAGE and visualised with western blotting with anti-ICP27 antibody 
(1113)  and  showed  NUP  62  co-precipitated  ICP27  from  wt  infected  and 
transfected cell extracts (lanes2 and 4) but did not co-precipitate in  27 (lane 3). 
Also NGS did not show any ICP27 band (lane 6). Lane 1 showing input that is 
10% of HSV-1 wt infected cell extract lysate. Lane 7 showed immunoprecipitation 
of ICP27 from pCMV-27 transfected BHK cell and western blot with anti ICP27 
antibody indicated ICP27 band in size of 63 KDa and some truncates of that.  
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Figure 3.17:  Anti nucleoporin 62 antibody (H-122) used to 
co-immunoprecipitate HSV-1 ICP27 from extracts of HeLa 
cells infected and uninfected with HSV-1.  
 
Co-immunoprecipitation experiment was carried out by using anti-NUP 62 (H-122). 
HeLa cell infected with HSV-1 wt and HSV-1 mutants M16,  27 (MOI=10) and 
mock  infected  lysates  mixed  with  antibody  as  well  as  wt  infected  extract  with 
normal  rabbit  serum  (NRS).  Samples  were  run  on  10%  SDS-PAGE  gel  and 
samples visualised with western blotting with anti-ICP27 antibody (1113) and anti-
NUP 62 (H-122) to show interacting proteins. Samples were untreated or treated 
with RNase I to remove RNA from interaction. 
 
Panel I: The complexes formed were visualised with western blotting with anti-
ICP27 antibody (1113) and showed NUP 62 co-precipitated ICP27 from wt and 
M16 infected cell extracts  without  RNase I  treatment  (lanes  1  and  2)  and  with 
RNase I treatment (lanes 6 and 7) but did not co-precipitate from  27 and mock 
infected cells in both conditions (lanes 3, 4, 8 and 9). Also NRS did not show any 
ICP27 band (lane 10). Lane 5 showing input that is 10% of HSV-1 wt infected cell 
extract lysate.  
 
Panel II: Above membrane was stripped and western blotted with anti-NUP 62 (H-
122) and showed antibody precipitated NUP 62 from all lysates (lanes 1, 2, 3, 4, 6, 
7, 8 and 9) except NRS sample (lane 10). A single band in lane 5 at about 62 KDa 
corresponds to the size of NUP 62.  
 
Panel III: To confirm panel II and presence of NUP 62 in all lanes, samples 
were separated on SDS PAGE and western blotted with anti FG-repeat NUPs 
414  antibody  and  showed  NUP  62  levels  in  all  lysates  used  in  this 
experiment.  
 
Panel  IV:  Schematic  representative  of  the  position  of  M15  and  M16  ICP27 
mutants.                                                                                                                     Chapter 3, Figures              
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Figure 3.18: Monoclonal anti FG-repeat NUPs 414 used to 
co-immunoprecipitate HSV-1 ICP27 from extracts of HeLa 
cells infected and uninfected with HSV-1.  
 
To  examine co-immunoprecipitation  of ICP27  with FG-repeat nucleoporins anti-
414 monoclonal antibody was mixed with HSV-1 wt and mutant  27 (MOI=10) and 
mock infected HeLa cell extracts as well as HSV-1 wt infected cell extract with 
normal  goat  serum  (NMS)  and  tested  in  presence  and  absence  of  RNase  I. 
Samples were run on 6% SDS-PAGE and analysed by western blotting with anti-
ICP27 antibody (1113) and anti 414 antibody. 
 
Lysate 17+    27  mock
N
M
S
,
1
7
+
I
n
p
u
t
,
1
7
+
17+     27   mock
RNase I       _         _       _        _                 +        + +
α 414, IP α 414, IP
66KDa
45KDa
ICP27
1         2        3         4       5         6       7        8 
I
Lysate 17+    27  mock
N
M
S
,
1
7
+
I
n
p
u
t
,
1
7
+
17+     27   mock
RNase I       _         _       _        _                 +        + +
α 414, IP α 414, IP
66KDa
45KDa
ICP27
1         2        3         4       5         6       7        8 
I
N
M
S
,
1
7
+
I
n
p
u
t
,
1
7
+
17+     27   mock Lysate 17+   27  mock
RNase I       _         _       _        _                 +        + +
α 414, IP α 414, IP
220KDa
97KDa
66KDa
45KDa
p62
Nup98
Nup153
Nup214
1         2        3        4        5        6        7        8
II
N
M
S
,
1
7
+
I
n
p
u
t
,
1
7
+
17+     27   mock Lysate 17+   27  mock
RNase I       _         _       _        _                 +        + +
α 414, IP α 414, IP
220KDa
97KDa
66KDa
45KDa
p62
Nup98
Nup153
Nup214
1         2        3        4        5        6        7        8
N
M
S
,
1
7
+
I
n
p
u
t
,
1
7
+
17+     27   mock Lysate 17+   27  mock
RNase I       _         _       _        _                 +        + +
α 414, IP α 414, IP
220KDa
97KDa
66KDa
45KDa
p62
Nup98
Nup153
Nup214
N
M
S
,
1
7
+
I
n
p
u
t
,
1
7
+
17+     27   mock Lysate 17+   27  mock
RNase I       _         _       _        _                 +        + +
α 414, IP α 414, IP
220KDa
97KDa
66KDa
45KDa
p62
Nup98
Nup153
Nup214
17+     27   mock Lysate 17+   27  mock
RNase I       _         _       _        _                 +        + +
α 414, IP α 414, IP
220KDa
97KDa
66KDa
45KDa
p62
Nup98
Nup153
Nup214 220KDa
97KDa
66KDa
45KDa
p62
Nup98
Nup153
Nup214 220KDa 220KDa
97KDa 97KDa
66KDa 66KDa
45KDa 45KDa
p62 p62
Nup98 Nup98
Nup153 Nup153
Nup214 Nup214
1         2        3        4        5        6        7        8
II                                                                                                                    Chapter 3, Figures              
  193 
Panel I: The complexes formed visualised with western blotting with anti-ICP27 
antibody (1113) and showed FG repeat nucleoporins co-precipitated ICP27 from 
wt infected cell extracts in both without and with RNase I treatment (lanes 1 and 6) 
but did not co-precipitate with  27 in both conditions (lanes 2 and 7). Also NMS 
did not show any ICP27 band (lane 4). Lane 5 showing input that is 10% of HSV-1 
wt infected cell extract lysate.  
 
Panel II: Above membrane was stripped and western blotted with anti FG repeat 
414  antibody  and showed  anti 414 antibody  precipitated  a range  of FG  repeat 
nucleoporins from all lysates (lanes 1, 2, 3, 6, 7 and 8) except NMS sample (lane 
4). The various bands in lane 5 correspond to different FG repeat nucleoporins 
including NUP 214, NUP153, NUP 98 and NUP 62.  
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Figure  3.19:  Mapping  the  interacting  regions  of  ICP27 
with NUP 62 using GST pull down assay.  
 
Series  of HSV-1 wt and mutants ICP27 HeLa cell extracts (MOI=10) incubated 
with  full  length  fusion  protein  GST-NUP  62.  Pulled  down  complexes  were 
separated by SDS-PAGE and analysed by western blot. 
 
Panel I: Bound pulled down proteins western blotted with anti ICP27 antibodies 
1113 and 1119 NUP 62 pulled down ICP27 from wt, d1-2, d2-3, d3-4, d4-5, d5-6 
and d6-7 (lanes 1, 2, 9, 10, 11, 12, 13, 14 respectively) but not from M15, M16, 
 27, mock, dLeu and GST alone (3, 4, 6, 7, 8 and 15 respectively). Lane 2 shows 
RNase I treated sample and lane 5 showing input that is 10% of HSV-1 wt infected 
cell extract lysate. 
 
Panel II: Unbound pulled down proteins western blotted with anti ICP27 mix up 
1113  and  1119  and  showed  presence  and  amount  of  ICP27  in  different  cell 
extracts (lanes 1, 2 and 5-14) and absence of ICP27 in  27, mock infected HeLa 
cell extracts (lanes 3 and 4). 
 
Panel III: Schematic diagram of ICP27 showing the position of the mutants 
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Figure  3.20:  GST-TAP  interacts  in  vitro with  His-tagged 
ICP27 and pulls down ICP27 from HeLa wt HSV-1 infected 
cell extracts   
 
Pull down assay and western blot with antibodies.  
Panel I: Lysates from E.coli expressing GST-TAP, GST alone, GST-NUP 62 and 
His-ICP27 were incubated with glutathione agarose beads or with Ni-NTA agarose 
beads.  Bound  purified  GST  fusion  proteins  and  GST  alone  were  mixed  and 
incubated with purified His-ICP27 and were eluted with SDS-sample buffer and 
analyzed on SDS-PAGE followed by western blotting with anti-ICP27 Ab (1113). 
Lane 1 showing input that is 10% of lysate His-ICP27. Lane 2 GST-NUP 62 pulled 
down ICP27. Lane 3 GST alone did not pull ICP27 down. Lane 4 GST-TAP pulled 
down ICP27. The position of ICP27 is indicated.  This is the same blot as in Panel 
I in Figure 3.9. 
Panel II: GST-TAP pull-down assays were performed with equal amount of protein 
from HeLa infected cell extracts (MOI=10). Samples were analyzed on SDS-PAGE 
followed  by  western  blot  with  anti-ICP27  Ab  (1113).  Lane  1,  HeLa  HSV-1  17+ 
infected cell extract input. Lane 2, GST alone with HeLa HSV-1 17+ infected cell 
extract.  Lane  3,  GST-TAP  with  HeLa  HSV-1  17+  infected  cell  extract.  Lane  4, 
GST-TAP with HeLa  27 infected cell extract.  
Panel  III:  Lysates  from  E.coli  expressing  GST-TAP,  were  incubated  with 
glutathione  agarose  beads  beads.  Bound  purified  GST-TAP  fusion  protein 
analyzed on SDS-PAGE followed by western blotting with anti-GST Ab. Significant 
expression of GST-TAP was achieved and indicated. Bands lower down shows 
smaller truncate of that protein. 
Panel IV: Samples analyzed on SDS-PAGE followed by western blot with anti-
NUP 62 Ab showed level of NUP 62 in above experiment. Lane 1, GST alone with 
HeLa HSV-1 17+ infected cell extract. Lane 2, GST-TAP with HeLa HSV-1 17+ 
infected  cell  extract.  Lane  3,  GST-TAP  with  HeLa   27  infected  cell  extract.
Lysate 17+                        17+                      27
1                            2                           3  
66KDa p62
IV
GST-TAP GST
Lysate 17+                        17+                      27
1                            2                           3  
66KDa 66KDa p62 p62
IV
GST-TAP GST                                                                                                                    Chapter 3, Figures              
  198 
 
 
 
Figure  3.21:  ICP27  and  TAP  co-immunoprecipitate  from 
HeLa cell extracts 
 
ICP27 co-precipitated TAP: Immunoprecipitation test was carried out by mixing 
anti-ICP27 antibodies 1113 and 1119 with HSV-1 wt and HSV-1 mutant ICP27 
M15  and  HSV-1  null   27  and  mock  infected  HeLa  cell  extracts  (MOI=10). 
Complexes formed were separated on a 6% SDS-PAGE gel followed by western 
blotting with anti-TAP and ICP27 antibodies.  
Panel I shows co-precipitation of TAP in 17+ infected  HeLa cell extracts in the  
presence of RNase I (lane 2) by ICP27 but no co precipitation with M15,  27 and 
mock infected (lanes 3,4 and 5). Input, 10% of mock infected HeLa cell extract 
corresponding to TAP around 75 KDa in lane 1 and the lower band could be due 
cellular protein that crosses reaction with this antibody. 
Panel II shows precipitation of ICP27 in 17+ and M15 infected  HeLa cell extracts 
in the presence of RNase I (lane 2 and 3) by its antibody but no co precipitation in 
 27 and mock infected cell extracts (lanes 4 and 5).  
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Figure 4.1: ICP27 and its homologue ORF57 interact with 
NUP 98 in the GST pull down assay.  
 
Nuclear and cytoplasmic HeLa cell extracts were used in a GST pull down with 
GST-ICP27, GST-ORF57 and GST alone and were western blotted with anti NUP 
98 (L-20) antibody. GST-ICP27 interacted with nuclear (lane 2) and cytoplasmic 
(lane 7) NUP 98 and did not interact with GST in nuclear extracts (lane 3). Also 
GST-ORF57 interacted with nuclear (lane 4) and cytoplasmic (lane 8) NUP 98. 
Lane  5  is  a  Rainbow  marker  lane.  Lane  1  showing  input  that  is  10%  of  mock 
infected cell extract lysate  
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Figure 4.2: NUP 98 interacts with ICP27 in the pull down 
assay.  
GST-NUP 98 (66-515) and GST alone expressed and purified and mixed with 
lysates of HeLa cells infected with wt HSV-1 and mutant HSV-1 and used in 
pull down assay 
 
Panel I: GST-NUP 98 (66-515) and GST incubated with HSV-1 wt and ICP27 null 
mutant  27 and mock infected HeLa cell extract (MOI=10) and analysed by 10% 
SDS-PAGE and western blotted with anti ICP27 antibody 1113. The blot showed 
interaction of NUP 98 with wt ICP27 (lane 2) but not with  27 and mock infected 
cell extracts nor with GST alone (lanes 3, 4 and 5). Lane 1 showing input that is 
10% of HSV-1 wt infected cell extract lysate 
Panel II: Unbound samples run on SDS-PAGE and western blotted against ICP27, 
showed presence of ICP27 in lysates of HeLa cell infected with HSV-1 wild type 
used in this pull down assay.      
 
Panel  III:  Above  membrane  stripped  and  western  blotted  with  anti  GAPDH 
antibody.                                                                                                                     Chapter 4, Figures              
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Figure  4.3:  ICP27  co-immunoprecipitated  from  cell 
extracts by using anti NUP 98 antibodies.  
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Panel  of  HSV-1  wt  and  mutant  ICP27  HeLa  infected  cell  lysates  (MOI=10) 
incubated with anti NUP 98 for co-immunoprecipitation experiments. 
Panel I: Anti NUP 98 (L-20) goat antibody used for immunoprecipitation followed 
by SDS-PAGE and western blotted with anti ICP27 1113 antibody. As shown in 
HSV-1 wt 17+ (lane 3) and point mutant M15 (lane5) infected cell lysates, ICP27 
was co-precipitated but not in  27 and mock infected cell lysates (lanes 4 and 6). 
Lanes 1 and 2 shows input mock and HSV-1 17+ infected cell lysates showing the 
position of ICP27. Also normal goat serum did not precipitate ICP27 from HSV-1 
wt 17+ infected cell (ane 7). 
Panel  II:  Anti  NUP  98  (H-300)  rabbit  antibody  used  for  immunoprecipitation 
followed by SDS-PAGE and western blotted with Anti ICP27 1113 antibody. As 
shown in both RNase I treated and untreated HSV-1 wt 17+ (lanes 2 and 7) and 
another  point  mutant  M16  (lanes  3  and  8)  infected  cell  lysates,  ICP27  co-
precipitated but not in  27 and mock infected cell lysates (lanes 4 and 6). Lanes 1 
and  6 showing  input that is 10% of HSV-1  wt infected cell extract lysate. Also 
normal  rabbit  serum  did  not  precipitate  ICP27  from  wt  17+  infected  cell  lysate 
(lane11). 
Panel III: Anti NUP 98 (L-20) goat antibody used for immunoprecipitation followed 
by SDS-PAGE and western blotted with anti NUP 98 (L-20) antibody. As shown 
anti  NUP  98  (L-20)  antibody  did  not  precipitate  NUP  98  from  infected  and 
uninfected cells. 
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Figure 4.4: Recombinant GST-NUP 153 interacts directly 
with ICP27 in the pull down assay.  
 
GST-NUP 153 incubated with wt HSV-1 17+ HSV-1 infected HeLa cell extracts 
(MOI=10) followed by RNase I traetment. 
Panel  I:  Pull  down  assay  samples  were  run  on  10%  SDS-PAGE  and  western 
blotted with anti ICP27 antibody 1113 and showed interaction of ICP27 and NUP 
153 in the presence (lane 1) of RNase I. Lane 3 showing input that is 10% of HSV-
1 wt infected cell extract lysate. ICP27 was not precipitated with GST alone (lane 
2). 
Panel II: Unbound samples of this pull down assay run on 10% SDS-PAGE and 
western blotted with anti ICP27 antibody 1113 that showed ICP27 in both GST 
alone (lane 1) and GST-NUP 153 (lane 2) pull down samples. 
Panel  III:  Above  unbound  membrane  stripped  and  western  blotted  with  anti-
GAPDH  antibody.  Lane  1,  HSV-1  wt  infected  cell  extract  incubated  with  GST 
alone; lane 2, HSV-1 wt infected cell extract incubated with GST-NUP 153. 
Panel  IV: Coomassie blue stained 6% SDS-PAGE gel showing  the  expression 
and  purification  of GST-NUP 153.  Lane  1 bound  purified GST-NUP 153 fusion 
protein; lane 3, unbound purified GST-NUP 153 fusion protein.   
Panel  V:  Western  blotted  6%  SDS-PAGE  gel  showing  the  expression  and 
purification of GST-NUP 153 using anti NUP 153 antibody. Lane 1 bound purified 
GST-NUP  153  fusion  protein;  lane  3,  unbound  purified  GST-NUP  153  fusion 
protein.                                                                                                                       Chapter 4, Figures              
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Figure 4.5: Anti-NUP 153 antibody co-immunoprecipitated 
ICP27 from HSV-1 infected cell extracts.  
 
Specific  monoclonal  antibody  against  nucleoporin  153  was  used  to  co-
immunoprecipitate ICP27 from HSV-1 infected cell lysates (MOI=10). 
 
Panel  I:  Range  of  HSV-1  wt  and  mutant  HeLa  infected  cell  lysates 
immunoprecipitated with anti NUP 153 antibody and run on a 6% SDS-PAGE gel 
and  followed  by  western  blotting  with  anti-ICP27  antibody  (1113).  Data 
demonstrated nucleoporin 153 co-precipitated ICP27 from HSV-1 wt infected cell 
extracts (lane 4) but not from its null mutants 27lac Z (lane 2) and  27 (lane 3) and 
mock infected cell extracts (lane 5). Also co-immunoprecipitation with NMS did not 
bring down ICP27 from wt infected cell extract (lane 6). Lane 1 showing input that 
is 10% of HSV-1 wt infected cell extract lysate 
 
Panel II: Anti-NUP 153 antibody precipitated NUP 153 in all samples (lanes 1, 2, 
3, 4, 5) except (lane 6) where normal mouse serum (NMS) was used as a control 
antibody and approximately a 153 KDa band corresponding to nucleoporin 153 
was detected with mock input sample (lane 1). The lower bands about 55 KDa 
represent heavy chains of the antibody (lanes 2, 3, 4, 5, 6).     
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Figure 4.6: Mapping the interacting regions of ICP27 with 
NUP 153 using GST pull down assay.  
 
Series of wt and ICP27 mutant HeLa HSV-1 infected cell extracts (MOI=10) 
incubated with fusion protein GST-NUP153 in the presence of RNase I and 
pulled down and separated by 10% SDS-PAGE gel and analysed by western 
blot. 
 
Panel  I:  Bound  pulled  down  proteins  western  blotted  with  anti  ICP27 
antibodies1113 and 1119 and showed NUP 153 pulled down ICP27 from wt, d2-3, 
d3-4, d4-5, d5-6, d6-7 and partially d1-2 and M16 (lanes 1, 2, 4, 5, 6, 7, 8, 9, 10 
and 12 respectively) but not with  27, mock, dLeu and M15 (13, 14, 3 and 11 
respectively). Lane 1 shows RNase I non-treated sample of wt infected cell extract 
and lane 15 showing input that is 10% of HSV-1 wt infected cell extract lysate. 
Panel II:Unbound pulled down proteins western blotted with anti ICP27  antibodies 
1113  and  1119  and  showed  presence  and  amount  of  ICP27  in  different  cell 
extracts (lanes 1-12 and 15) and absence of ICP27 in  27, mock infected HeLa 
cell extracts (lanes 13 and 14) 
 
Panel  III:  Unbound  samples  membrane  stripped  and  western  blotted  with  anti 
GAPDH antibody showed the relative concentrations of the proteins, lanes 5, 8 
and 13 showing low amount of the protein because of using less lysate.  
 
Panel IV: Schematic representative of ICP27 mutants.                                                                                                                     Chapter 4, Figures              
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Figure 4.7: NUP 214/CAN interacts with ICP27 in the pull 
down assay.  
 
Purified GST fusion protein NUP214/CAN (aa 1690-1894), (aa 1690-2090) and 
GST alone incubated with wt 17+ HSV-1 and mutant ICP27 HSV-1 (MOI=10) 
and mock infected HeLa cell extracts and separated on 10% SDS-PAGE and 
analysed by using anti ICP27 antibody. 
 
Panel I: Western blot with anti ICP27 1113 antibody showed ICP27 pulled down 
by NUP 214 in HSV-1 17+ infected cell lysate (lanes 1 and 7) but not with HSV-1 
 27 and mock infected cell lysates (lanes 2, 3, 6 and 8). Also GST alone did not 
bring down ICP27 from HSV-1 wt 17+ cell extract (lanes 4 and 9). Lane 5 showing 
input that is 10% of HSV-1 wt infected cell extract lysate. 
 
Panel  II:  Unbound  cell  extracts  of  this  experiment  fractionated  on  a  gel  and 
western blotted with anti ICP27 1113 antibody showing the presence of ICP27 in  
HSV-1 17+ infected cell sample (lane 2) and absence in  27 and mock infected 
cell  lysates  (lanes  3,  4,  7  and  9).  Lanes  4  and  8  presents  unbound  ICP27  in 
interaction with GST alone. Lane 6 did not presents unbound ICP27 in HSV-1 17+ 
infected could be due to very efficient interaction with NUP 214. 
 
Panel III: The above panel II membrane western blot reprobed with anti GAPDH 
antibody.                                                                                                                     Chapter 4, Figures              
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Figure  4.8:  ICP27  and  NUP  214/CAN  co-
immunoprecipitate from HeLa cell extracts.  
 
Immunoprecipitation test carried out by mixing anti-NUP 214 (N-15) antibody 
with HSV-1 wt, M16 point mutant, ICP27 null  27 (MOI=10) and mock infected 
HeLa cell extracts. Also HSV-1 wt infected cell extract incubated with normal 
goat serum (NGS) was used as a control.  
Panel I: Complexes formed were separated on a 10% SDS-PAGE followed by 
western blotting with anti-ICP27 (1113) antibody. Lanes 1 and 7, co-precipitation 
of ICP27 in HSV-1 17+ infected cell extract in the absence and presence of RNase 
I; lanes 2 and 8, co-precipitation of HSV-1 mutant M16 ICP27 under non RNase I 
treated  and  RNase  I  treated  condition  respectively;  lanes  3,4,9  and  10, 
demonstrates there are no protein precipitated in HSV-1  27 and mock infected 
cell  extracts;  lane  6,  no  precipitation  of  ICP27  by  normal  goat  serum;  lane  5, 
showing input that is 10% of HSV-1 wt infected cell extract lysate.  
Panel II: The first six lanes of Panel I were stripped and western blotted with anti-
FG repeat NUP 414 antibody showing precipitation of NUP 214. Lane 1, 17+ HSV-
1 infected cell extract in absence of RNase I; lane 2, HSV-1 mutant M16 ICP27 
infected cell extract under non-RNase I treatment; lane 3, HSV-1  27 infected cell 
extract in absence of RNase I; lane 4, mock infected cell extract in absence of 
RNase I, lane 5, showing input that is 10% of HSV-1 wt infected cell extract lysate; 
lane 6, 17+ HSV-1 infected cell extract incubated with NGS in presence of RNase 
I.                                                                                                                                                        Chapter 4, Figures              
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Figure 4.9: Mapping the interacting regions of ICP27 with 
NUP 214 using GST pull down assay.  
 
Fusion protein GST-NUP 214 (1690-2090) was used to pull down ICP27 from 
a panel of the HSV-1 ICP27 wt and mutated viruses.  
 
Panel I: HeLa cells were infected with wt HSV-1 and HSV-1 ICP27 mutant viruses 
(MOI=10).  Cell  extracts  were  incubated  with  GST-NUP  214  (1690-2090)  and 
complexes formed  were separated on a 10% SDS-PAGE gel and western blotted 
with  either  anti  ICP27  antibody  1113  or  1119.  GST-NUP  214  (1690-2090) 
interacted with wt ICP27 in the presence (lane 1) and absence (lane 10) of RNase 
I. HSV-1 Mutant ICP27 M11, d1-2, d2-3, d4-5, d5-6, d6-7 and d3-4 (lanes 4, 8, 9, 
11, 12, 13 and 14 respectively) also interacted with GST-NUP 214. HSV-1 ICP27 
mutants   27,  M15,  M16  and  dLeu  (lanes  2,  5,  6  and  7  respectively)  did  not 
interact. Also mock-infected cell extract did not show any ICP27 band (lane 3). 
GST  alone  in  lane  16  did  not  pull  down  ICP27  from  17+  HSV-1  infected  cell 
extract.  
 
Panel II: Unbound samples run on 10% SDS-PAGE gel and western blotted with 
anti ICP27 1113 and 1119 antibodies and demonstrated presence of ICP27 wt and 
mutants in the samples except in  27 and mock infected cell extracts. 
 
Panel  III:  First  five  lanes  of  the  membrane  from  Panel  1  were  stripped  and 
western blotted with anti GST antibody showing presence and similar amounts of 
input GST-NUP 214 (1690-2090) (lanes 1-5) and GST alone (lane 6) used in this 
experiment. 
 
Panel IV: Schematic representative of ICP27 mutants. 
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Figure 5.1: Optimum expression of GST-Rae1 obtained at 29° ° ° °C 
Coomassie blue stained 10% SDS-PAGE gel showing the purified proteins from 
the bacterial lysates bound to Glutathione 4B sepharose. Full length GST-Rae 1 is 
marked. 
Panel  I,  bound,  purified  GST  fusion  protein  from  bacterial  cultures  containing 
GST-Rae  1  and  negative  control  no  GST-Rae  1  expressing  plasmids  were 
induced with IPTG at 29°C (lane 1 GST-Rae 1 and lane 2 negative control pUC 
plasmid).  
Panel  II,  bound,  purified  GST  fusion  protein  from  bacterial  cultures  containing 
GST-Rae  1  and  negative  control  no  GST-Rae  1  expressing  plasmids  were 
induced with IPTG at 37°C (lane 1 GST-Rae 1 and lane 2 negative control  pUC 
plasmid).                                                                                                                     Chapter 5, Figures              
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Figure 5.2: Maximum expression of GST-Rae1 obtained using BL21-Codon 
plus-RP competent E.coli cells 
10% SDS-PAGE gel showing the purified protein from the bacterial lysates bound 
to Glutathione 4B sepharose.  
Panel I, bacterial cultures of BL21 and BL21-codon plus-RP competent E.coli cells 
containing GST-Rae1 expressing plasmids  were induced with IPTG at 29°C (lane 
1 BL21-codon plus-RP and lane 2 BL21). 
Panel  II,  Purified  GST-Rae1  from  BL21-codon  plus-RP  was  analysed  using  a 
Protein 200 Plus LabChip kit (Agilent technologies) (lane 1), and western blotting 
with anti-GST antibody (lane 2, bound to beads. lane 3 unbound to beads) in order 
to monitor expression, protein concentration and purity. Full length GST-Rae1 is 
marked. 
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Figure 5.3: GST-Nucleoporin 107 and GST- Rae 1 do not interact with ICP27 
from His-ICP27. 
 
Panel I: Western blot of purified GST-NUP 107 fusion protein and GST alone with 
anti-GST antibody. Lane 1 shows expression of GST alone and lane 2 expression 
of GST-NUP 107. 
 
Panel II: Lysates from E. coli expressing GST-NUP 107, GST-Rae 1, GST alone, 
GST-TAP and His-ICP27 were incubated with glutathione agarose beads or with 
Ni-NTA agarose beads respectively. Bound purified GST fusion proteins and GST 
alone  were  mixed  and  incubated  with  purified  His-ICP27  and  were  eluted  with 
SDS-sample buffer and analyzed on SDS-PAGE followed by western blotting with 
anti-ICP27 antibody (1113).  
Lane 1, showing input that is 10% of His-ICP27 input; lane 2, GST-alone did not 
pull down ICP27; lane 3, GST-Rae 1 did not pull ICP27 down; lane 4, GST-NUP 
107 could not pull down ICP27; lane 5, But GST-TAP pulled down ICP27. The 
position of ICP27 is indicated.                                                                                                                     Chapter 5, Figures              
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Figure 5.4: ICP27 is expressed as early as 2 hours post infection during a 
time course study 
 
Panels I, II and III Shows western blots for ICP27 with monoclonal anti-ICP27 
Ab  (H1113)  in  HeLa  infected  cell  extracts  at  various  times  and  MOI  after 
infection with wt HSV-1, ICP27 null D D D D27 virus and mock infected cells. HeLa 
cells were grown in 175 mm flasks and infected with wt HSV-1 strain 17+, D27 
HSV-1 and mock infected with an MOI=10 at 1-8 hpi, MOI=1 at 12-16 hpi and 
MOI=0.1  at  24-48  hpi.  Samples  were  collected  at  various  time  points  post-
infection,  cells  pelleted,  lysed  in  Hepes  buffer  and  then  in  SDS  loading  buffer, 
separated by 10% SDS-PAGE and visualised by western blotting with anti-ICP27 
monoclonal  antibody  (H1113).  Then  membranes  were  stripped  and  western 
blotted with anti GAPDH antibody. Samples used in lanes: 1, 4, 7, 10, 13, 16, 19, 
22, 25 and 28 were mock infected cell extracts. Lanes 2, 5, 8, 11, 14, 17, 20, 23, 
26 and 29 were HSV-1 17+ infected cell extracts. Lanes 3, 6, 9, 12, 15, 18, 21, 24, 
27 and 30 wereHSV-1 D27 infected cell extracts. 
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Figure 5.5: Various nucleoporins expressed during a time course study of 
HeLa cells infected by wt HSV-1 and ICP27 null mutant virus 
 
 
Panels I, II and III Show western blots for nucleoporins with monoclonal anti 
FG-repeat 414 Ab in HeLa cells infected at various times and various MOI 
after infection with wt HSV-1, ICP27 null ( 27) virus and mock infected cells 
that demonstrates expression of nucleoporins. HeLa cells were grown in 175 
mm flasks and infected with wt HSV-1 strain 17+, D27 HSV-1 and mock infected 
cells  by  MOI=10  at  1-8  hpi,  MOI=1  at  12-16  hpi  and  MOI=0.1  at  24-48  hpi. 
Samples were collected at various time points post-infection, cells pelleted, lysed 
in Hepes buffer and then in SDS loading buffer, separated by 10% SDS-PAGE 
and  visualised  by  western  blotting  with  anti-414  monoclonal  antibody.  Samples 
used  in  lanes:  1,  4,  7,  10,  13,  16,  19,  22,  25  and  28  were  mock  infected  cell 
extracts. Lanes 2, 5, 8, 11, 14, 17, 20, 23, 26 and 29 were HSV-1 17+ infected cell 
extracts. Lanes 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30 were HSV-1 D27 infected cell 
extracts.  
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                     Chapter 5, Figures              
  225 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
o
c
k
M
o
c
k
+
o
p
t
+
l
i
p
Y
F
P
-
I
C
P
2
7
G
F
P
 
a
l
o
n
e
Lysates
1             2          3            4   
NUP 98
NUP 62
220KDa
97KDa
66KDa
NUP 214
NUP 153
I
M
o
c
k
M
o
c
k
+
o
p
t
+
l
i
p
Y
F
P
-
I
C
P
2
7
G
F
P
 
a
l
o
n
e
Lysates
1             2          3            4   
NUP 98 NUP 98
NUP 62 NUP 62
220KDa 220KDa
97KDa 97KDa
66KDa 66KDa
NUP 214 NUP 214
NUP 153 NUP 153
I
M
o
c
k
M
o
c
k
+
o
p
t
+
l
i
p
Y
F
P
-
I
C
P
2
7
G
F
P
 
a
l
o
n
e
GAPDH
Lysates
1               2              3              4
97KDa
66KDa
45KDa
YFP-ICP27
45KDa
II
M
o
c
k
M
o
c
k
+
o
p
t
+
l
i
p
Y
F
P
-
I
C
P
2
7
G
F
P
 
a
l
o
n
e
GAPDH
Lysates
1               2              3              4
97KDa 97KDa
66KDa 66KDa
45KDa 45KDa
YFP-ICP27 YFP-ICP27
45KDa 45KDa
II                                                                                                                    Chapter 5, Figures              
  226 
Figure 5.6: Transient co-transfection study of ICP27 showed no change in 
expression level of nucleoporins.  
 
Transient transfection of enhanced yellow fluorescent protein ICP27 (EYFP-
ICP27) plasmid, which expresses ICP27 in HeLa cells. After 24 hpi, infected 
lysates  were  run  on  6%  SDS-PAGE  and  western  blotted  with  specific 
antibodies.  
 
Panel I: Expression level of NUPs after western blotting with anti FG-repeat NUPs 
414 antibody in control samples (lanes 1, 2 and 3) and transfected sample (lane 
4). 
 
Panel II: Samples visualised by western blotting with anti GFP antibody to test 
presence of ICP27 in the transfected sample as it shown appropriate GFP and 
YFP-ICP27 (lanes 3 and 4). 
Stripped  membrane  immunoblotted  against  GAPDH  indicate  equal  amount 
proteins used in this experiment shown in the bottom of this panel.                                                                                                                      Chapter 5, Figures              
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Figure 5.7: Nuclear and cytoplasmic expression of ICP27 and nucleoporins 
during a time course study of HeLa cells mock infected and infected with wt 
HSV-1 and ICP27 mutants 
 
 
Panels I, II, III and IV Shows western blots for ICP27, nucleoporins and ICP4 
in HeLa infected cells at a 6 and 12 h after infection with wt HSV-1, ICP27 null 
D D D D27  virus,  M15  and  mock  infected  cells  that  demonstrate  distribution  of 
nuclear and cytoplasmic expression of these proteins. HeLa cells were grown 
in a 175 mm flask and infected with wt HSV-1 strain 17+,  27, M15 and mock 
infected by MOI=10 at 6 and 12 hpi. Samples were collected at various time points 
post-infection, cells were pelleted, and nuclear and cytoplasmic fractions prepared 
according  to  the  manufacturer’s  instructions  (Active  Motif).  Proteins  were 
separated by  10% SDS-PAGE and visualised  by  western  blotting  with  different 
antibodies.  Then  membranes  were  stripped  and  western  blotted  with  anti-ICP4 
antibody. Samples used in lanes: 1-4 were mock infected (MI) cell extract. Lanes 
5-8  were  17+  infected  cell  extract.  Lanes  9-12  were  D27  infected  cell  extract. 
Lanes 13 and 14 were M15 just at 12 hpi. 
Panel I: Nuclear and cytoplasmic expression of ICP27 western blotted with anti-
ICP27 antibody 1113. 
Panel II: Nuclear and cytoplasmic expression of NUP 98 western blotted with anti-
NUP 98 (L-20) antibody.  
Panel III: Nuclear and cytoplasmic expression of NUP 62 western blotted with anti-
NUP 62 (N-19) antibody. 
Panel IV: Nuclear and cytoplasmic expression of ICP4 western blotted with anti-
ICP4 antibody showed expression of this protein in wt, M15 and D27.                                                                                                                     Chapter 5, Figures              
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Figure 5.8: Expression profile of wt and SADET mutant 
ICP27.  
To show the profile of protein expression and predicted size of the proteins, 
HSV-1 wt ICP27 and ICP27 SADET mutant were transfected into HeLa cells. 
Transfected cells were harvested after 24 hours and Bradford assay carried 
out  to  determine  protein  concentration.  Equal  amounts  of  lysates  were 
fractionated on 10% SDS-PAGE and western blotted with antibodies shown. 
6µg DNA used for transfection  regarding 60 mm dishes. 
 
 
Panel  I:  Transferred  membranes  western  blotted  with  anti  ICP27  antibody 
showing varying expression levels of SADET mutant ICP27s (lanes 2-7). 
Panel II: Another transferred membrane western blotted with anti ICP27 antibody 
showing varying expression levels of SADET mutant ICP27s (lanes 1-7). 
 
Panel III: Above membrane (Panel I) stripped and western blotted against GAPDH 
showed roughly similar amount of proteins used in each lane (lanes 1-7).    
Panel  IV:  Above  membrane  (Panel  II)  stripped  and  western  blotted  against 
GAPDH showed roughly similar amount of proteins used in each lane (lanes 1-7).                                                                                                                        Chapter 5, Figures              
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All of the above mutations were introduced into the expression plasmid pCMV-27 
that contains the ICP27 ORF under the control of a HCMV IE promoter (Leiper, 
2004). 
*  Removed  from  further  experiments  because  of  lack  of  details  that  was 
impossible to get.     
D  to  G  and  ET 
deletion 
SAG 
ET deletion  SAD 
S  to  G  and  ET 
deletion 
GAD 
--------*  R1A*  
SA deletion  DET  
D to G  SAGET 
S to G  GADET  
E to G  SADGT  
Y to A  Y505 
T to G  SADEG 
SADET  to 
AGAGT 
AGAG 
SADET  to 
AGAGA 
AGAGA 
 
WT  SADET 
Amino acid  
changes 
Mutants 
Table 5.1: ICP27 SADET mutants and their amino acid changes 
used  
in this project                                                                                                                     Chapter 5, Figures              
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Lysates   SADET GADET SADGT SADEG SAGET  SAG     SAD     GAD    INPUT    DET    Y505
RNase I        - - - - - - - - - -
ICP27
66KDa
45KDa
1             2            3            4            5          6            7            8           9             10       11 
Antibody
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Figure  5.9:  SADET  region  involvement  in  interaction  of 
ICP27  and  nucleoporins  by  using  immunoprecipitation 
assay under non RNase I treatment condition.  
 
Immunoprecipitation experiments performed with a range of cell lysates 24 h 
after  transfection.  Plasmids  expressing  ICP27  SADET  mutants  were 
transfected into HeLa cells. Lysates were prepared after 24 h and incubated 
with anti ICP27 antibody. Bound and unbound samples were separated by 
10%  SDS-PAGE  and  transferred  to  nitrocellulose  membrane  and  western 
blotted with specific antibodies. 
 
Panel  I:  Membranes  western  blotted  with  anti  ICP27  antibody  showed 
precipitation of ICP27 in all samples. 
 
Panel  II:  Above  membranes  stripped  and  western  blotted  with  anti  NUP  414 
antibody showed co-precipitation of NUP 62 in some of the samples (lanes 1, 4, 6, 
7 and 11) but not with others (lanes 2, 3, 5, 8 and 10).  
 
Panel III: Rest of samples run and visualised by western blotting with anti hnRNP 
K antibody showed co-precipitation of hnRNP K by all the wt and SADET ICP27 
mutants. 
 
Panel  IV:  Unbound  samples  run  and  western  blotted  with  anti  ICP27  antibody 
showed presence of ICP27 in all samples. 
 
Panel  V:  Above  unbound  samples  membranes  stripped  and  western  blotted 
against GAPDH showed equal amount proteins used in this experiment.  
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Figure 5.10: SADET region involvement in interaction of 
ICP27  and  nucleoporins  by  using  immunoprecipitation 
assay under RNase I treatment condition.  
 
Immunoprecipitation experiments performed with a range of cell lysate after 
24  h  of  to  transfection.  Plasmids  expressing  ICP27  SADET  mutants  were 
transfected into HeLa cells. Lysates were prepared after 24 h and incubated 
with  anti  ICP27  antibody  and  treated  with  RNase  I.  Bound  and  unbound 
samples  were  separated  by  10%  SDS-PAGE  gel  and  transferred  to 
nitrocellulose membrane and western blotted with specific antibodies. 
 
Panel  I:  Membranes  western  blotted  with  anti  ICP27  antibody  showed 
precipitation of ICP27 in most of samples. 
 
Panel  II:  Above  membranes  stripped  and  western  blotted  with  anti  NUP  414 
antibody showed co-precipitation of NUP 62 to some of the samples (lanes 1, 2, 3, 
4, 11 and 12) but not with others (lanes 5, 6, 7, 8 and 10).  
 
Panel III: Rest of samples run and visualised by western blotting with anti hnRNP 
K antibody showed co-precipitation of hnRNP K by all the wt and SADET ICP27 
mutants. 
 
Panel  IV:  Unbound  samples  run  and  western  blotted  with  anti  ICP27  antibody 
showed presence of ICP27 in all samples. 
 
Panel  V:  Above  unbound  samples  membranes  stripped  and  western  blotted 
against GAPDH showed equal amount proteins used in this experiment.  
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Figure  5.11:  Time  course  study  of  expression  of  ICP27 
and FG repeat nucleoporins in HeLa cells infected with wt 
and mutant HSV-1. 
 Hela cells were infected with wt HSV-1 and HSV-1 mutants  27 and M16 or 
mock  infected.  Cells  were  harvested  at  3,  6.5,  9.5  (MOI=10),  16  and  22 
(MOI=1)  hpi  and  protein  concentration  obtained  by  Bradford  assay.  Equal 
amounts of protein were fractionated on 6% SDS-PAGE and transferred to 
nitrocellulose membrane and western blotted with anti ICP27 antibody 1113 
and anti FG-repeat NUPs 414. 
Panel I: Membranes were western blotted against ICP27 and showed expression 
of wt ICP27 from 3 hpi (lane 1) that increased after 6.5 and 9.5 hpi at MOI=10 
(lanes 5,9) but expression of M16 ICP27 is shown from 6.5 hpi and enhanced until 
9.5  hpi  (lanes  6,  10).  Also   27  and  mock-infected  samples  did  not  show  any 
ICP27 expression. 
Panel II: Shows expression of wt ICP27 and M16 at 16 hpi (lane 1) that increased 
until 22 hpi at MOI=1 (lanes 5). Also  27 and mock-infected samples did not show 
any ICP27 expression. 
Panel III: Above membranes (Panel I) were stripped and western blotted against 
FG-repeat  NUPs  showing  roughly  similar  levels  of  nucleoporins  in  infected 
samples at MOI=10 and different time of infection (lanes 1-12).    
Panel IV: Above membranes (Panel II) were stripped and western blotted against 
FG-repeat  NUPs  showing  roughly  similar  levels  of  nucleoporins  in  infected 
samples  at  MOI=1  and  different  time  of  infection  (lanes  1-8).                                                                                                                    Chapter 5, Figures              
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Figure  5.12:  Immunoprecipitation  profile  of  HSV-1  wild  type  and  mutant  ICP27 
HeLa infected cell  extracts at different  post infection times. Equal amounts of 
proteins from HeLa cell extracts infected with HSV-1 wt, M16,  27 and mock 
infected at different times were incubated with anti ICP27 antibody. Samples 
were either treated or untreated with RNase I and fractionated on 6% or 10% 
SDS-PAGE and transferred to nitrocellulose membranes and western blotted 
with anti ICP27 antibody. 
 
Panel I: Precipitation of ICP27 at 3 hours post infection on 6% SDS-PAGE gel. 
Panel II: Precipitation of ICP27 at 6.5 hours post infection on 6% SDS-PAGE gel. 
Panel III: Precipitation of ICP27 at 6.5 hours post infection on 10% SDS-PAGE gel 
and RNase I absence. 
Panel IV: Precipitation of ICP27 at 9.5 hours post infection on 6% SDS-PAGE gel. 
Panel V: Precipitation of ICP27 at 16 hours post infection on 6% SDS-PAGE gel 
Panel VI: Precipitation of ICP27 at 22 hours post infection on 6% SDS-PAGE gel. 
Panel VII: Precipitation of ICP27 at 22 hours post infection on 10% SDS-PAGE 
gel and RNase I absence. 
The input lane in each case was a lysate of HeLa cells infected with wild type 
HSV-1 17+ for 8hpi at on MOI=10 and it is 10% of HSV-1 wt infected cell extract 
lysate.                                                                                                                     Chapter 5, Figures              
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Figure 5.13: Immunoprecipitation test with anti FG-repeat 
NUPs 414 used in time course study. 
 Equal  amount  of  proteins  from  HeLa  cells  infected  with  HSV-1  wt  and  HSV-1 
mutants M16 and  27 and mock infected at different times were incubated with 
anti  414  antibody.  Samples  were  either  treated  or  untreated  with  RNase  I 
fractionated on 6% SDS-PAGE and transferred to nitrocellulose membranes and 
western blotted with anti 414 antibody. Less amounts of input used in this gels. 6 
of HSV-1 wt infected cell extract lysate used as a input. 
Panel I: Precipitation of FG repeat nucleoporins showed at 3 hours post infection. 
Panel  II:  Precipitation  of  FG  repeat  nucleoporins  showed  at  6.5  hours  post 
infection  
Panel  III:  Precipitation  of  FG  repeat  nucleoporins  showed  at  9.5  hours  post 
infection  
Panel  IV:  Precipitation  of  FG  repeat  nucleoporins  showed  at  16  hours  post 
infection  
Panel  V:  Precipitation  of  FG  repeat  nucleoporins  showed  at  22  hours  post 
infection                                                                                                                     Chapter 5, Figures              
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Figure 5.14: Co-immunoprecipitation profile of wild type 
and mutants ICP27 HeLa infected cells at different post 
infection time. 
 
 
Equal amounts of proteins from HeLa cells infected with HSV-1 wt and HSV-
1 mutants M16 and  27 and mock infected at different times were incubated 
with anti FG-repeat 414 antibody. Samples were either treated or untreated 
with RNase I, fractionated on 6% SDS-PAGE and transferred to nitrocellulose 
membranes and western blotted with anti ICP27 antibody.10% of HSV-1 wt 
infected cell extract lysate used for input. 
 
Panel I: Co-precipitation of ICP27 showed at 9.5 hours post infection.  
 
Panel II: Co-precipitation of ICP27 showed at 16 hours post infection. 
 
Panel III: Co-precipitation of ICP27 showed at 22 hours post infection. 
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Figure  6.1:  Schematic  diagram  of  interaction  of  ICP27 
with nucleoporins. 
ICP27 may interacs with several FG-repeat nucleoporins NUP 62, NUP 153, NUP 
214/CAN. It interacts with TAP that is associated with these nucleoporins in the 
nucleo-cytoplasmic  transport  machinery.  The  solid  lines  represent  proved 
interactions and the dotted lines represents possible interactions. 
                                                                                     
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Regions of ICP27 involved in interaction with 
nucleoporins. 
Mapping studies of ICP27 interaction with different NUPs showed that: 
NUP 62 interacts with dLeu, M15 and M16 regions of ICP27 
NUP 153 interacts with dLeu and M15 regions of ICP27 with contribution of d1-2 
and M16 
NUP 214 interacts with dLeu, M15 and M16 regions of ICP27   
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Figure 6.3: Proposed involvement of ICP27 and NUPs in 
transport of cargo-dependent ICP27. I: The ICP27/mRNA complex 
binds first to NUP 153. It  is then handed to the other FG-repeat NUPs such as 
NUP  98  and  NUP  62  to  translocate  through  the  central  pore,  and  pass  to  the 
cytoplasmic face of the NPC by interaction with cytoplasmic face NUPs such as 
NUP  214.  Finally,  dissociation  of  the  complex  occurs  in  the  cytoplasm.  II: 
Representation of the complex formed of ICP27 with viral RNA that might interact 
with NUP 153 FG-repeat-binding site to position in the nuclear periphery of the 
NPC. 
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Figure  6.4:  A  model  of  ICP27  nucleocytoplasmic 
trafficking:  Possible  unphosphorylated  ICP27  could  constitutively  shuttle 
between  the  nucleus  and  the  cytoplasm  via  direct  interactions  with  the 
nucleoporins. This carrier-independent translocation pathway facilitates export and 
import of the ICP27 through the NPC. 
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Figure  6.5:  Possible  association  of  ICP27  and  TAP  in 
interaction with nucleoporins for transport of cargoes.  
 
A complex of cargo that can interact with ICP27 that is in complex with TAP could 
translocate through the nuclear pore complex and mediate transport between the 
nucleus and the cytoplasm (I-VI).   
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Figure  6.6:  Possible  association  of  ICP27  and  CRM1  in 
interaction with nucleoporins for export of cargoes.  
 
A  cargo  complex  could  interact  with  two  transport  factors  ICP27  and  CRM1 
simultaneously  and  translocate  through  the  nuclear  pore  complex  to  transport 
between the nucleus and the cytoplasm (I-VI).   
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